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LIST OF ABBREVIATIONS
5-MTHF 5-methyl-tetrahydrofolate
95%CI 95% Confi dence interval
AA Arachidonic acid
Aβ Amyloid beta
AChE Acetylcholinesterase
AD Alzheimer’s disease
ADMA Asymmetric dimethylarginine
ANOVA Analysis of variance
ApoE Apolipoprotein E
ApoJ Apolipoprotein J
APP Amyloid precursor protein
A.U. Arbitrary units
AUC Area under the curve
BACE β-Site APP-cleaving enzyme
CDR Clinical dementia rating
CNS Central nervous system
CpG Cytosine guanine phosphodiester
CSF Cerebrospinal fl uid
CT Computed tomography
CV Coeffi cient of variation
DDAH Dimethylarginine dimethylaminohydrolase
EEG Electro encephalogram
ELISA Enzyme-linked immunosorbent assay
ER Endoplasmatic reticulum
FTLD Frontotemporal lobar degeneration
H2O2  Hydrogen peroxide 
Hcy Homocysteine
HPLC High pressure liquid chromatography
LA Linoleic acid
LP Lumbar puncture 
Lyso-PC Lysophosphatidylcholine
mAbs Monoclonal antibodies
MCI Mild cognitive impairment
MD Mixed-type dementia
MiRNA MicroRNAs
MMA Methylmalonic acid
MMSE Mini-mental state examination
MRI Magnetic resonance imaging
MS Mass spectrometry
NINCDS-ADRDA National Institute of Neurological and 
 Communicative Disorders and Stroke – 
 the Alzheimer’s Disease and Related 
 Disorders Association
NTP Neuronal thread protein`
NFT Neurofi brillary tangles
NO Nitric oxide
NOS Nitric oxide synthase
pAb Polyclonal antibodies
PC Phosphatidylcholine
PET Positron emission tomography
PHF Paired helical fi laments
PS1 Presenilin 1
PS2 Presenilin 2
PSEN1 Presenilin 1
Ptau Hyperphosphorylated tau
ROC Receiver operating characteristic
SAH s-Adenosyl-homocysteine
SAM s-Adenosyl-methionine
SAP Serum amyloid P component
SD Standard deviation
SDMA Symmetric dimethylarginine
SMC  Subjective memory complaints
SP Senile plaques
SPECT Single photon emission computed tomography
WMH White matter hyperintensities
WML White matter lesions
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INTRODUCTION
Dementia is characterised by a progressive decline in cognitive 
function far beyond what might be expected from normal aging. The ability 
to differentiate the signs and symptoms of the most common dementia 
syndromes – Alzheimer’s disease (AD), vascular dementia, frontotemporal 
dementia, and dementia with Lewy bodies – is essential to dementia care 
and management.
AD is the most common form of dementia. It starts slowly and fi rst 
involves the parts of the brain that control memory and language. People 
with AD may have trouble remembering things that happened recently or 
the names of people they know. Over time, symptoms get worse. People 
may not recognize family members or have trouble speaking, reading or 
writing. In the Netherlands the prevalence of AD is over 250.000 and the 
annual incidence is more than 20.000.
1  Post-mortem diagnosis of defi nite Alzheimer’s disease
Neuropathological changes in the brains of patients with dementia have 
been studied since the end of the 19th century. In 1906 Alois Alzheimer 
described a patient, a woman in her fi fties with an ‘unusual disease of 
the cerebral cortex’. The patient, Auguste D., suffered from memory 
loss, disorientation, and hallucinations and she died only 55 years old. 
Post-mortem, various abnormalities of the brain were demonstrated. 
The cerebral cortex was thinner than normal and senile plaques (SP), 
previously only encountered in elderly people, were found in the brain 
along with neurofi brillary tangles (NFT). Alzheimer marked off the disease 
as a separate clinical and pathological entity and the disease was named 
AD. Today, the defi nite AD diagnosis is still generally based on the same 
basic post-mortem fi ndings as in 1906.
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2  Diagnosis of ‘probable’ Alzheimer’s disease
Many criteria have been proposed to diagnose AD but only those 
proposed by McKahnn et al. in 1984 have survived and are still being 
used.1 The ante-mortem clinical diagnosis of ‘probable’ AD, as coined by 
McKahnn et al. was primarily focused on exclusion but is nowadays more 
and more aided by ancillary investigations.2 
Physical and neurological examination of the patient is the starting 
point, followed by standard laboratory tests and review of all medications, 
primarily meant to exclude other causes of memory complaints. 
2.1  Memory tests and diagnosis of dementia 
Mini Mental State Examination score
This quick and simple to use test is most commonly used for screening 
patients with memory problems and contributes to a possible diagnosis 
of dementia. The mini-mental state examination (MMSE) test is used to 
screen for the presence of cognitive impairment over a number of areas. 
Cognition is defi ned as mental activity such as memory, thinking, attention, 
reasoning, decision making and dealing with concepts. On average people 
with Alzheimer’s disease lose 2 to 4 points each year on the MMSE.
The MMSE may be insensitive in highly educated people and those 
who have mild dementia. These diffi culties underscore the need for a 
number of different tests when diagnosing diseases like AD or any other 
condition where cognition is affected.
The Clock drawing test
Visuo-spatial and executive dysfunctioning are a common and early 
sign of dementia and the clock-drawing test is a valuable tool for screening. 
To draw a clock, put in all the numbers, and set the hands at ten past 
eleven is a simple test that can be used as part of a neurological test or 
as a screening tool for AD and other types of dementia. Clock drawing is 
strongly correlated with the MMSE score in patients with various cognitive 
dysfunctions. Both aforementioned tests are recommended by the 
“Nederlands Huisartsen Genootschap” to be done by general practioners 
in the Netherlands for screening.
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2.2 Brain Imaging
New imaging technologies have revolutionized our understanding of 
the structure and function of the living brain. Researchers are studying 
whether the use of magnetic resonance imaging (MRI) and other imaging 
methods may be expanded to play a more direct role in diagnosing 
AD. Many studies have shown that the brain of people with AD shrink 
signifi cantly as the disease progresses. It has been shown that shrinkage 
in specifi c brain regions may be an early sign of AD. However, scientists 
have not yet agreed upon standardized values that would establish the 
signifi cance of a specifi c amount of shrinkage for any individual person 
at a single point in time. White matter lesions (WML) also have been 
associated with AD.3 Structural imaging provides information about the 
shape, position or volume of brain tissue. Structural techniques include 
MRI and computed tomography (CT).
Functional imaging reveals how well cells in various brain regions 
are working by showing how actively the cells use sugar or oxygen. 
Functional techniques include positron emission tomography (PET) and 
functional MRI. A promising area of functional imaging research focuses 
on developing tracer compounds that will attach to key abnormal brain 
deposits implicated in AD. For example, preliminary data suggests that one 
such tracer, called Pittsburgh compound B, may attach to beta-amyloid 
and “light up” in a PET scan. PET and other functional imaging methods 
suggest that those with AD typically have reduced brain cell activity in 
certain regions. However, as with the shrinkage detected by structural 
imaging, there is not yet enough information to translate these general 
patterns of reduced activity into diagnostic information about individuals. 
At this time, PET is used primarily in research studies in the hope of 
gaining further knowledge about its potential for wider use in diagnosing 
AD and monitoring progression and response to treatment. 
2.3 Biomarkers for Alzheimer’s Disease
A biomarker is a characteristic that is objectively measured and 
evaluated as an indicator of normal biologic processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention.4
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In the research criteria, developed by McKahn et al.1 cerebrospinal fl uid 
(CSF) examination was recommended as an exclusion procedure for non-
AD dementia. Currently, however, biomarkers may play an additional role 
in the diagnostic process. One of the problems in AD is that symptoms of 
disease appear to develop only after a substantial degree of cell loss has 
already occurred in the brain. Effective biomarker tests should be positive 
before such devastating damage happens. For the development of AD 
there are three hypotheses, resulting in potential biomarkers. 
2.3.1 The amyloid hypothesis
It is possible to measure biomarkers in CSF that refl ect the central 
pathogenic processes of the brain, resulting in SP and NFT.2
Amyloid β(1-42) in CSF 
AD is caused by abnormal degradation of amyloid precursor protein 
(APP), a membrane-bound protein. An alternative cleavage by β- and 
γ-secretases of APP leads to formation of Aβ(1-40) and Aβ(1-42). Normally, 
the majority of Aβ released is Aβ(1-40), and only about 10% consist of 
insoluble Aβ(1-42). Overproduction of Aβ(1-42) or failure to clear this 
peptide leads to AD, primarily through amyloid deposition, demonstrated 
as SP, associated with cell death.
In patients with AD, a decrease in CSF concentration of Aβ(1-42) to 
about 50% of that in control individuals has been observed. For the most 
commonly used method, the commercial ELISA of Innogenetics,5 sensitivity 
and specifi city fi gures are available from 13 different studies.6 With 
specifi city at 90%, the mean sensitivity of CSF Aβ(1-42) to discriminate 
between AD and normal ageing is 86%. However, CSF Aβ(1-42) may also 
be decreased in dementia with Lewy bodies, frontotemporal degeneration, 
and vascular dementia,6 limiting its use in the differential diagnosis of 
dementia.
Tau protein in CSF
Tau protein is a human brain phosphoprotein that bind to microtubules 
in the neuronal axon, thereby promoting assembly and stability of the 
microtubules. In the human brain six isoforms may be present. The NFT 
found in brains of AD patients are neuronal inclusions of paired helical 
fi laments, consisting of mainly hyperphosphorylated forms of tau.
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It has been shown that in the early stage of AD total tau levels in CSF 
are increased. This indicates that total tau would be a sensitive marker 
for incipient AD. But elevated levels of CSF total tau were also detected 
in patients with other dementias and other acute or chronic neurological 
diseases.7 For the frequently used assay, the Innogenetics ELISA,8 the 
pooled sensitivity and specifi city from 36 studies with 2500 patients and 
1400 controls were 81% and 90%, respectively.6
Hyperphosphorylated tau protein in CSF
Characteristic for NFT is the presence of hyperphosphorylated tau 
(Ptau). In AD different Ptau epitopes in CSF may be increased. Ptau 
phosphorylated at threonine 181, 231, and serine 199, 235, 396, and 
404 has been studied. For Ptau-181, a commercial method is available9 
and worldwide this is the most studied isoform. Eleven different studies 
have been published, including about 800 AD patients and 370 control 
subjects.6 At a specifi city of 92% AD was discriminated from normal aging 
with a mean sensitivity of 80%, with a considerable variety among studies 
for Ptau-181 as well as the other isoforms.
2.3.2 The oxidative stress hypothesis
A growing body of evidence from animal and human studies suggest 
that ageing-related decrease in peroxisomal function may play a role in 
mammalian ageing processes.10 It is likely that the role of peroxisomes 
in ageing is a result of complex interactions between changes in lipid 
metabolism and oxidative stress. One can speculate that ageing related 
changes in peroxisomal activity could infl uence the organism in a way to 
peroxisomal diseases, though with milder functional consequences.
Among the major peroxisomal functions are oxidation and respiration, 
fatty acid β-oxidation, and cholesterol synthesis. The role of peroxisomes 
in ageing is not well understood due to a lack of data, in part because 
human peroxisomal disorders mainly affect children or young adults. 
However, numerous peroxisomal metabolic pathways produce high 
amounts of hydrogen peroxide (H2O2). The release of H2O2 takes place in 
the peroxisome, an organelle involved in the metabolic processes of major 
importance for membrane lipid composition and function. The occurrence 
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of reactive oxygen species with lipid components in the same organelle 
is likely to result in alterations that may modify peroxisomal function 
and, subsequently, the lipid composition and function of the membranes. 
Antioxidant activities (catalase) help the peroxisomes to prevent such 
changes by balancing the levels in reactive oxygen species. However, a 
number of age-related changes in peroxisomal H2O2-generating activities, 
antioxidant activities and lipid metabolism may alter the balance between 
pro- and antioxidants which may result in major changes in the function 
of peroxisomes, membranes, and cells. Such changes are consistent with 
both free-radical and membrane theories of ageing.11-13
Consequently, the function of peroxisomes may be crucial for late-
onset AD. For the development for a sensitive and/or a specifi c marker for 
AD, some characteristic peroxisomal parameters may be studied, e.g. the 
oxidation of unsaturated fatty acids in phospholipids.
2.3.3 The infl ammation hypothesis
More than 20 years ago, immunohistochemical studies showed that 
senile plaques in brain tissue of AD patients contained complement 
activation products.14-16 Akiyama et al.17 reviewed all known amyloid 
associated factors and described them as a heterogeneous group of 
proteins, including complement factors, acute-phase proteins, and 
pro-infl ammatory cytokines. Cerebral Aβ deposits in the brain are the 
consequence of an impaired balance between the production and the 
removal of the Aβ peptide. Despite the elevated amount of Aβ observed in 
the brain of late onset or sporadic AD, no clear increase in Aβ production 
was found. The accumulation of Aβ in the form of plaques in late onset 
or sporadic AD cases was therefore proposed to be caused by ineffi cient 
elimination of Aβ from the brain.18 Removal of Aβ from the brain can 
occur through the actions of proteolytic enzymes that degrade Aβ19-21 
followed by uptake, and subsequent intracellular degradation by glial cells, 
astrocytes and microglia. Impaired removal of Aβ may result in initiation of 
glial cell activation and local infl ammatory responses. This infl ammatory 
response occurs relatively early in the disease process and may lead to 
removal of the initiating agent by activated glial cells, but eventually to 
neurodegeneration. 
Chapter 1
18
Most infl ammation related and also amyloid associated factors normally 
are produced at low levels in the brain, and can be detected in CSF. 
Possible biomarkers for AD are C1q, a part of the fi rst component C1 of 
the classical complement pathway, and the pentraxin Serum Amyloid P 
component (SAP).
2.3.4 Other origins of potential biomarkers 
Methylated arginine
It has been reported that dimethylarginine dimethylaminohydrolase 
(DDAH), an enzyme that hydrolyses asymmetric dimethylarginine (ADMA) 
into citrulline and dimethylamine, is specifi cally elevated in neurons 
displaying cytoskeletal abnormalities and oxidative stress in AD, whereas 
it was undetectable in the neurons of age-matched healthy controls.22,23 
Increased DDAH activity in AD, by lowering ADMA concentrations, could 
lead to increased nitric oxide (NO) production and consequently to NO-
mediated oxidative damage. These changes in DDAH activity may be 
refl ected by altered concentrations of ADMA and its breakdown products 
in CSF of AD patients compared to age-matched control subjects.
Homocysteine and methylation of DNA
Methylation of cytosine bases occurs by DNA methyltransferases 
that require S-adenosylmethionine (SAM) as donor of the methyl 
groups. In this transmethylation reaction SAM is demethylated into 
S-adenosylhomocysteine (SAH) which can be hydrolyzed to yield 
homocysteine.24 Homocysteine can be methylated to methionine by 
transfer of a methyl group from 5-methyltetrahydrofolate in a process 
requiring vitamin B12 and folic acid. The transmethylation cycle is 
completed by the conversion of methionine and ATP into SAM.
Since homocysteine formation from SAH is a reversible process, 
increased homocysteine levels, either in the brain or in the circulation, may 
be associated with accumulation of SAH.25 This is illustrated by the fi nding 
that administration of SAM to neuroblastoma cell cultures downregulates 
both presenilin 1 (PS1) gene expression and Aβ(1-40) production.27
It is conceivable that the transmethylation cycle in the brain of AD 
patients may be altered and that this alteration leads to hypomethylation of 
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the promotor of the PS1 gene, to over-expression of PS1 and to increased 
levels of Aβ peptides.
Homocysteine and white matter hyperintensities
One of the problems encountered is, that pure AD is relatively uncom-
mon. 
In a retrospective clinico/pathological study including 1050 elderly 
demented patients, 62.9% of the cases were clinically diagnosed as 
probable-possible AD, whereas at autopsy, 86% of the cases had AD 
related pathology, of which 43% were pure AD, 23% AD with vascular 
lesions, and 11% AD with Lewy body pathology.28 
Therefore, it can be expected that also most AD and mild cognitive 
impairment cases at advanced age have secondary contributing pathologic 
abnormalities.29 
The involvement of homocysteine metabolism in the development of 
vascular lesions is suggested, because high levels of homocysteine are 
considered to be a risk factor for white matter hyperintensities (WMH), 
also expressed as white matter lesions.3 
Homocysteine is partially metabolised through the transsulfuration 
pathway, in which homocysteine condenses with serine to cystathionine, 
in a vitamin B6-dependent reaction. Thus, vitamin B6 is important in the 
reduction of a potentially toxic excess of homocysteine.25 Low levels of 
vitamin B6 are related to cognitive decline. Although the exact underlying 
mechanism is still unknown, homocysteine might be the link between B6 
levels and the degree of WMH. 
We hypothesized that the development of vascular lesions in the brain 
may be mediated by an increase in homocysteine and we therefore studied 
the relationship between vitamin B6 levels and the presence of WMH on 
MRI in patients with AD.
Homocysteine is also converted into methionine by the transmethylation 
pathway, which requires both folate and vitamin B12. We also therefore 
investigated whether homocysteine metabolism (homocysteine, vitamin 
B12, folate, and vitamin B6) is associated with the occurrence of WMH in 
AD.
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3 Aim of this thesis
In the general introduction, Chapter 1, the role of biochemical markers 
in the diagnosis of AD is described and after reviewing the ‘state of the art’ 
concerning these biomarkers (Chapter 2). The fi rst aim was to introduce 
the commercially available tests for Aβ(1-42), total tau protein, and 
hyperphosphorylated tau protein in CSF (Innogenetics, Gent, Belgium) in 
the Alzheimer Center for routine purposes. We investigated the storage 
and processing conditions of CSF samples, for longitudinal follow-up of 
patients and for research purposes, and we compared the commercial 
Aβ(1-42) test with an “in house” assay that is frequently used in the United 
States (Chapter 3 and 4).
Secondly we investigated some pathophysiological aspects of AD to 
fi nd new biomarkers. Immunohistological studies of senile plaques in 
brain tissue of AD patients show the presence of complement activation 
products and SAP. Possible biomarkers for AD are C1q, a part of the fi rst 
component C1 of the classical complement pathway, and SAP (Chapter 
5).
DDAH is specifi cally elevated in neurons displaying cytoskeletal 
abnormalities in AD patients, whereas it was undetectable in neurons of 
age-matched healthy controls. These change in DDAH activity may be 
refl ected by altered concentrations of ADMA and its breakdown products 
in CSF of AD patients compared to age-matched control subjects. In 
Chapter 6 this was investigated.
AD is characterised by shrinkage of the brain and loss of neurons. Ageing-
related decrease in peroxisomal function may play a role in mammalian 
ageing processes. It is likely that the role of peroxisomes in ageing is a 
result of complex interactions between changes in lipid metabolism and 
oxidative stress. PC, an important constituent of cell membranes, may be 
converted to lyso-PC by oxidation, causing instability and cell loss. We 
hypothesize that oxidation may lead to changed concentrations of PC and 
lyso-PC in the CSF, refl ected in lyso-PC/PC-ratio of AD patients, because 
of the susceptibility of the unsaturated acyl-chains of PC for oxidation 
(Chapter 7).
The transmethylation cycle of homocysteine is important as SAM is 
an important donor of methyl groups. It is conceivable that this cycle in 
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the brain of AD patients may be altered and that this alteration leads to 
hypomethylation of the promotor of the PS1 gene, to overexpression 
of PS1 and to increased levels of Aβ peptides. The concentrations of 
5-MTHF, MMA, SAM, SAH and the SAM/SAH-ratio in CSF of AD patients 
was compared to controls in Chapter 8.
Pure AD is relatively uncommon and co-morbidity of vascular lesions 
is often observed. The involvement of homocysteine in the development 
of vascular lesions, expressed as WMH, is suggested as high levels of 
homocysteine is a risk factor. Vitamin B6 is important in the reduction of a 
potentially toxic excess of homocysteine, by the transsulfuration pathway. 
Homocysteine might be the link between B6 levels and the degree of 
WMH, and therefore, in Chapter 9, we investigated the relation between 
the vascular lesions and vitamin B6 in plasma.
However, homocysteine is also converted into methionine by the 
transmethylation pathway, which requires both folate and vitamin B12. 
We therefore investigated in Chapter 10 whether this homocysteine 
metabolism (homocysteine, vitamin B12, folate, and vitamin B6 in plasma) 
is associated with the occurrence of WMH in AD.
Finally, six years experience with the above-mentioned commercial 
assays, for biochemical diagnosis of AD was evaluated and reported 
in Chapter 11, and the summary and future perspectives are shown in 
Chapter 12.
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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder 
of unknown aetiology, characterized by irreversible cognitive and physical 
deterioration. It is a major cause of morbidity and death in the elderly and a 
growing public health problem as life expec tancy in the general population 
increases. AD is both genetically and phenotypically a heterogeneous 
disorder. An early-onset familial type is recognized, as well as a later onset, 
sporadic type. The diagnosis is made on clinical grounds, with the aid 
of a small number of additional investigations, using consensus criteria.1 
However, at autopsy about 10%-20% of clinically diagnosed AD patients 
are found to have other conditions than AD. Therefore, genetic and/or 
biochemical markers, that support the clinical diagnosis and that can 
distinguish AD from cognitive symptoms attributable to ageing and from 
other dementias will be of great value. The identifi cation of such accurate 
markers for the early diagnosis of AD is mandatory for the development of 
effi cient pharmacological treatment since therapy should be initi ated at an 
early stage of the disease, before extensive and irreversible brain damage 
has occurred.
According to a recent Consensus report2 the ideal biomarker for AD 
should fulfi l the following criteria:
 — detect a fundamental feature of the neuropathology 
 — be validated in neuropathologically confi rmed cases 
 — have a sensitivity >85% for detecting AD 
 — have a specifi city of 75-85% or more for distinguishing AD from other 
causes of dementia
Moreover, a useful biomarker should be precise, reliable and inex-
pensive; it should be convenient to use and not harmful to the patient.
An ideal biomarker would be helpful in confi rming the diagnosis AD in 
epidemiological screening, in predictive testing, in monitoring progression 
and response to treatment, and studying brain-behaviour relationship.
The diagnostic utility of more than 60 substances in serum and 
cerebrospinal fl uid (CSF), such as trace ele ments, metals, neuro-
transmitters, (neuro)peptides, proteins, amino acids, and purines, has 
been reviewed by Basun3 and by van Gool and Bolhuis.4 None of the 
parameters described by these authors appeared to be useful to support 
the diagnosis of AD. 
Genetic and biochemical markers for Alzheimer’s disease: recent developments
27
Here, we review current hypotheses regarding the pathogenic 
mechanisms in AD and subsequently describe new genetic and biochemical 
markers for the disease. 
NEUROPATHOLOGICAL CHARACTERISTICS OF 
ALZHEIMER’S DISEASE
The neuropathological hallmarks of AD are senile (neuritic) plaques 
(SPs) and neu rofi brillary tangles (NFTs). Several types of SPs can be 
distinguished, but all plaques contain extracellular deposits of amyloid-β 
peptide (Aβ) that include abundant amyloid fi brils with non-fi brillar forms. 
Aβ is generated during proteolytic processing of amyloid precursor protein 
(APP) (Figure 1). For that reason, APP and its derivates could provide 
good biologi cal markers. 
NFTs are intraneuronal lesions occurring in large numbers in the AD 
brain. The major components of NFTs are hyperphosphorylated, insoluble 
forms of tau protein, associated with microtubules. The insoluble tau 
aggregates in the NFTs are often conjugated with ubiquitin, a feature 
that is also found in other intraneuronal proteinaceous inclusions in 
aetiologically diverse disorders such as Parkinson’s disease and diffuse 
Lewy-body disease.
Furthermore, apolipoproteins E and J (ApoE and ApoJ), as well as 
glycosylated acetylcholinesterase (AChE), protein S-100, and neuronal 
thread protein (NTP) have been demonstrated in the deposits in AD brain. 
Therefore, measurement of these parameters in CSF or other body fl uids 
as a diagnostic marker for AD would appear promising.
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Figure 1. Post-translational processing of amyloid precursor protein. The 
largest of the known APP alternate splice forms comprises 770 aminoacids. A 
17-residue signal peptide occurs at the N-terminus. Neurons express a more 
abundant 695-residue isoform, missing a 56-aminoacid motif that is homologous 
to the Kunitz-type of serine protease inhibitors. Proteolytic cleavage of APP 
by α-secretase after residue 687 enables secretion of soluble sAPP-α and 
retention of the C83 peptide in the membrane. The latter can undergo cleavage 
by γ-secretase after residues 711 or 713 to release P3 peptides (A). Alternative 
proteolytic cleavage after residue 671 by β-secretase results in the secretion of 
the sAPP-β molecule and the retention of C99 peptide. The latter undergoes 
cleavage by γ-secretase at residues 711 or 713 to release the Aβ1-40 and Aβ1-42 
peptides (B).
 
GENETIC VARIANTS OF ALZHEIMER’S DISEASE
AD is the most common form of dementia in the elderly, affecting 5-10% 
of the population aged over 65 years. It is well known that some Alzheimer 
pati ents have a fam ily history of AD and a genetic predisposition to the 
disease. Estimates of the proportion of genetically based AD cases vary 
widely, but an established AD related gene mutation occurs in less than 
1% of all AD patients. 
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Mutations or polymorphisms in specifi c genes (presenilin-1, presenilin-2 
and APP genes) have been found in early-onset familial AD. In contrast 
to deterministic genetic mutations, genetic factors may modify the risk of 
developing AD. Alleles of ApoE are the most powerful risk factors.
BIOMARKERS
Both genetic and biochemical markers for the different types of AD have 
been described in recent years (Table 1). The utility of these and other 
markers and of the risk factor ApoE genotype will be critically evaluated 
in this review.
Table 1. Summary of useful genetic and biochemical markers for Alzheimer’s 
disease
Early onset, familial type
– Genetic markers
Presenilin-1 gene mutations
amyloid precursor protein gene mutations
presenilin-2 gene mutations
– Biochemical markers
plasma/CSF Aβ1-42 peptide
CSF tau protein
Late-onset sporadic type
– Biochemical markers
CSF Aβ1-42 peptide
CSF tau protein
CSF AD7c-NTP
A β1-42 peptide =amyloid β1-42 peptide; CSF =cerebrospinal fl uid; NTP =neuronal thread 
protein
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Genetic markers
Amyloid precursor protein mutations
It has long been known that AD in certain families can occur in a familial 
form that transmits as an autosomal dominant trait (familial early onset 
AD).
 A major step in understan ding the pathological process leading to AD 
was the disco very that mutations in the APP gene on chromosome 21 
are associ ated with the disease.5-8 This fi n ding is in accordance with the 
observation that individuals with trisomy 21 (Down’s syndrome), with a 
lifelong increase in APP expression, develop Alzheimer encephalo pathy 
by their forties or fi fties. Patients affected by Down syndrome  develop SPs, 
containing amyloid depositions as early as the second and third decade 
of life, which may be the result of an increased gene dosage of APP. In 
1991 a missence mutation in the APP gene was detected in early onset 
AD,6 and one year later a double muta tion at the N-terminal of APP was 
found in an extended Swedish family.5 All eight reported APP missence 
mutations linked to AD result in chronically elevated levels of a specifi c APP 
degradation product, the Aβ1-42 peptide, in the brain. However, mutations 
in the APP gene are rare causes of AD, and only about 25 families have 
been found worldwide.9 Nevertheless, these mutations have proved to be 
highly informative about the pathogenic mechanisms of AD in general. For 
example, transgenetic expression of mutant APP in mice provided the fi rst 
reproducible animal models of AD.10
Presenilin mutations
A genetic linkage was found between early-onset Alzheimer fami-
lies and chromosome 14.11,12 The gene product, prese nilin-1 (PS1), is 
a previously unknown protein of 467 amino acids. To date9,13 at least 35 
different mutations in the conserved domains of the protein have been 
identifi ed in fami lies with early-onset AD and this number is increasing 
rapidly.
Shortly after the discovery of PS1, another gene was identifi ed that 
codes for presenilin-2 (PS2). The DNA sequence, on chro mosome 1, was 
found to be 67% homologous to that encoding for PS1. Until now, two 
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gene mutations of PS2 have been described in AD patients.14,15 Finding 
a mutation especially in the PS1 or APP gene has a high predictive value 
for the development of AD. PS1 and PS2 are homologous, polytopic 
membrane proteins that have so far been localized in the endoplasmic 
reticulum (ER) and in the Golgi apparatus in mammals. They are expressed 
in most cell types, including neurons. The presenilin holoproteins undergo 
endoproteolysis, generating stable N- and C-terminal fragments, that 
associate into higher molecular mass complexes in Golgi-type vesicles.16 
The most clearly identifi ed functions of presenilins are in em bryo nic 
develop ment,17 for the proper formation of the axial skeleton, normal 
neurogenesis and survival of proge nitor cells and neurons in specifi c brain 
subregions.18
Furthermore, PS1 regulates the intramembraneous proteolysis of APP, 
thereby promoting the formation of Aβ.19 Dif fe rent investiga tors have 
found that presenilin mutations increase γ-se cretase cleavage of APP, so 
increa sing the forma tion of the Aβ peptides, particularly Aβ1-42.13,20,21
Tau mutations
The tau gene has so far not been found to be a site of mutations in 
familial AD.
Apolipoprotein E polymorphism
An important chapter in Alzheimer’s disease research concerns the 
role of ApoE isoforms in the disease. ApoE is a plasma protein involved 
in the transport of cholesterol. In the central ner vous system (CNS), ApoE 
is produced by astrocytes and is implicat ed in growth and repair of the 
nervous system during develop ment or after injury. 
The ApoE gene is localised on chromosome 19 and presents three 
alleles (ε2, ε3 and ε4) determining ApoE polymorphism. Pericak-Vance et 
al.22 described evidence for a linkage in late-onset familial AD. Analysis of 
ApoE alle les in AD patients and controls de mon stra ted a highly sig nifi  cant 
association of ApoEε4 and late-onset familial AD .
Approximately 40%-50% of all patients with AD carry the ε4 alle le, 
compared with 15-25% of controls.23,24 Individuals hetero zy gous for ε4 
have a 3 to 4 times increased risk of developing AD and in ε4 homozygo tes 
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there is a six to eight times increased risk. The disease-promoting effect 
of inheriting one or two ε4 alleles seems to involve enhanced aggregation 
and/or decreased clearance of Aβ.25-28
The ε4 allele is a risk factor for, but not an invariant cause of AD. In 
a meta-analysis of 5,930 patients who met the criteria for probable or 
defi nitive AD and 8,607 controls, the ApoE ε4 allele was identifi ed as a 
major risk factor in all ethnic groups studied (Caucasian, Afri can American, 
Hispanic and Japanese), across all ages between 40 and 90 years, and 
equally in men and women.29
To evaluate the usefulness of the ApoE genotype as an adjunct in the 
diagno sis of AD in persons with dementia, the data of clinical diagno ses 
and diagnoses obtained at autopsy in 2,188 patients from 26 AD centers 
in the USA were pooled.30 The clinical criteria for the diagnosis of AD were 
highly sensitive (93%), but the specifi city was low (55%), resulting in a 
high false positive rate. 
By contrast, the sensitivity and specifi city of the ApoE ε4 allele were 
65% and 68%, respectively. Thus, these test characteristics are not 
suffi cient to allow the sole use of ApoE genotyping as a diagnostic test for 
AD, especially not in presymptomatic individuals, but should be reser ved 
for demented patients.31 However, sequential use of the ApoE genotyping 
of patients who fulfi l the clinical criteria for AD signifi cantly improves the 
specifi city of the clinical diagno sis, reducing the false positive rate but also 
decreasing the sensitivity. 
A recently found genetic polymorphism in the transcriptional regulation 
region of ApoE may also be linked with AD risk.32,33
Biochemical markers 
Table 1 summarizes useful biochemical markers.
First we describe the APP metabolism in relation to the working 
hypotheses on the pathological mechanisms in AD, as this information is 
essential in evaluating the different biochemical markers.
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Amyloid precursor protein metabolism
APP is a membrane-bound protein encoded by a gene on chromosome 
21. It comprises a group of ubiquitously expressed polypeptides whose 
heterogeneity arises from both alternative splicing and post-translational 
processing34 (Figure 1). Neurons express an isoform of 695-aminoacid-
residue; non-neuronal cells throughout the body express 751/770 residue 
splice forms. The difference between these forms is the presence of an 
exon encoding for a 56-amino-acid motif, homologous to the Kunitz-type 
of serine protease inhibitors. Functions that have been postulated for 
APP include inhibition of certain serine proteases, enhancement of cell-
substrate adhesion, neurotropic and other growth-promoting effects, and 
neuroprotective properties.
APP is composed of a large extracellular domain at the N-terminal site, 
followed by a trans-membrane domain and an intracellular domain of 47 
amino acid at the C-terminus. 
The biosynthetic pathway of APP begins in the endoplasmatic reticulum 
(ER), as with all membrane proteins.35 A putative role of presenilins is the 
regulation of traf fi cking of APP in the constitutive secretory pathway lea-
ding to full maturati on of the APP-holoprotein in the trans-Golgi network.
Cleavage of the 770-residue after residue 687 by a protease designated 
α-secretase creates a large, soluble fragment (sAPP-α) that is released 
from the cell surface into the lumen of the vesicle and a membrane-retained 
C-terminal fragment of 83 aminoacids (C83) (Figure 1). In most cell types, 
a minority of all APP molecules undergoes α-secretase cleavage. An 
alternative cleavage by β- and γ-secretases leads to Aβ formation (Aβ1-40 
and Aβ1-42). The proteolytic action of β-secretase on APP is essential for 
the generation of Aβ peptides. Recently β-secretase has been defi nitively 
identifi ed by several groups.36 Beta-secretase is identical to β-site APP-
cleaving enzyme (BACE), also known as Asp-2. Most Aβ is extracellular 
and only small amounts can be detected inside the cell. Aβ can be detected 
in plasma and CSF of humans and other mammals. Normally, the majority 
of Aβ released is Aβ1-40. Only about 10% of Aβ extends to amino acid 42, 
Aβ1-42.9,37 The routing of APP through these pathways is under the control 
of phosphorylation, in particular by protein kinase C, a mechanism that is 
defective in sporadic AD fi broblasts. 
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The Aβ1-42 peptide, aggregates far more rapidly into amyloid fi brils than 
does Aβ1-40 peptide.
Finally, the endosomal-lysosomal pathway is activated for the 
degradation of the C-terminal fragment left over by secretase processing 
and for the degradation of the full-length APP molecules recycling from 
the cell surface or derived direct ly from the biosynthetic pathway.
Working hypotheses on AD pathological mechanisms 
The relationship between the observed lesions in the brain and the AD 
disease process has long been debated. Two broad hypotheses about the 
mechanism have emerged,9,10,35 the amyloid cascade hypothesis and the 
infl ammatory and neurotoxic cascade hypothesis. According to the amyloid 
cascade hypothesis both familial and sporadic variants of AD are caused 
by amyloid accumulation, especially Aβ1-42, in the brain. Overproduction 
of Aβ1-42 or failure to clear this peptide leads to AD, primarily through 
amyloid deposition associated with cell death. Indeed, crossing mice 
transgenic for mutant APP with mice expressing a PS1 mutation results in 
a substantially accelerated AD-like phenotype with AD-like Aβ1-42 plaques 
occurring early in life.38 Moreover, the ability of presenilin mutations 
to selectively enhance Aβ1-42 deposition in the brain has been directly 
demonstrated in AD patients carrying these mutations.39,40 Evidence has 
recently emerged to support a direct involvement of presenilins in the 
γ-secretase cleavage of APP.41
According to the infl ammatory and neurotoxic cascade theory, Aβ1-
42 accumulation and diffuse plaque formation is associated with local 
microglial activation, cytokine release, reactive astrocytosis and a multi-
protein infl ammatory response,42-44 including the binding of the C1q 
component of the classical complement cascade by Aβ and the triggering 
of this cascade. There is evidence that this Aβ initiated infl ammatory and 
neurotoxic process, includes excessive generation of free radicals and 
peroxidative injury to protein and other macromolecules in neurons.45,46 
Moreover, altered ionic homeostasis, in particular excessive calcium entry 
into neurons, may result in neuronal dysfunction and cell death.47-49
It is possible that Aβ accumulation triggers the hyperphosphorylation of 
tau protein which precedes the assembly of these molecules into fi laments.
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 In a recent study Schenk et al.50 found that, in a mouse model of AD, 
immunization with Aβ inhibits the formation of SPs and the associated 
dystrophic neurites, underlining the central role of Aβ in developing AD. 
These results raise the possibility of future vaccination against human AD.
Amyloid precursor protein and metabolites
The discovery of disease-causing muta tions in the APP gene has fi rmly 
established a key role for APP and Aβ in the pathogenesis of AD. Therefore, 
it seems reasonable to detect and quantitate APP and its metabolites in 
plasma, serum or CSF and determine whether chan ges in concentrations 
occur during development of AD.51
Amyloid precursor protein 
Since APP is a membrane bound protein, assays for APP in CSF 
measure the soluble or secreted derivate, generated by α/β-secretase 
cleavage. Henriksson et al.52 reported markedly lower concentrations of 
APP in lumbar CSF of patients with AD compared with healthy controls, 
whereas ventricular CSF did not show any difference. Other studies did 
not discriminate in the site of collection of the CSF sample. In AD patients, 
substantially lower APP concentra tions were found in some studies, while 
other studies showed relatively small reductions.37,53-55 CSF APP does 
not seem to be a reliable biomarker for AD. 
Amyloid-β peptide 
The central pathological event in Alzheimer’s disease is the deposition 
of Aβ as amyloid fi brils within the SPs and cere bral blood vessels. It has 
been shown that Aβ is a normal component of plasma and CSF.56
Another study57 ident ifi ed soluble Aβ forms of 4kD, 3kD, and 3.7kD in 
AD brains but not in control brains free of amyloid depo sits. This indi cates 
that, in healthy brain, Aβ is normally removed or bound to other prot eins. 
Fail ure of this protective mechanism might cause amyloid formation and 
deposition in AD. 
There is no signifi cant dif ference in CSF total Aβ peptide concentrations 
between AD patients, healthy con trols and neurological controls; and 
therefore measuring total Aβ (Aβ1-40 + Aβ1-42) has no clear diagnostic 
utility. 37,58-60 However, Nitch et al.61 as well as Hock et al.37 showed 
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that CSF Aβ levels were inversely correlated with a functional measure of 
dementia severity, indicating that determination of CSF-Aβ can be used to 
monitor the course of the disease in an individual patient.
Aβ(1-40); Aβ(1-42) peptides 
 — In the cortex of two familial AD patients with an APP mutation a 
remark able predominance of Aβ1-42-positive over Aβ1-40-negative 
plaques was found.62 Diffuse plaques, representing the earliest 
stage of Aβ deposit ion, were exclusively positive for Aβ1-42, but com-
pletely negative for Aβ1-40. During the disease, also aggre gation of 
the more sol uble Aβ1-40 into fi brils can occur.63
 — As shown in Table 2, several studies64-69 have reported no difference 
in the CSF Aβ1-40 concentration between AD patients, healthy 
controls and neurological con trols. However, decreased levels of 
Aβ1-40 were reported in early- and mid-stage AD.66 
In contrast, many studies have shown that concentrations of CSF Aβ1-42 
are signifi cantly redu ced in patients with AD compared with age-matched 
normal subjects or patients with neurological disease. 
Presumably, concentrations of soluble Aβ1-42 concentration in brain 
interstitial fl uid decrease as the peptide becomes increasingly insoluble 
and forms deposits in the form of large numbers of diffuse and senile 
plaques. The drop in soluble Aβ1-42 in brain is refl ected by a decline in the 
concentration of soluble peptide in CSF. CSF Aβ1-42 seems to be a good 
biomarker for AD.
 — In a limited number of studies the mean concentration of plasma 
Aβ1-42 was reported to be consistently and signi fi cantly increased in 
subjects with each type of mutated gene known to be related with 
early-onset familial AD in comparison with age-matched controls.13 
However, the mean plasma Aβ1-42 concentration was not increased 
in subjects with late-onset sporadic AD. Insuffi cient data about 
plasma Aβ1-42 do not allow any fi rm conclusion about the potential 
diagnostic utility of measuring plasma Aβ1-42 in late-onset AD.
 — Studies are in progress on the diagnostic utility of detecting Aβ 
peptides in human urine, but no clear conclusion is available as yet.
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Tau-protein
Tau protein is a human brain phosphoprotein that binds to microtubules 
in the neuronal axons, thereby promoting micro tubule assembly and 
stability. Multiple tau isoforms are produced from a single gene through 
alternative mRNA-splicing. In adult human brain six isoforms are found, 
ranging from 352 to 441 amino acids. 
The NFTs found in brains of AD patients are neuronal inclusions 
consisting of paired helical fi laments (PHF), of which the main protein 
com ponents are the six hyperphosphorylated tau proteins. The increased 
phosphorylation causes lack of binding to microtubules and is believed to 
be responsible for self-assemble into the PHF. Current evidence suggests 
that protein kinases or protein phosphatases are involved in the abnormal 
hyperphosphorylation of tau.70
It has been demonstrated that CSF tau levels increase in the early 
stage of AD,71-74 with the highest concentrations found in the mid-stage 
of the disease.75 These results suggest that increases in tau can be 
detected even in patients with very mild impairment and short duration of 
the symptoms. It is unclear whe ther the eleva tion of CSF tau is a result of 
dying neurons, dystrop hic neuri tes, or the generation of NFTs. 
Using enzyme-linked immunosorbant assays (ELISAs), several studies 
have shown that the concentrations of CSF tau are signifi cantly elevated 
in AD patients compared with normal elderly control subjects (Table 3). 
However, elevated levels of CSF tau were also detected in patients with 
other dementias and acute or chronic neurological diseases.79,83-89
Therefore, the value of the CSF tau in discriminating AD from other 
neurological diseases may be limited. In addition to its potential as a 
diagnostic aid, simultaneous measurement of Aβ1-42 and tau in the same 
CSF sample, may become useful as predictor of the progression to AD in 
individuals with memory impairment who do not meet clinical criteria for 
dementia. Detecting elevated concentrations of tau in CSF is a promising 
ante-mortem marker for AD, and might possibly be useful for monitoring 
progression of disease and response to treatment.2
The development of assays incorporating more specifi c anti-tau 
antibodies can distinguish normally and abnormally phosphorylated tau 
may enhance the discriminative power of such assays.90,91
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Table 3. Cerebrospinal fl uid tau protein concentrations of Alzheimer’s disease 
(AD) patients, healthy controls, and controls with neurological diseases (NC) or 
non-Alzheimer-type dementia (DNAT) as reported in different studies.
Ref AD n Controls n NC/DNAT N
76   10.9 (4.9) 27   0.1 (0.5) 51   3.9 (7.4) 129
35  361 (166) 71 190 (80) 26   235 (104)  25
77 1430(739) 24 816 (355) 14   790 (579)  26
64   407 (241) 37 212 (102) 20   168 (63)  32
71 509 (255) 36 177 (82) 14   163 (58)  19
78  820 (90) 14 380 (120) 36 < 600  12
79   77.2 (45.5) 70   9.0 (4.5) 19    27.8 (38.7) 106
80  722 (76) 39 173 (12) 30   320 (40)  12
81  279 (100) 23  26 (11) 36    88 (61)  23
82  251 (36) 31  51 (7) 30   126 (104)  39
72  524 (351) 81 293 (140) 33   403 (248)  40
67  489 (298) 93 217 (128) 41   220 (113)  89
83  796 (382) 43 190 (157) 18   357 (193)  18
Results are given in ng/L and expressed as mean (standard deviation). n =number of 
patients.
Neuronal Thread Protein
Neuronal thread proteins (NTPs) are a family of molecules that are 
expressed in brain, and are immunologically related to pancreatic 
thread protein. They are normally present in neurons and are found 
in large amounts in association with NFTs.92 There are at least 6 NTP 
immunoreactive species. Increased CNS expression of a 41 kDa NTP 
is correlated with dementia in AD.93 The gene coding for this NTP has 
been cloned and sequenced, and the protein (produced by recombinant 
techniques) has been used to generate both monoclonal and polyclonal 
antibodies to NTP (AD7C-NTP). Ghanbari and Ghanbari94 developed an 
ELISA with a monoclonal antibody as catcher and polyclonal antibodies 
for detection. 
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In post-mortem CSF, the mean concentration of AD7C-NTP in cases of 
confi rmed AD (n =121) was higher than in 19 age-matched control cases. 
In CSF from individuals with early possible or probable AD (n =89), AD7C-
NTP was also elevated in comparison to the concentrations in CSF from 
18 age-matched controls. The concentrations in AD patients were also 
elevated in comparison to controls with other neurological diseases (n 
=41; specifi city =98%) and ambulant patients with Parkinson’s disease (n 
=32; specifi city =84%).95 Therefore, NTP in CSF appears to be a promising 
marker for the diagnosis of AD (Table 1). Additional studies are required to 
establish the exact sensitivity and specifi city of this marker.
Apolipoprotein E
Since ApoE is associated with Aβ in SPs, several groups have 
measured ApoE in CSF, in addition to ApoE genotyping.96 Plasma 
ApoE seems to have limited ability to cross the blood-brain bar rier and 
ApoE in CSF is essentially derived from the brain. Therefore, the CSF 
concentration may refl ect cerebral ApoE produc tion. ApoE is known to 
have a general function in brain repair. After injury, ApoE is produced and 
secre ted by as trocytes, to scavenge cholesterol and other membrane 
lipids from degenerating axons and myelin sheets. At the time of sprouting 
and remyelinization, neuronal growth cones take up and re-use the lipids 
in membrane and myelin synthesis. This process of membrane lipid re-
utilization may be an important repair mechanism in various degenerative 
brain disorders, and impairment of this mechanism might contribute to an 
earlier presentation of degenerative disorders. Increased re-utilization of 
ApoE-lipid complexes in the brain may explain the lower concentration of 
CSF ApoE in AD.97 However, ApoE has also been found to bind to Aβ in 
vitro, and to be adsorbed onto the Aβ deposits in SPs.98 Moreover, ApoE 
binds tau protein, the principal component of NFTs. Yamada et al.99 found 
increased mRNA levels encoding for ApoE in AD brain, which suggests 
increased ApoE production.
Various studies reported signifi cantly reduced CSF ApoE concentra-
tions in AD pa tients, compared with healthy controls, irrespective of the 
ApoE genotype. However, other investigators found no differen ce or a 
signifi cant increase.97,100-105 The control patients with neurological 
disease generally demonstrated similar concentrations to those of the AD 
patients, thus limiting the usefulness of ApoE quantifi cation.
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Melanotransferrin
In several neurodegenerative diseases, including AD and Parkinson’s 
disease, large quantities of iron are deposited in high quan tities in the CNS. 
Iron depositions can directly harm tissues by catalyzing the generation of 
oxygen radicals. Jefferies et al.106 have identifi ed a novel pathway of iron 
uptake into mammalian cells, independent of the transferrin receptor. The 
melanotransferrin molecule, also known as p97 protein, is  essential for this 
pathway. In brain tissue derived from AD patients, melanotransferrin was 
detected in a subset of reactive microglia associated with SPs, indicating 
that the iron uptake through this alter native pathway plays a role in AD.
Kennard et al.107 have demonstrated that p97 concentrations [mean 
(standard deviation)] are consistently elevated in the serum of AD patients 
[43.8 (11.6) ng/ml; n =17], compared with controls [7.0 (3.3) ng/ml; n =15]. 
There was no over lap between the groups, and the correlation between  age 
and p97 serum concentration was not signifi cant. However, a signifi cant 
correlation was found between disease progression and increased p97 
serum concentrations. Extra polation of these data suggests that the p97 
concentration may begin to increase about two years before the fi rst 
clinical symptoms of AD. Quantitation of melanotransferrin in serum is a 
promising candidate as biomarker for AD.
Apolipoprotein J
ApoJ (clusterin) is a lipoprotein present in most, if not all, physiological 
fl uids, in particular in plasma and CSF.108-110 In normal CSF, ApoJ 
appears to be complexed with Aβ,111 in particular with Aβ1-40. Using a well-
characteri zed in situ perfused guinea pig brain-model it was demonstrated 
that ApoJ may faci litate receptor mediated transport of Aβ1-40-ApoJ 
complexes across the blood-brain barrier and the blood-CSF barrier.112
ApoJ is overexpressed in res ponse to neuronal inju ry. Avai lable 
information supports the view that its basic function is main tenance of 
membrane integrity in an environ ment that exposes cells to membrane-
desta bili zing fac tors, that occur normally or are generated in abnor mal, 
degene rative situa ti ons.109 ApoE and ApoJ may have com ple men tary 
func ti ons in lipid homeos tasis during CNS degene ra tion and synaptic 
remodel ling. Howe ver, the roles may be oppo site with respect to Aβ 
deposi tions in SPs, in which ApoE ac ts as a pathological chaperone, 
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where as ApoJ would be func ti oning as a physiological chaperon of Aβ.113 
ApoJ concentrations in the hippo campus of AD sub jects were 60% higher 
(p<0.001) than in non-demen ted controls.114 In post-mortem human 
brains ApoJ concentrations have been shown to be about 40% higher in 
AD patients than in con trols.115 
As elevation of ApoJ may be indicative of tissue injury, it will be important 
to measure its concentrations in CSF. To date, no method for measuring 
ApoJ in CSF has been published, but Jenkins et al.110 presented a 
competitive ELISA for plasma ApoJ. It might be possible to modify this 
method for quantitation of ApoJ in CSF.
S-100 protein
S-100 is located in the cytoplasm and nuclei of cells, that express it 
as well as in synaptosomes and synaptic membranes. S-100 is a dimer 
comprising two separate subunits, α and β. The subunit S-100-β has been 
implicated in development and maintenance of the nervous system and 
may also play a role in neuro pathology because of its specifi c localization 
and selective overexpression in AD.
CSF concentrations of S-100 protein in AD, and also in patients with 
frontotemporal dementia and other non-neurological conditions, were 
found to be signifi cantly increased, compared with healthy controls,116 
pointing to a lack of specifi city of S-100. Nevertheless, further studies on 
the value of serum and CSF S-100 concentrations in the diagnosis of AD 
seem to be justifi ed.
Glycosylated Acetylcholinesterase
There is no consistent change in acetylcholi nesterase (AChE) activity 
in CSF of AD patients, and the large overlap with con trols pre vents the 
use of AChE as a dia gnostic marker for AD. 
As AChE in the AD brain is highly glycosylated, the hydrophobic 
property of anomalous AChE may serve as a seed of amyloid fi brils in 
senile plaques.117 Lectin-binding analysis of CSF AChE of AD patients 
showed a signifi cant difference in glycolysation (p<0.01), compared with 
controls. Preliminary results suggest that glycosylated CSF AChE may 
be a diagnostic marker for AD, with a sensitivity as high as 80% and a 
specifi city of 97%.118 
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Combination of markers
The ApoE genotype does not infl uence CSF total Aβ concentration, as 
similar values of CSF Aβ are found in AD patients with ApoE ε3/3, ε3/4, 
and ε4/4 alle les.61 However, Galasko et al.68 demonstrated a negative 
correlation between CSF-Aβ1-42 levels and the number of ApoE ε4 alleles. 
It has been reported79 that increased concentrations of CSF tau protein 
are independent of the ApoE genotype, as well as age of disease onset, 
and clinical stage. However, in other studies,119,120 CSF tau concentration 
was found to be related to ApoE genotype. AD patients carrying the ApoE 
ε4 allele demonstrated higher CSF tau concentrations than AD patients 
without the ε4 allele, and the highest value of CSF tau was found in 
patients with two ε4 alleles. The ApoE genotype should be considered in 
inter preting CSF tau concentrations.Determination of the ApoE genotype 
can incre ase the specifi city and sensitivity of the clinical diagnosis. 
Combined analysis of Aβ1-42 and tau in CSF64 is interesting. In a plot of 
tau versus Aβ1-42, the high tau/low Aβ1-42 quadrant was highly predictive 
for AD, whereas the low tau/high Aβ1-42 quadrant contained control 
individuals only. It was found that patients with low CSF Aβ1-42 and high 
CSF tau have a strong likelihood of having AD (22/23 =96%). Conversely, 
patients who exhibit low tau and elevated Aβ1-42 were free of AD (28/28 
=100%).
These results have been reproduced by Mulder et al. (unpublished 
data). Eighteen controls (18/20) and no patients (0/20) scored low tau/high 
Aβ1-42, and one control as well as eighteen AD patients showed high tau/
low Aβ1-42 values. Similar results were obtained in a Japanese multicentre 
study,67 and the sensitivity improved in a longitudinal evaluation.
Galasko et al.68 studied 82 patients with probable AD, including 
24 with very mild dementia [Mini-Mental State Examination (MMSE) 
score > 23/30)], 60 normal elderly control subjects, and 74 subjects 
with neurological disorders. High CSF tau and low CSF Aβ1-42 levels 
discriminated AD patients from elderly controls. However, in subjects in 
the neurological control group with a CSF-profi le suggesting AD, follow-up 
at autopsy would be required to decide whether the CSF results are false 
positives, or whether AD is the primary or concomitant cause of dementia. 
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The multicentre study of Hulstaert et al.69 also confi rmed the value of a 
combined determination of markers. 
We conclude, that the combined analyses of CSF Aβ1-42 and CSF 
tau can discriminate AD patients from normal elderly control subjects, 
supporting the use of these parameters to distinguish early AD from aging. 
To discriminate AD from other forms of dementia, especially vascular 
and frontotemporal dementia, studies are needed to develop more 
sensitive methods for current and potential markers.
Other potential markers 
AD involves profound biochemical and molecular alterati ons in the 
CNS. Increased phosphory lation of tau and other cytoskele tal proteins 
has been demonstrated in neu rons,121 as well as aberrant expression of 
genes modulated with neuritic sprou ting such as the growth associated 
protein, GAP-43,122 consti tutive endothelial nitric oxide synthase,123 
transforming growth fac tor β,124 and metal lothionine-3.125 An increa-
sed expression of genes associated with glial cell acti vation, such as 
glial fi brillary acidic protein,126 and α1- antichymotrypsin127 is also found. 
Moreover, there are alterations in ex pres sion of genes coding for proteins 
protecting neurons from either cytotoxic or program med cell death, inclu-
ding gly copro tein-2,128 ca thep sin D,129 superoxi de dis mutase 1,130 mito-
chondrial cyto chro me oxidase,131 C1q com ponent of com ple ment,132 
Calbin din D28k,133 and Bcl-2.134 
Advanced glycation end products (AGEs) may play an important role 
in the pathogenesis of AD. These are mainly found in NFTs and in about 
5% of the SPs. However, SPs and NFTs were also AGE-positive in non-
Alzheimer neurodegenerative diseases.135 All these alterations in CNS 
may lead to chan ges in CSF concentrations of AGEs.
Another recent fi nding is the presence of molecular misreading mutant 
forms of APP and ubiquitin in SPs and NFTs in AD brains.136 In this study 
mutant APP was detected in 15/21 AD pa tients, while aberrant ubiquitin 
was present in all patients. CSF ubiquitin is largely of intrathecal origin, 
which indicates that mutant ubiquitin may also be present in CSF and 
might be a potential sensitive biomarker for AD.137 
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CONCLUSIONS
Our present knowledge of the aetiology of AD mainly focuses on the 
amyloid cascade hypothesis. The genetic and the sporadic variant may 
have a common pathophysiology, where disturbances in APP metabolism 
occur as an early event.
Genetic markers such as PS1, PS2 and APP have been found to 
be reliable markers in diagnosing familial AD. A large polymorphism in 
the gene encoding for α2-macroglobulin has been associated with an 
increased risk for late-onset AD.138 
It can be predicted that, within a decade, a sizeable number of additional 
genes will be implicated, most of them probably acting as polymorphic 
risk factors in some populations.10 There is consensus, that searching for 
PS1, PS2 and APP genetic markers should be limited to probands and 
families with a pattern of early onset AD, in a strict research setting.
Concentrations of CSF Aβ1-42 are signifi cantly reduced in pa tients with 
familial AD in comparison to controls with neurological disease and normal 
subjects. In sporadic AD, signifi cantly decreased levels of CSF Aβ1-42 are 
found in many patients, but there is some overlap with the control groups. 
Measuring levels of CSF Aβ1-42 in conjunction with other parameters, 
particularly CSF tau pro tein and ApoE genotype, could be potenti ally 
useful for supporting early diagnosis of AD. Commercial kits are available 
for quantifi cation of tau protein and Aβ1-42 as well as determination of the 
ApoE genotype.
AD7C-NTP is elevated in CSF samples from individuals with early 
possible or probable AD, in comparison to the CSF concentrations of age-
matched controls. The levels in AD patients were higher than those in the 
controls with neurological disease and ambulant patients with Parkinson’s 
disease. Therefore, CSF AD7C-NTP appears to be a promising marker for 
the diagnosis of AD. However, additional studies are required to confi rm 
the sensitivity and specifi city of this test.
ApoE genotyping might be reserved for patients who meet the clinical 
criteria for AD, as the ApoE geno type in those patients can sig nifi  cantly 
improve the specifi  city of the clinical diagno sis, reducing the false posi tive 
rate but also decreasing the sensi tivity. 
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Serum melanotransferrin concentrations and CSF glycolysated AChE 
are elevated in AD patients. Preliminary studies of these markers seems 
promising, but further work is necessary.
Age-related increase in CSF S-100 concentration might be important in 
the pathogenesis of AD. However, increased concentrations of S-100 are 
also found in the CSF of patients with frontotemporal dementia or following 
cardiac operations or head trauma, stressing the lack of specifi city of this 
marker.
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ABSTRACT 
Background: Reported concentrations of amyloid β (1-42) (Aβ42) and 
tau in cerebrospinal fl uid (CSF) differ among reports. We investigated 
the effects of storage temperature, repeated freeze/thaw cycles and 
centrifugation on concentration of Aβ42 and tau in CSF.
Methods: Stability of samples stored at -80°C was determined by use 
of an accelerated stability testing protocol according to the Arrhenius 
equation. Aβ42 and tau concentrations were measured in CSF samples 
stored at 4, 18, 37, and -80°C. Relative CSF concentrations (%) of the 
biomarkers after one freeze/thaw cycle were compared with those after 
two, three, four, fi ve, and six freeze/thaw cycles. In addition, relative Aβ42 
and tau concentrations in samples not centrifuged were compared with 
samples centrifuged after 1, 4, 48, and 72 h. 
Results: Aβ42 and tau concentrations were stable in CSF when stored 
for a long period at -80°C. CSF Aβ42 decreased by 20% during the fi rst 
2 days at 4, 18 and 37°C compared with -80°C. CSF tau decreased 
after storage for 12 days at 37°C. After three freeze/thaw cycles, CSF 
Aβ42 decreased 20%. CSF tau was stable during six freeze/thaw cycles. 
Centrifugation did not infl uence the biomarker concentrations.
Conclusions: Repeated freeze/thaw cycles and storage at 4, 18 and 
37°C infl uence the quantitative result of the Aβ42 test. Preferably, samples 
should be stored at -80°C immediately after collection.
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INTRODUCTION
In the last decade many studies have been set out to fi nd an appropriate 
biochemical marker for the diagnosis of Alzheimer’s disease (AD). Several 
authors have shown that the sensitivity and specifi city of amyloid β (1-42) 
( Aβ42) and total tau in cerebrospinal fl uid (CSF) are high when comparing 
AD patients with controls.1,2 However, when comparing AD with other 
types of dementia,3 overlap occurs, hampering clinical utility. Ideally, the 
diagnostic value of biomarkers needs to be validated in neuropathologically 
confi rmed cases, but most studies use clinical criteria as the reference 
standard, with the risk of circular reasoning. Furthermore, the use of 
markers in clinical practice still needs to be established, as most studies 
have been carried out in research settings with selected patient samples.4 
A recent metaanalysis5 demonstrated considerable variability in 
absolute concentrations of both markers among centers, even when using 
the same commercial assay. This variability could also be attributable 
to differences in patients or to a difference in processing and storage 
methods among centers. 
Few published studies have investigated which factors produce a major 
infl uence on the quantitative outcome of the INNOTESTTM β-amyloid (1-
42) ELISA.6,7 An important confounding factor is the tendency of both 
Aβ42 and tau to adhere to glass or hard plastic tubes,4 reducing the 
concentration. Furthermore, repeated freeze/thaw cycles seem to play 
a role in the decrease of CSF Aβ42, although different methods have 
been used to investigate this phenomenon. One study6 showed a large 
decrease of CSF Aβ42 between the fi rst and second freeze/thaw cycle, 
whereas no difference was found between Aβ42 concentrations in fresh 
CSF and CSF that had been frozen and thawed once.7 No studies have 
been published regarding the stability of both Aβ42 and tau in CSF when 
stored frozen at -20 or -80°C for many years. Knowing sample stability at 
freezing temperatures is especially important for longitudinal studies in 
which samples are stored for long periods and analyzed simultaneously 
with samples stored for short periods to minimize interassay variability.
 In this study, we sought to answer the following questions: What are 
the stabilities of Aβ42 and tau in CSF samples stored at -80°C for several 
years? What are the stabilities of Aβ42 and tau in samples stored at 4, 
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18 (room temperature), and 37°C up to 3 weeks, (to investigate the effect 
of mailing)? What is the effect of repeated freeze/thaw cycles on Aβ42 
and tau concentrations in CSF? What is the effect of centrifugation? 
Awareness of preanalytical factors that may infl uence the concentrations 
of the markers could improve collaboration with other neurologic research 
centers or memory clinics and provide more reliable results. Our fi nal aim 
was to formulate standardized conditions, which will be crucial when the 
use of Aβ42 and tau becomes standard practice for the (early) diagnosis 
of AD. 
MATERIALS AND METHODS
Participants
Twenty-three individuals provided CSF for the entire study: 3 AD 
patients, 5 patients with mild cognitive impairment (MCI), 5 patients with 
frontotemporal lobar degeneration (FTLD), 1 patient with mixed-type 
dementia (MD), and 9 controls with no dementia. All subjects gave informed 
consent to participate in the study. Four subjects entered the accelerated 
stability testing protocol. For the analysis of tau in this experiment, one 
sample was excluded, because the results were higher than the values 
for the highest callibrator. Two of the four individuals whose CSF was 
used in the accelerated stability testing protocol also participated in the 
freeze/thaw experiment. In addition, 13 other individuals provided CSF for 
the freeze/thaw experiments: 5 for the comparison of unfrozen CSF with 
CSF frozen/thawed once, plus 8 for the comparison of samples frozen 
and thawed once with samples subjected to several freeze/thaw cycles. 
Six individuals provided CSF for the centrifugation experiment, including 
one who provided an additional hemolytic CSF specimen, which was not 
centrifuged and was compared with the baseline specimen.
Lumbar puncture
CSF was obtained by lumbar puncture in the L3/L4 or L4/L5 
intervertebral space, using a 25 gauge needle, and was collected in 12-
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mL polypropylene tubes. A small amount of CSF was used for routine 
analysis, including total cells, total protein, and erythrocytes. Therefore, 
CSF samples were centrifuged as soon as possible (with a maximum 
of 2 h after collection) at 2100g for 10 min at 4°C. CSF samples were 
kept at room temperature until centrifugation. After centrifugation, CSF 
was pipetted into polypropylene tubes, in 0.11-, 0.2-, or 0.5-mL aliquots, 
depending on the experiment for which the CSF was to be used. 
Accelerared stability testing protocol
To study the stability at -80°C we used an accelerated stability testing 
protocol based on the principle of the Arrhenius equation,8 which describes 
a linear relationship between the logarithm of the reaction rate constant 
(e.g., the degradation rate) and the inverse of the absolute temperature. 
We used the result from samples stored at three temperatures 4, 18 and 
37°C to calculate the rate constant. 
The principle and calculations for this protocol applying the Arrhenius 
method are given in the Appendix at the end of this article. 
Participants
Two patients and two controls participated in the accelerated stability 
experiment. One patient was a 73 year-old man with MD, and the other a 
54 year-old female with probable AD according to the clinical criteria.9 The 
controls were two spouses, without dementia, of patients: a 77 year-old 
man and 58 year-old female.
Samples
After centrifugation, samples were divided into 0.5- and 0.2-mL 
aliquots. The 0.5-mL aliquot from each patient was stored immediately 
at -80°C (193 K), to determine the baseline values for Aβ42 and tau. The 
other thirty 0.2-mL aliquots from each patient were stored at 4°C (277 
K), room temperature 18°C (291 K) and 37°C (310 K), 10 tubes at each 
temperature. After 1, 2, and 3 days and up to 22 days, one tube stored 
at each of the three different temperatures was removed and frozen at 
-80°C until analysis. All 30 samples from each patient were thawed and 
analyzed, in duplicate, simultaneously in one run. 
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Freeze/thaw cycles
To compare unfrozen CSF with CSF frozen/thawed once, we stored, 
in polypropylene tubes two 0.2-mL aliquots of CSF from fi ve individuals 
(three with MCI and two FTLD) for 2 days at 4 or -80°C until analysis. The 
concentrations of Aβ42 and tau in the aliquots that has not been frozen 
and thawed (stored at 4°C) were compared with the concentrations in the 
aliquots that have been thawed once (stored at -80°C). All aliquots were 
tested in duplicate.
Because most samples are stored at -80°C until analysis, the best way 
to simulate daily practice is to compare samples subjected to one freeze/
thaw cycle with samples that have undergone several freeze/thaw cycles. 
Therefore, CSF from 10 individuals (1 patient with MD, 3 patients with 
FTLD, 1 patient with MCI, and 5 controls without dementia) was centrifuged 
and aliquoted into six 0.11-mL portions. One tube from each patient was 
kept at -80°C until analysis and the concentrations of Aβ42 and tau in this 
aliquot were used as baseline value (100%). The other fi ve tubes from 
each patient were stored at -80°C and thawed two, three, four, fi ve, or six 
times at room temperature for 2 h and stored again at -80°C until analysis. 
The relative Aβ42 and tau concentrations (%) in the samples from the 
10 patients were compared with the baseline value (100%) and plotted 
against the number of freezing/thaw cycles. 
Infl uence of time to centrifugation
CSF of fi ve patients (two with AD, one with MCI, and two controls 
without dementia) was aliquoted into fi ve 0.5-mL polypropylene tubes. 
Tube 1 was centrifuged at 2100g for 10 min at 4°C within 2 hours after 
CSF collection and then stored immediately at -80°C. The concentrations 
of Aβ42 and tau measured in tube 1 were used as baseline value. Tubes 
2, 3, and 4 were stored at 4°C and centrifuged after 4, 48 and 72 hours. 
After centrifugation, the supernatant was pipetted into polypropylene 
tubes and stored frozen for a maximum of up to 1 month until analysis. 
Tubes 5 were not centrifuged at all and was kept for 4 days at 4°C before 
storage at freezing temperature. Relative Aβ42 and tau concentrations 
(%) in samples not centrifuged were compared with those in samples 
centrifuged after 1, 4, 48, and 72 h. In addition, we compared a hemolytic 
CSF sample (28 800 erythrocytes/mL, which is equivalent to 0~0.5% 
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whole blood contamination), obtained after a traumatic lumbar puncture 
from a patient with MCI, that has not centrifuged but has been stored at 
-80°C, with a sample from the same patient centrifuged within 2 h and 
stored at 4°C until analysis.
Analysis of Aβ42 and tau
Aβ42 concentrations for all experiments were determined with the 
INNOTEST β-amyloid (1-42) sandwich ELISA (Innogenetics). Monoclonal 
antibody 21F12, which is highly specifi c for the COOH terminus of the 
Aβ42 peptide, was used as capturing antibody, and the biotinylated 
monoclonal antibody 3D6, specifi c for the NH2 terminus, was used as 
detector antibody.6 For tau quantifi cation we used the INNOTESTTM hTau 
Antigen sandwich ELISA (Innogenetics) which is constructed to measure 
both total tau and phosphorylated tau with monoclonal antibody AT120 as 
capturing antibody and HT7 and BT2 as detection antibodies.10 For the 
stability experiment, performed at Innogenetics, the mean intra-assay CVs 
were calculated from the differences between duplicate measurements. 
The mean CVs for Aβ42 were 6.2% at Aβ42 concentrations ≤ 500 ng/L 
(N=61) and 7.2% at Aβ42 concentrations > 500 ng/L (N=59). For tau, the 
mean intraassay CVs were 8.7% at tau concentrations ≤ 300 ng/L, N=61) 
and 13% at tau concentrations > 300 ng/L (N=26). The mean CVs at the 
VU Medical Center laboratory were calculated based on the SD for the 
difference between duplicate measurements (SD x 100/mean) of a total 
of 60 routine samples. For Aβ42, mean CV was 4.0% at concentrations in 
the low range (125-300 ng/L), 2.9% at concentrations in the middle range 
(600-800 ng/L), and 3.4% at concentrations in the high range (1000-2000 
ng/L). For tau the CVs were 6.5% at low concentrations (75-200 ng/L), 
4.7% at concentrations in the middle range (500-700 ng/L) and 4.6% at a 
concentrations in the high range (900-1200 ng/L). The mean interassay 
CVs for three different pools, evaluated in advance and tested in the 
stability, centrifugation and freeze/thaw experiments, were 12.1% for Aβ42 
(N=7) and 8.1% for tau (N=7). Mean recoveries from 4 samples to which 
1:1 dilutions for the highest callibrators for Aβ42 or tau were added were 
77% (range 73%-81%) for Aβ42 and 109% (range 108%-112%) for tau. 
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RESULTS
Stability at -80°C according to the Arrhenius equation
The relative concentrations of Aβ42 and tau in CSF from the four and 
three patients, assayed on consecutive days, were calculated at 4, 18 and 
37°C, with the baseline value (-80°C) set at 100%. We plotted the relative 
concentrations (%) vs the days of heat stress, and calculated the rate 
constants at each investigated temperature [kT; Table 1]. The calculated 
kT values, determined at the three temperatures, were not different from 
zero, indicating that Aβ42 and tau are stable in CSF when stored at -80°C.
Table 1. Rate constants (k) for Aβ42 and tau
Temperature, K kT of Aβ42 kT of tau
277 -0.0043 (0.04) 0.0018 (0.03)
291 -0.0032 (0.03) -0.0016 (0.03)
310 0.050 (0.03) -0.039 (0.03)
Percentages of remaining measurable protein were plotted vs days of 
heat stress at each temperature. Mean (SD) k values were determined for 
the three temperatures as the slope of the best-fi t line.
 
Stability during mailing conditions
When we plotted the mean CSF Aβ42 values from samples of four 
patients stored at the three different temperatures against time, protein 
concentrations were highest at baseline (-80°C), and during the fi rst two 
days, the concentrations decreased by ~20%, in samples stored at 4, 18, 
and 37°C (Figure 1). 
Thereafter, the concentration of CSF Aβ42 remained relatively stable 
up to 22 days, although we observed considerable variability between 
aliquots from the same individual. Plots for tau showed that the protein 
is stable in CSF at 4 and 18°C, whereas the concentration decreased at 
37°C after ~12 days (Figure 2). 
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Figure 1. Relative concentrations of Aβ42 in CSF samples stored at 4, 18, and 
37°C. Mean percentages of Aβ42 plotted vs time, in CSF samples collected from 
four patients and stored at 4, 18, and 37°C compared with the baseline sample, 
stored at -80°C and stated as 100%.
Freeze/thaw cycles
We found no difference between the concentrations of Aβ42 and tau 
in CSF that had not been frozen/thawed and CSF that had undergone 
one freeze/thaw cycle (visualized for Aβ42 in Figure 3A). The mean (SD) 
relative concentrations (%) of Aβ42 vs the number of freeze/thaw cycles 
are shown in Figure 1B. The Aβ42 concentration decreased by ~20% after 
three freeze/thaw cycles, after which the concentrations remained relatively 
unchanged, at 80% of the baseline concentration during six freeze/thaw 
cycles. The change in concentration varied among individuals, ranging 
from no change in the samples from one patient to a large decrease from 
an other. 
We could not demonstrate a difference between samples with high 
(≥ 550 ng/L, n=5) and low concentrations (<550 ng/L, n=5) of Aβ42. 
The mean (SD) relative concentrations (%) of tau vs the number of freeze/
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thaw cycles are shown in Figure 3C. We observed no change in tau 
concentrations during six freeze/thaw cycles.
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Figure 2. Relative concentrations of tau in CSF samples stored at 4, 18, and 
37°C. Mean percentages of tau, plotted vs time, in CSF samples collected from 
four patients and stored at 4, 18, and 37°C compared with the baseline sample, 
stored at -80°C and stated as 100%.
Infl uence of time to centrifugation
We found no difference between Aβ42 and tau concentrations in 
CSF samples that were stored at 4°C and centrifuged after 1, 4, 48 or 
72 h. Furthermore, there was no difference between the concentrations 
of these markers in samples stored frozen after centrifugation and that 
were not centrifuged and stored for 4 days at 4°C. In addition, we found 
no signifi cant difference in Aβ42 and tau concentrations in the hemolytic 
sample not centrifuged and stored at -80°C (Aβ42 = 662 ng/L; tau = 232 
ng/L) and the sample centrifuged and stored at 4°C (Aβ42 = 596 ng/L; tau 
230 ng/L).
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DISCUSSION
Using the Arrhenius approach, we showed that the Aβ42 and tau 
concentrations are stable in CSF samples frozen immediately and stored 
for a longer period at -80°C. In addition, the concentration of Aβ42 in 
CSF decreased by ~20% during the fi rst two days when stored at 4, 18, 
and 37°C, and then remained constant for up to 22 days although with 
considerable variability among the aliquots from the same individual. 
Tau concentrations in CSF remained stable at 4 and 18°C, but showed 
a decrease after 12 days when stored at 37°C. After three freeze/thaw 
cycles, the concentration of Aβ42 in CSF decreased by 20%, whereas 
tau remained stable during six freeze/thaw cycles. Centrifugation did not 
infl uence the result for either biomarker.
To the best of our knowledge, the stability of Aβ42 and tau in CSF 
samples stored at -80°C for many years has not been systematically 
investigated previously. Only two studies concluded that Aβ422,5 and tau5 
remained stable in CSF when stored >6 months at -70 or -80°C. The fi rst 
study showed that the correlation between Aβ42 measured at different 
times during 1 year and reanalysis at one time was high (r=0.96).2 
Unfortunately, the slope of the line is not mentioned in that study, and this 
could give more accurate information about degradation of the protein. 
The second study found no relationship between CSF Aβ42 or tau 
concentrations and shelf life.5 In our study we investigated the long-term 
stability at -80°C with an accelerated stability testing protocol according 
to the Arrhenius method. We found no signifi cant decrease in Aβ42 or tau 
concentrations at 4, 18, and 37°C except for tau at 37°C and then only 
after 12 days. The degradation constant, therefore, was not different from 
zero, and no Arrhenius plot or projected stability time could be calculated. 
From this we conclude that both proteins are very stable in CSF and that 
the samples can be stored for a very long period at -80°C. However, a 
real-time stability experiment performed in the future is needed to confi rm 
our data.
The stabilities of various forms of Aβ in CSF samples stored at different 
temperatures have been described in two studies11,12 that measured the 
proteins with in-house ELISAs. In the fi rst study,11 the immunoreactivity 
of CSF Aβ40 and Aβ42 decreased by 8% and 10% when kept for 24 h 
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at 20°C, but remained stable the fi rst 24 h at 4°C. In the second study,12 
CSF total Aβ concentrations were measured and found to be unstable 
if samples were stored at -20°C, 4°C and room temperature, with the 
largest decrease during the fi rst day and plateauing after the third day. 
Although different assay formats were used, measuring different types 
of Aβ, the abovementioned fi ndings support our results of a decrease in 
Aβ42 concentrations in CSF during the fi rst 2 days for samples stored at 
4, 18, and 37°C compared with storage at -80°C . Although incubation 
at higher temperatures could have an effect on the binding capacity of 
Aβ42,6,13,14 storage of CSF at different temperatures does not seem 
to affect the Aβ42 concentration,6 which is supported by our fi ndings, 
showing comparable CSF Aβ42 concentrations in samples stored at 4°C 
or 37°C. There was a difference in Aβ42 concentration only between 
samples stored at -80°C immediately after collection or stored at higher 
temperatures after collection. An interesting fi nding in one study11 was 
that the antibody-binding capacity of synthetic Aβ42 was lower in CSF 
than in H2O. In addition, Aβ42 concentrations were lower in artifi cial 
CSF with physiologic concentrations of albumin than without albumin. 
An explanation for this fi nding could be the that the binding of Aβ42 to 
albumin masked the epitope recognized by Aβ42-specifi c antibodies.15,16 
This binding of Aβ42 to other proteins might also cause the low recovery 
rate of the Aβ42 ELISA, although Vanderstichele et al.6 and others could 
not fi nd interference with Aβ by other proteins, including albumin.17 
However, interference experiments are largely dependent on the protocol 
being used or on whether preincubation is needed. Furthermore, results 
are also dependent on which medium is used, e.g. artifi cial CSF, human 
CSF, or another medium such as sample diluent.6 The difference in 
Aβ42 concentrations between samples stored at -80°C and at higher 
temperatures could also be the result of binding of Aβ42 to other proteins, 
but conformational changes, aggregation18 or degradation may be involved 
as well. The variability in Aβ42 concentrations among centers5 might very 
well be attributable to the procedure for sample treatment during the fi rst 
hours after collection, with in one center immediately freezing samples 
on dry ice, and another center storing samples at room temperature until 
further processing (our center). This is an important factor to be considered 
and investigated further in future multicenter studies.
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Our fi nding of decreased concentrations of Aβ42 in CSF after repeated 
freeze/thaw cycles is in agreement with the outcome of several other 
studies,6,11,12 and stresses again the importance of avoiding freeze/
thaw cycles in order to minimize the risk of falsely low Aβ42 values. The 
decrease in Aβ42 in CSF after repeated freeze/thaw cycles might also be 
explained by the same physicochemical mechanisms, i.e., conformational 
change in the fi brillary β-sheeted Aβ42 protein or masking of the epitope 
by binding to other proteins, that lead to a decrease in Aβ42 concentrations 
during the fi rst 2 days in CSF samples stored at 4°C. This is sustained by 
our fi nding of comparable CSF Aβ42 concentrations in samples that have 
not been subjected to a freeze/thaw cycle (stored for two days at 4°C) vs 
samples that has been subjected to one freeze/thaw cycle. 
Tau protein is considered to be very stable, and repeated freeze/thaw 
cycles do not seem to infl uence the concentration of this protein. Therefore, 
it is quite remarkable that tau decreases after storage for 12 days at 37°C. 
At this temperature, the protein may be degraded by proteases, form 
aggregates, or undergo conformational changes, producing a form that is 
not detectable by one or both anti-tau antibodies used in the ELISA.10 Little 
is known about the relationship between CSF tau and temperature. The 
pathologic core protein of paired helical fi laments, consisting of a portion 
of tau, is found to be protease- and heat-resistant,19 but the aggregation 
of tau into paired helical fi laments has been demonstrated to increase at 
temperatures above 30°C.20 The tau protein is generally highly soluble, 
but the aggregated pathologic form found in neurofi brillary tangles in the 
brain might not be released in the CSF. The nature of tau in CSF is not 
well documented, but previous studies have revealed molecular masses 
of tau in lumbar CSF ranging from 25 to 80 kDa.21 The low molecular-
mass (25-kDa) form is not found in the brain, suggesting that CSF tau is 
truncated when released into the CSF, probably as a result of degradation 
processes occurring in the brain. The truncated forms of tau in CSF should 
be well recognized by the anti-tau antibodies because they cover only a 
small part of the large full-length molecule. We speculate that storage of 
CSF for 12 days at 37°C might lead to a change of the truncated form of 
tau into a more aggregated form, which is undetectable by the antibodies 
used in the ELISA.10
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In conclusion, both Aβ42 and tau are stable stored in CSF at -80°C 
for a long period, but Aβ42 in CSF samples stored at 4, 18, and 37°C 
decreased by ~20% during the fi rst 2 days compared with the baseline 
value (-80°C). Furthermore, the concentration of Aβ42 in CSF is infl uenced 
by the number of freeze/thaw cycles. To avoid these diffi culties, it is best 
to process CSF as soon as possible after collection and store it at -80°C 
for long storage. Preferably, CSF samples should be shipped on dry ice 
when stored frozen. 
Niki SM Schoonenboom was partly funded through a grant from 
Alzheimer Nederland, Bunnik (V2001-023). Additional funding was 
received from the Stichting Alzheimer and Neuropsychiatry Foundation 
(Amsterdam, The Netherlands). 
APPENDIX
Estimation of stability by the Arrhenius method
The best way to determine the stability of analytes in body fl uids is to 
perform a real-time stability experiment. This can be done by storing paired 
aliquots of a sample and measuring the concentrations of the proteins after 
certain time points, varying from some months to many years, taking into 
account that the sample is thawed once. However, this approach requires 
long experimental periods. Moreover, in real-time stability studies, protein 
measurements must be performed at the beginning, during and at the end 
of the study. These measurements can often not be performed with the 
same batches of reagents. An increased interassay CV may be the result.
Therefore, estimation of protein stability should rather be performed 
using an accelerated stability testing protocol. The kinetics of protein 
denaturation are comparable to that of a fi rst-order reaction, which 
means that the degradation rate is proportional to the concentration of 
the respective analyte. The equation for the accelerated stability testing 
protocol is: 
-d[c]/dt = k[c] or lnct/c0 = -k.t 
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where c0 is the initial protein concentration, ct is the concentration after 
time t, and k is the rate constant. The rate constant, which is dependent 
on the temperature, is determined at three fi xed temperatures, 4, 18, and 
37ºC, assuming that at -80ºC the concentration remains constant during 
the time of the storage experiment. Afterward, the Arrhenius equation is 
applied, using the following formula:
ln kt = A + E/R
in which A = the preexponential factor and E/R = the slope of the equation. 
Using the equation of the best-fi t line, it is possible to calculate the 
degradation rate constant at every desired temperature: 
ln kT = A + B/T     or     y =A + Bx. 
A and B have fi xed values. By substituting the temperature of interest, 
e.g., -80º C (193 K), k193 is calculated. We can calculate the time after 
which 90% or 95% of Aβ42 or tau can be recovered, by substituting ct/c0 = 
0.90 or 0.95 in the equation: 
ln(0.90) = -k193.t
-0.105 = -k193.t 
t = 0.105/k193 
or
ln(0.95) = -k193.t 
-0.0513 = -k193.t 
t = 0.0513/k193.
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Amyloid β 42 (Aβ42) concentrations in cerebrospinal fl uid (CSF) are 
used to identify Alzheimer disease (AD)1 but reported concentrations 
differ among studies, as does diagnostic accuracy.2 These differences 
may relate to the patient and control groups studied,3 processing and 
storage methods,4 intra- and interassay variation of the assays, or to the 
reagent antibodies used. A recent metaanalysis2 stressed the importance 
of standardizing assays for Aβ42 in CSF. In most studies, CSF Aβ42 
was reported to be decreased, but in two studies CSF Aβ42 was not 
signifi cantly changed in AD,2 and in 1 study,5 it even increased in the early 
stages of disease. These dissimilarities might refl ect the specifi cities of 
the antibodies incorporated in the assays.
The fi rst aim of our study was to compare concentrations of Aβ42, as 
measured by two different assays in the same CSF samples. The fi rst 
assay, widely used in Europe,6 uses 2 monoclonal antibodies (mAbs) and 
detects the full-length Aβ42 peptide: Aβ (1-42).7 The second assay [Aβ 
(N-42)], used mainly in the United States,8 detects both full-length Aβ42 
and Aβ peptides truncated at the .NH2-terminus.9 
The second aim of our study was to compare diagnostic accuracies of 
the assays for patients with AD compared with controls without dementia 
and patients with frontotemporal lobar degeneration (FTLD).
Finally, we investigated the relationship between CSF Aβ (1-42) and 
Aβ (N-42) concentrations and albumin ratio, age, disease duration, and 
disease severity.
Between October 2000 and December 2002, we recruited 39 AD 
patients, 24 FTLD patients, and 30 non-dementia controls at the Alzheimer 
Center of the VU University Medical Center (VUMC). All patients 
underwent a standardized investigative battery.3  A diagnosis of ‘probable’ 
AD was made according to the NINCDS-ADRDA criteria;10 the clinical 
picture of FTLD (including frontotemporal dementia, semantic dementia, 
and progressive aphasia) was based on international clinical diagnostic 
criteria.11 Disease duration was defi ned as the time in years between the 
fi rst symptoms by history and the lumbar puncture. 
The control group (N=30) consisted of 20 persons with subjective 
memory complaints, who had undergone the same battery of examinations 
as the patients; 5 spouses of patients; 3 individuals with a positive 
family history for AD, all without memory complaints; one patient with a 
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suspicion of intracranial hypertension; and one patient with a possible 
neuritis vestibularis. No controls developed dementia within one year. The 
Mini Mental State Examination (MMSE) score12 was used as a measure 
of global cognitive impairment. The study was approved by the ethics 
review board of the VUMC. All patients and controls gave written informed 
consent.
CSF was collected and stored as described previously.4 The albumin 
ratio (serum albumin/CSF albumin) was used as a measurement of the 
intactness of the blood brain barrier. Except for 1 FTLD patients and 2 
controls, the blood-brain barriers of the patients were intact (Table 1).
The INNOTESTTM β-AMYLOID(1-42) (Innogenetics) used mAb 21F12, 
which binds the COOH-terminus of the Aβ42 peptide (amino acids 36-
42), as capture antibody and biotinylated mAb 3D6, which bind the NH2-
terminus (amino acids 1-6) as detection antibody.6 Aβ (1-42) peptides 
from Bachem were used for calibration. This test was performed at the 
Department of Clinical Chemistry, VUMC, Amsterdam.
The sandwich ELISA for Aβ (N-42) uses the commercially available mAb 
6E10 (Signet Labs), specifi c to an epitope covering N-terminal amino acid 
residues 1-17 of Aβ42, as capture antibody, and the polyclonal antibody 
R165 as detector antibody. R165 was made by immunizing rabbits with 
conjugated Aβ(33-42) peptides (Ana Spec). Aβ(1-42) from Bachem was 
used for calibration, although production procedures for the calibrators 
were slightly different between the 2 laboratories. This test was performed 
at the New York site according to an in-house protocol. 
For statistical analysis, we used SPSS (Ver. 11.0). Passing and 
Bablok regression analyses13 were performed with Medcalc Ver. 4.30 
(Medcalc Software) and we also prepared a Bland-Altman plot.14 For 
group differences, we applied the Kruskall-Wallis test, followed by the 
Mann Whitney U-test applying the Bonferroni correction. The χ2 test with 
continuity correction was used to test group differences within genders.
The sensitivities and specifi cities for CSF Aβ (1-42) and Aβ (N-42) were 
calculated. Cut points corresponded with a sensitivity > 85%,15 but if a 
higher sensitivity obtained for a reasonable specifi city, it was used. ROC 
curves were constructed, and the areas under the curves (AUCs) were 
calculated and compared.16 Spearman correlations were calculated. A 
test was considered signifi cant at P < 0.05. All reported tests are 2-tailed 
unless stated otherwise.
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The CSF Aβ (1-42) and Aβ (N-42) concentrations were not statistically 
signifi cantly different (Table 1 and Figures 1 and 2 in the Data Supplement 
that accompanies the online version of this Technical Brief at http://www.
clinchem.org/content/vol51/issue6/). Concentrations of both CSF Aβ (1-
42) and Aβ (N-42) were signifi cantly lower in AD patients than in patients 
with FTLD and in controls (Table 1). CSF Aβ (1-42) concentrations 
differed signifi cantly between FTLD and controls, whereas CSF Aβ( N-42) 
concentrations did not differ signifi cantly between the two groups (Table 
1). The ratio of Aβ (1-42) to Aβ (N-42) differed only signifi cantly between 
AD and FTLD patient groups. 
ROC curves for CSF Aβ (1-42) and Aβ (N-42) are shown in Figure 1. 
In AD patients vs controls, the sensitivity and specifi city for CSF Aβ (1-
42) were 90% and 93%, respectively at 473 ng/L, and for CSF Aβ (N-42) 
they were 90% and 87%, respectively, at 383 ng/L. The AUCs were not 
different (Figure 1A) for Aβ (1-42) and Aβ (N-42) [0.94, (95%confi dence 
interval, 0.86-0.99) and 0.92 (0.83-0.97), respectively, P = 0.47]. 
When we compared the AD and FTLD patient groups, we obtained 
specifi city of 67% for CSF Aβ (1-42), at a sensitivity of 85% (448 ng/L). For 
CSF Aβ (N-42) the specifi city was 75% at a sensitivity of 87% (373 ng/L). 
The AUCs for CSF Aβ (N-42) and Aβ (1-42) tended to be different [Figure 
1B; 0.87 (0.76-0.97) and 0.77 (0.64-0.90); P =0.045]. 
The AUCs for CSF Aβ (1-42) and CSF Aβ (N-42) in distinguishing FTLD 
from controls were signifi cantly different [Figure 1C; 0.69 (0.55-0.81) and 
0.54 (0.39-0.67); P=0.007] but the discriminatory value was small for Aβ 
(1-42) and negligible for Aβ (N-42) (with the confi dence interval for the 
AUC including 0.5).
We found no signifi cant correlation of either CSF Aβ (1-42) or Aβ (N-42) 
with albumin ratio, MMSE score, age, or disease duration (AD and FTLD) 
in either group.
The absolute concentrations of CSF Aβ (1-42) and Aβ (N-42) were 
comparable. However, in earlier studies, concentrations of CSF Aβ (N-
42) ranged from 36 to 623 ng/L in AD patients and from 111 to 629 ng/L 
in controls.8,17,18 The reason for the low CSF Aβ (N-42) concentrations 
measured in these studies could be a difference in the affi nity of the Aβ 
(N-42) polyclonal antiserum samples or the purity and solubility of the 
peptides used as callibrators.8 The sensitivity of an ELISA depends 
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largely on the binding characteristics of the antigen, which may vary with 
temperature and buffer solutions, or among different reagent lots.6 In 
addition, the affi nity of the antibodies used in the assays might vary for 
the various Aβ42 peptides involved in the pathogenesis of AD, including 
oligomers of the Aβ42 peptide. A future study exchanging callibrators and 
antibodies among various ELISAs is necessary for harmonization. 
ROC curve analysis revealed no difference in the ability of the 2 assays 
to discriminate AD patients from controls. In addition to the C-terminal 
heterogeneity, various N-terminally truncated peptides are found in the Aβ 
pools of AD brains.19,20 These peptides are considered to play a role in 
the increasing Aβ42 production in developing AD. We speculate that Aβ 
(1-42) and Aβ (N-42) concentrations go hand in hand at a certain stage 
of disease, in mild to moderate AD as well as in controls. Because the 
N-terminally truncated Aβ42 peptides can be demonstrated early in the 
disease process,9 they might be promising markers for the preclinical 
diagnosis of AD, when used simultaneously with Aβ (1-42).21
Several authors found decreased Aβ (1-42) in CSF from a subset of 
FTLD patients.3,22 Very little information is available about the CSF Aβ 
(N-42) concentration in FTLD.17 The reason for a decrease of CSF Aβ (1-
42) in FTLD is unknown, although there might be a relationship with the 
presence of an e4 allele or with age.23 Interestingly, a few studies have 
shown the involvement of 3 mutations in the presenilin 1 gene (PSEN1) 
in familial forms of FTLD.24-26 These possible ‘loss of function’ PSEN1 
mutations might act as inhibitors of the γ-secretase cleavage of APP,27 
leading to a decrease of Aβ (1-42) in the brain. Although most FTLD 
patients included in our study have the sporadic form of FTLD, we cannot 
exclude the possibility of mutation in the PSEN1 gene in some of them.
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Online data supplement
Table S1. Passing and Bablok regression equations
N Equation Slope 95% CI Intercept 95% CI
AD 39 Y=0.71X+35 0.51-1.01 -39 - +106
FTLD 24 Y=1.17X-39 0.89-1.59 -230 - +99
Controls 30 Y=1.36X-245 0.81-2.44 -947 - +89
All subjects 93 Y=1.12X-67 0.95-1.3 -140 - -3
AD = Alzheimer’s disease; FTLD = frontotemporal lobar degeneration. CI = confi dence 
interval. Variable X = Aβ (1-42), variable Y = Aβ (N-42).
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Figure S1. Plot of Aβ (N-42) versus Aβ (1-42) per diagnostic category 
AD = Alzheimer’s disease, FTLD = frontotemporal lobar degeneration. The line was drawn 
using the formula Y=1.12X-67.
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SUMMARY
Serum amyloid P component (SAP) and complement C1q are found 
highly co-localized with extracellular fi brillar amyloidβ (Aβ) deposits in 
Alzheimer’s disease (AD) brain. Confl icting data were reported earlier 
about the cerebrospinal fl uid (CSF) levels of SAP and C1q in AD compared 
to controls. The objective of the present study was to compare the levels 
of Aβ1-42, tau, C1q and SAP in CSF of a well characterized group of 
AD patients and controls, and to assess the association with dementia 
severity.
Signifi cantly decreased CSF levels of Aβ1-42 were observed in the 
AD group (480 ± 104 ng/L) as compared to controls (1,040 ± 213 ng/L), 
whereas tau levels were signifi cantly higher in patients with AD (618 ± 
292 ng/L) than in controls (277 ± 136 ng/L). Combining the results of 
Aβ1-42 and tau measurements resulted in a clear separation between the 
AD group and the controls. No signifi cant differences in CSF levels of 
SAP and C1q were observed between the well characterized AD patients 
and non demented control group. Furthermore, we could not demonstrate 
a correlation between SAP and C1q CSF levels and the severity of the 
disease, expressed in Mini-Mental State Examination (MMSE) scores. 
Therefore, in our opinion these factors can be excluded from the list of 
potentially interesting biomarkers for AD diagnosis and progression. 
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INTRODUCTION
Biochemical markers for Alzheimer’s disease (AD) could be of value 
for improvement of the diagnostic accuracy, monitoring the progression 
of the disease and for evaluation of the effi cacy of therapy. Ideally, these 
biomarkers should refl ect the pathogenetic processes that contribute to 
the progression of the disease and the neuropathological changes that 
occur in the brain. An altered metabolism of the amyloid precursor protein 
(APP) with increased production of its Aβ1-42  fragment or a reduced Aβ1-
42 removal (Xia, 2000) seems to be the crucial factor in the pathogenesis 
of AD (Selkoe, 1999). AD most likely results from a complex sequence 
of steps involving multiple factors beyond the production and deposition 
of Aβ alone. These fi ndings have led to the concept that AD may be an 
amyloid-driven process with the neuritic tau pathology (neurofi brillary 
tangles and neuropil threads) and chronic infl ammation of vulnerable 
regions of brain being important secondary phenomena that are closely 
related with the syndrome of dementia (Selkoe, 1999; Akiyama et al., 
2000). A key event in the pathological cascade is the aggregation of 
fi brillar Aβ peptide in plaques that are closely associated with neuritic 
and glial alterations (Rozemuller et al., 1989). The fi brillar Aβ plaques 
were found to be associated with serum amyloid P component (SAP) and 
complement factors, such as C1q, in contrast to the diffuse non-fi brillar 
Aβ plaques (Zhan et al., 1995; Eikelenboom and Veerhuis, 1996). SAP is 
a normal plasma protein produced in the liver that is known to co-deposit 
in amyloid deposits in all types of amyloidosis. It has been suggested that 
SAP is a signifi cant factor maintaining the persistence of amyloid due to 
its proteinase resistance (Emsley et al., 1994). Recently, SAP was shown 
to be locally produced in the brain (McGeer et al., 2001). Similar to C1q, 
of which the expression is markedly upregulated in affected brain regions 
in AD (Yasojima et al., 1999), local production of SAP is increased in AD 
brains (McGeer et al. 2001).
In vitro studies have shown that fi brillar Aβ can bind complement 
protein C1q and activate the classical complement pathway (Rogers et 
al., 1992). The activated complement products can play a crucial role in 
the activation and recruitment of microglia, that are clustered around the 
congophilic Aβ deposits in the parenchyma (Eikelenboom and Veerhuis, 
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1996). The formation of the amyloid/microglia complex is a relatively early 
pathogenetic event that precedes the process of severe destruction of the 
neuropil (Arends et al., 2000).
The subsequent steps of the pathological cascade, from APP/ Aβ 
metabolism to fi brillar Aβ induced infl ammatory response and paired helix 
fi lament formation of tau, may be promising targets for future drug therapy. 
Determination of these proteins, which are involved in several key steps 
of the pathological cascade, could be helpful for diagnostic procedures 
or drug monitoring, if the pathological processes would be fully refl ected 
in changes of cerebrospinal fl uid (CSF) levels of these proteins. Recent 
studies consistently report decreased levels of Aβ1-42 and increased levels 
of tau in CSF from AD patients (Galasko et al., 1998; Hulstaert et al., 1999; 
Tapiola et al., 2000). Only a few papers have been published about C1q 
and SAP levels in CSF as diagnostic markers for AD (Hawkins et al., 1994; 
Smyth et al., 1994; Kimura et al., 1999). Some of these studies report 
altered C1q and SAP levels in AD patients, but the data are inconsistent. 
In the present study we compared the levels of Aβ1-42, tau, C1q and 
SAP in CSF of a well defi ned group of AD patients and controls, and 
assessed the association with dementia severity. 
PATIENTS AND METHODS
Patients and controls
Twenty patients (10 male and 10 female, mean age 67.3 ± 7.7 years) 
were recruited from the Memory Clinic at Huddinge University Hospital, 
Sweden. All fulfi lled the DSM-IV criteria for dementia and NINCDS-
ADRDA criteria for “probable“ AD. Twenty controls (7 men and 13 women, 
mean age 67.3 ± 10.4 years) were recruited from the Swedish Pensioner 
Society and spouses of the patients. Inclusion criteria for the controls 
were lack of memory complaints and absence of dementia, and no serious 
untreated systemic or cerebral disorders. The lower limit of mini mental 
state examination (MMSE) for the controls was set at 26 points, while the 
MMSE scores of the AD cases included varied from 5 to 26. Well-treated 
common systemic disorders were accepted; for example hypertension, 
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hypothyroidism and diabetes mellitus. Abuse of alcohol or narcotics was 
not accepted. Individuals with contraindications for a lumbar puncture 
(LP) such as treatment with warfarin or acetylsalicylic acid were excluded. 
Subjects with one or more relatives with any kind of dementia were defi ned 
as having a family history of dementia.
Patients and controls went through an extensive dementia investigation 
including physical examination, magnetic resonance imaging (MRI), single 
photon emission computed tomography (SPECT), electroencephalography 
(EEG), neuropsychological tests as well as blood and urine laboratory 
tests (including blood counts, electrolytes, liver enzymes, TSH, vitamin 
B12, folic acid, and ApoE genotyping). The fi nal clinical diagnosis after 6 
month of follow-up was used for the classifi cation as either AD or control.
These studies have been approved by the Medical Ethical Commission 
of the Huddinge University Hospital, Karolinska Institute, Huddinge, 
Sweden.
Apolipoprotein E genotyping
For ApoE genotyping, DNA was extracted from peripheral white blood 
cells using standard methods. The ApoE genotype was determined using 
a non-radioactive solid phase micro-sequencing method on micro titer 
plates (Affi Gene APOE, Sangtec Medical, Bromma, Sweden).
CSF Analysis
CSF was obtained by lumbar puncture in the L3/L4 or L4/L5 interspace. 
The samples were collected in the forenoon with the patient sitting in an 
upright position. The samples were centrifuged at 1000 rev/min for 10 
min, aliquoted in 1 mL fractions, and then immediately frozen at -70oC 
and stored until assayed. The Aβ1-42 concentration was determined with 
the sandwich ELISA INNOTEST™ β-Amyloid(1-42) (Innogenetics, Gent, 
Belgium; Vanderstichele et al., 2000). A monoclonal antibody, which is 
highly specifi c for the C-terminus of the β-amyloid peptide, was used 
as capturing antibody, and a biotinylated monoclonal antibody, specifi c 
for the N-terminus, was used as detector. There was no cross-reactivity 
with Aβ1-40. For quantifi cation of tau we used the sandwich enzyme-
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linked immunosorbent assay, INNOTEST™ hTAU-Ag according to the 
manufacturer’s instructions (Innogenetics, Gent, Belgium; Vandermeeren 
et al., 1993).
CSF levels of SAP and C1q were determined with sandwich-type ELISAs. 
SAP was measured as described before (Familian et al., 2001). In brief: 
monoclonal anti-human SAP (aSAP-14) was used as the coating antibody 
and immuno-affi nity purifi ed biotinylated rabbit anti-human SAP (PaSAP) 
antibodies for detection. The plates were developed with streptavidin-
conjugated horse radish peroxidase, and 3,3’,5,5’-tetramethylbenzidin 
(TMB, Merck, Darmstadt, Germany) as a substrate. Results were referred 
to an in-house standard of purifi ed human SAP, isolated from recalcifi ed 
normal human plasma by affi nity column chromatography (Familian et al., 
2001). Intra- and interassay coeffi cients of variation were less than 15%. 
The ELISA for C1q was performed as described by Hoekzema et al. 
(1988) with monoclonal anti-C1q antibodies (anti-C1q-20 and anti-C1q–85, 
recognizing epitopes on the heads and stalks of C1q, respectively). Anti-
C1q-20 was used for coating and biotinylated anti-C1q-85 for detection. 
Results were referred to an in-house standard curve consisting of pooled 
human serum, calibrated with purifi ed C1q. There was no C1q detectable 
in C1q depleted human plasma.
Statistical Analysis
The statistical program MedCalc, version 4.30 (Schoonjans, Mariakerke, 
Belgium) was used to calculate and plot the Receiver Operating 
Characteristics (ROC) in order to determine optimal sensitivity, specifi city, 
and cut-off levels. Otherwise SPSS, version 7.5, was applied. Patients 
and controls were compared with the t-test (means). For the difference of 
CSF-SAP and CSF-C1q levels in regard to the various ApoE genotypes 
ANOVA was applied. Correlations with disease severity were calculated 
using the correlation coeffi cient r of Pearson, and 95% confi dence intervals 
(95% CI) are given. The level of statistical signifi cance p was set at 0.05. 
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RESULTS
In the AD group we found an increased expression of the ApoE ε4 
allele. In 14/20=70% patients, one (10 patients) allele or two (4 patients) 
ε4 alleles were present, whereas in the controls only in 2/20=10% one ε4 
allele was shown (p < 0.0001).
The mean concentration of Aβ1-42 in CSF was signifi cantly lower in AD 
patients than in controls, whereas the mean CSF tau level was signifi cantly 
increased in the AD group compared with controls. In contrast, we found 
that the mean CSF concentration of SAP and C1q did not differ signifi cantly 
between the AD patients and controls (Table 1).
Table 1. Mean concentrations ±  standard deviations of 20 controls and 20 AD 
patients of Aβ1-42, tau, C1q, and SAP in CSF, with the statistical signifi cance as 
calculated.
Parameter Controls AD patients P
Aβ1-42 (ng/L) 1040 ± 213 480 ± 104 < 0.0001
Tau (ng/L)  277 ± 136 618 ± 292 < 0.0001
C1q (μg/L)  396 ± 125 410 ± 108 0.69, n.s.
SAP (μg/L)   50 ± 34  60 ± 41 0.40, n.s.
For Aβ1-42 as well as tau, ROC analyses were performed. For Aβ1-42 
at a cut-off of 716 ng/L, the sensitivity was 100% and the specifi city 95%. 
For tau, at a cut-off of 360 ng/L, sensitivity and specifi city were both 90%.
In a plot of Aβ1-42 versus tau, the high tau/low Aβ1-42 quadrant was 
highly predictive for AD (18/19; 18 AD patients and 1 control), whereas the 
low tau/high Aβ1-42 quadrant contained control individuals only (Figure 1).
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Figure 1. A plot of combined analysis of Aβ1-42 and tau in CSF. The high tau/
low Aβ1-42 quadrant is highly predictive for AD, whereas the low tau/high Aβ1-42 
quadrant contains control subjects only.
Next, possible relations between the CSF markers and the MMSE as a 
marker of dementia severity were determined. No signifi cant correlations 
were observed between MMSE and any of the 4 parameters (Table 2). 
Table 2. The correlation coeffi cients, 95% confi dence interval (95%CI), and 
statistical signifi cance of Aβ1-42, tau, C1q, and SAP in CSF of 20 AD patients with 
MMSE (range 5-26).
Parameter    R  95% CI   p
Aβ1-42  0.13 -0.33-0.54 0.59
Tau  0.37 -0.08-0.70 0.10
SAP -0.31 -0.66-0.15 0.18
C1q  0.09 -0.37-0.51 0.70
Moreover, no difference was found between the various ApoE genotypes 
and levels of CSF-C1q (p=0.47) and CSF-SAP (p=0.16). 
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DISCUSSION
In this study of clinically well characterized AD patients and healthy, 
age matched controls we corroborated earlier fi ndings of CSF Aβ1-42 and 
tau levels being signifi cantly different between both groups. In CSF of the 
AD patients a decreased level of Aβ1-42 and an increased level of tau is 
found. Moreover, in agreement with the literature (Mayeux et al., 1998) 
14/20 (70%) of the AD patients were carrier of at least one ApoE ε4 allele. 
The other 2 markers studied, SAP and C1q, showed comparable CSF 
levels in both groups. For CSF-SAP our results are in agreement with the 
results of Kimura (1999), who studied 72 patients with AD and 9 normal 
control subjects, but are confl icting with an earlier report by Hawkins 
(1994), who demonstrated statistically signifi cant increased levels of CSF-
SAP in a group consisting of 51 AD patients versus a group of 50 controls, 
consisting of 17 healthy normal subjects and 33 non-AD diseased control 
subjects. These contrasting results could be attributed to the use of 
different control groups. More likely, however, are differences in sensitivity 
and specifi city of the used antibodies in the assay methods. 
With regard to CSF-C1q, Smyth et al. (1994) reported diminished CSF-
C1q levels in 45 AD patients, as compared to a heterogeneous group 
of 10 controls, diagnosed with probable vascular dementia, no dementia 
and isolated cognitive impairment, or alcohol dementia; nevertheless, the 
difference was statistically signifi cant (p=0,02). In our study, we compared 
well defi ned and documented AD patients with healthy controls with no 
signs of dementia or cognitive disturbance. Therefore, the latter groups 
seem to be more adequate to investigate the potential value of a biological 
marker. 
C1q as well as SAP are locally produced in the brain and their 
synthesis is upregulated in affected areas of AD brain (Yasojima et al., 
1999; McGeer et al., 2001). Nevertheless, no difference in CSF-C1q or 
CSF-SAP levels was observed between AD patients and controls (Table 
1). A possible explanation for this fi nding might be the accumulation of 
excess C1q and SAP in the plaques of AD patients, with consequently no 
aberrant values in CSF. In addition, we did not fi nd a correlation between 
the severity of the disease, expressed in the MMSE scores, levels of tau 
and Aβ1-42 , and CSF-SAP or CSF-C1q levels. However, Kimura et al. 
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(1999) showed a signifi cant positive correlation between CSF-SAP levels 
and cognitive function, measured by MMSE, in the AD patient group. The 
study of Smyth et al. (1994) showed a strong correlation between MMSE 
and CSF C1q levels in AD patients. 
The most likely explanation for the contrasting data about C1q and 
SAP CSF levels in AD and control subjects obtained by different groups 
seems to be the variation in methods and technical factors to determine 
the C1q and SAP levels in CSF. Standardization of the assays is urgent, 
because of the different “in-house” assays with variability in specifi city of 
the antibodies incorporated.
In summary, we have added evidence to the usefulness of measuring 
CSF Aβ1-42 and tau levels in distinguishing AD patients from controls. 
However, for SAP and C1q, closely associated with Aβ deposits in the 
brain, we failed to demonstrate differences in the CSF levels of AD patients 
and controls, and we could not show a correlation with different stages 
of the disease process.  Therefore, in our opinion, these markers are no 
proper biomarkers for AD diagnosis and progression.
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SUMMARY
Nitric oxide (NO) may play a role in the pathophysiology of Alzheimer’s 
disease (AD). Asymmetric dimethylarginine (ADMA), an endogenous 
inhibitor of NO synthase, is involved in regulation of NO production. Recently 
it has been reported that dimethylarginine dimethylaminohydrolase, 
an enzyme that hydrolyses ADMA into citrulline and dimethylamine, is 
specifi cally elevated in neurons displaying cytoskeletal abnormalities and 
oxidative stress in AD. We hypothesized that this could lead to altered CSF 
concentrations of ADMA in AD. Measurement of ADMA and dimethylamine 
in CSF revealed no signifi cant differences between AD patients (n=20) 
and age-matched control subjects (n=20). Our results suggest that in early 
stages of AD overall regulation of NO production by ADMA is not aberrant.
Key words: ADMA, Alzheimer’s disease, DDAH, dimethylamine, nitric 
oxide.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder 
of unknown etiology. Neuropathological hallmarks of AD are senile plaques 
and neurofi brillary tangles. The relationship between the observed lesions 
in the brain and the AD disease process has long been debated. Two 
broad hypotheses about the mechanism have emerged (Selkoe, 1999; 
Lannfelt, 1997). According to the amyloid cascade hypothesis, both 
familial and sporadic variants of AD are caused by amyloid accumulation, 
especially Aβ1-42, in the brain. Overproduction of Aβ1-42 or failure to clear 
this peptide leads to AD, primarily through amyloid deposition associated 
with cell death. According to the infl ammatory and neurotoxic cascade 
hypothesis, the damaged neurons, highly insoluble Aβ1-42 deposits, and 
neurofi brillary tangles provide stimuli for infl ammation, leading to local 
upregulation of complement, cytokines, acute phase reactants, and 
other infl ammatory mediators (Eikelenboom and Veerhuis, 1999). Nitric 
oxide (NO), derived from arginine by nitric oxide synthase (NOS), plays 
an important role as vasodilator and neurotransmitter, and is involved in 
cellular immune response. In addition, NO can react with superoxide to give 
the very reactive peroxynitrite that causes oxidative damage to proteins 
by nitration of tyrosine residues and may lead to cellular injury (Wiesinger, 
2001). There is ample evidence for the presence of nitrotyrosine modifi ed 
proteins in AD (Su et al., 1997; Smith et al., 1997; Hensley et al., 1998).
Methylation of proteins at arginine residues by protein-arginine 
methyltransferases is involved in the modulation of protein-nucleic acid 
interactions (Gary and Clarke, 1998). The main methylation product is 
asymmetric dimethylarginine (ADMA), in which both methyl groups 
are attached to the same terminal guanidino nitrogen. Symmetric 
dimethylarginine (SDMA), in which both terminal nitrogen atoms of the 
guanidino group are methylated, is formed in lower amounts, but is 
especially abundant in myelin basic protein (Gary and Clarke, 1998). Both 
ADMA and SDMA are released into the cytoplasm following proteolysis. 
Intracellular ADMA inhibits NOS activity, whereas SDMA is not inhibitory 
(Leiper and Vallance, 1999; Vallance et al., 1992). Recently it has been 
shown that even slightly elevated plasma concentrations of ADMA are 
associated with an increased risk of acute coronary events, underlining 
the clinical relevance of ADMA (Valkonen et al., 2001).
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Figure 1. Schematic representation of the interrelation between the 
ADMA/DDAH pathway and the arginine/nitric oxide system. ADMA 
is synthesized by methylation of arginine residues in proteins and is 
released during protein turnover. Upregulation of DDAH leads to increased 
degradation of ADMA into citrulline and dimethylamine. As a consequence 
of decreased ADMA concentrations, inhibition of NOS is relieved, resulting 
in increased synthesis of nitric oxide. Open arrows indicate changes in 
enzyme activities and concentrations of metabolites when DDAH activity 
is upregulated.
Many tissues contain the enzyme dimethylarginine dimethylamino-
hydrolase (DDAH), which hydrolyses ADMA into citrulline and 
dimethylamine (Ogawa et al., 1987; Leiper et al., 1999; Vallance, 2001). 
DDAH may therefore augment NO synthesis, by relief of NOS inhibition. 
DDAH has been isolated from bovine brain (Bogumil et al., 1998), and one 
isoform of human DDAH predominates in tissues that express neuronal 
NOS (Leiper et al., 1999). Upregulation of mRNA of DDAH after nerve injury 
has been described (Nakagomi et al., 1999). It was recently demonstrated 
that in AD patients DDAH is specifi cally elevated in neurons displaying 
cytoskeletal abnormalities and oxidative stress pathology, whereas it was 
undetectable in the neurons of age-matched healthy controls (Smith et al., 
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1998). Increased DDAH activity in AD, by lowering ADMA concentrations, 
could lead to increased NO production (Figure 1) and consequently to 
NO-mediated oxidative damage. We have tested whether changes in 
DDAH activity are refl ected by altered concentrations of ADMA and its 
breakdown product dimethylamine in CSF of AD patients compared to 
age-matched control subjects.
MATERIALS AND METHODS
Patients and controls
Twenty patients were recruited from the Memory Clinic at Huddinge 
University Hospital, Sweden. All fulfi lled the DSM-IV criteria for dementia 
and NINCDS-ADRDA criteria for ‘probable’ AD. Twenty controls were 
recruited from the Swedish Pensioner Society and spouses of the patients. 
Cognitive function was assessed by mini mental state examination (MMSE) 
score. The lower limit of MMSE for the controls was set at 26 points.
Patients and controls went through an extensive dementia investigation 
including physical examination, MRI, SPECT, EEG, neuropsychological 
tests as well as blood and urine laboratory tests. The fi nal clinical diagnosis 
was confi rmed after 6 months follow-up. Characteristics of AD cases and 
controls are shown in Table 1. The study was approved by the institutional 
ethics committee.
CSF analysis
CSF was obtained by lumbar puncture in the L3/L4 or L4/L5 interspace. 
The samples were collected in the forenoon with the patient sitting in an 
upright position. The samples were centrifuged at 1000 rpm for 10 min, 
aliquoted in 1 mL fractions and then immediately frozen at -70oC and 
stored until assayed.
Concentrations of Aβ1-42 and tau were determined by sandwich ELISA 
kits (Innogenetics, Ghent, Belgium).
Arginine, ADMA, and SDMA in CSF were measured simultaneously by 
HPLC using derivatization with ortho-phtaldialdehyde and fl uorescence 
detection (Teerlink et al., 2002). All samples were analyzed in a single 
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analytical series. The intra-assay precision for arginine, ADMA, and SDMA 
was 0.4%, 1.2%, and 0.8%, respectively.
Dimethylamine was analyzed by reversed-phase HPLC using 
derivatization with fl uorenylmethyl chloroformate and fl uorescence 
detection (Teerlink et al., 1997). Both intra-assay and inter-assay precision 
were better than 6%.
Statistics
Comparison of patients and controls was performed by t-test, after log-
transformation of parameters with skewed distribution. For MMSE scores 
the Mann-Whitney test was used, and for the M/F distribution we applied 
the Chi-square test. The level of statistical signifi cance was set at 0.05.
Table 1. Characteristics of AD cases and controls
AD Cases Controls P
Number of subjects 20 20
Gender (M/F) 9/11 7/13 NS
Age, years (mean ± SD) 69.3 ± 8.4 68.8 ± 7.8 NS
MMSE score (median [range]) 20.5 [7 – 26] 29 [27 – 30] <0.001
Arginine, μmol/L (mean ± SD) 26.0 ± 3.9 25.7 ± 4.0 0.79
ADMA, μmol/L (mean ± SD) 0.066 ± 0.012 0.065 ± 0.010 0.91
SDMA, μmol/L (mean ± SD) 0.161 ± 0.030 0.153 ± 0.031 0.40
Dimethylamine, μmol/L (mean ± SD) 2.37 ± 0.67 2.01 ± 0.63 0.095
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RESULTS
In CSF of the AD patients, decreased concentrations of Aβ1-42 compared 
to controls were found (364 ± 136 versus 830 ± 350 ng/L; P = 0.001). 
Concentrations of tau were increased in CSF of AD patients (558 ± 320 
versus 378 ± 179 ng/L; P = 0.036). These biochemical data corroborate 
earlier fi ndings and confi rm classifi cation of AD patients and controls by 
clinical examination with physical as well as neuropsychological tests. 
No differences between AD patients and controls with respect to CSF 
concentrations of arginine, ADMA, SDMA, and dimethylamine were 
observed (Table 1).
DISCUSSION
The main fi nding of our study is that CSF concentrations of the NOS 
inhibitor ADMA and its hydrolysis product dimethylamine in AD patients 
are not different from concentrations in age-matched control subjects. In 
addition, concentrations of arginine, the substrate of NOS, and SDMA did 
not differ between AD patients and controls. Therefore, our results suggest 
that in AD there are no alterations of NOS activity on the concentration of 
either substrate or the endogenous inhibitor ADMA.
Our study was based on the observation (Smith et al., 1998) that in 
AD patients the concentration of DDAH is increased in the cytoplasm of 
neurons with cytoskeletal pathology, whereas enzyme immunoreactivity 
was undetectable in the neurons of control subjects. Increased DDAH 
activity could lead to enhanced degradation of ADMA, resulting in 
increased NO production. We have tested this hypothesis by measuring 
ADMA and related compounds in CSF. As there are no diffusional barriers 
between the two compartments, CSF can be regarded as an extension 
of the intracellular fl uid of the brain, and its composition resembles brain 
interstitial fl uid (Klein, 2000). We developed a novel HPLC technique for the 
accurate measurement of arginine, ADMA and SDMA, with high sensitivity, 
allowing analysis of 0.2 mL volumes of CSF. The concentrations of CSF 
arginine are in close agreement with data obtained by amino acid analysis 
previously reported by us (Kuiper et al., 2000). CSF concentrations of 
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ADMA were approximately twofold higher than values reported recently 
for healthy controls (Abe et al., 2001). For SDMA and dimethylamine no 
literature data on CSF concentrations in AD are available. In this study we 
found that in CSF SDMA concentrations are 2-3 fold higher than ADMA 
concentrations, whereas in human plasma approximately equimolar 
amounts of ADMA and SDMA are present, i.e. 0.42 ± 0.06 μmol/L ADMA 
and 0.47 ± 0.08 μmol/L SDMA (Teerlink et al., 2002). This high SDMA/
ADMA ratio in CSF is in line with the fact that myelin basic protein is a 
major source of SDMA but not ADMA (Brahms et al., 2001; Gary and 
Clarke, 1998).
Obv iously, increased expression of DDAH in neurons of AD patients 
could lead to decreased ADMA concentrations. On the other hand, it is 
also conceivable that DDAH is upregulated as a response to increased 
ADMA concentrations. In either case the increased DDAH activity would 
lead to an increased dimethylamine production, which was not found 
in our study. Increased ADMA production could result from accelerated 
proteolysis associated with cell death and oxidative damage in AD. If this 
were the case, however, SDMA concentrations would probably also be 
increased, which we did not observe.
Our results do not corroborate recently reported data, showing reduced 
ADMA concentrations in AD patients compared to controls (Abe et al., 
2001). This discrepancy may be caused by the selection of patients, as 
Abe et al. included moderate to severe AD patients in their study (median 
MMSE=11.5), while we investigated mild to moderate AD patients (median 
MMSE=20.5).
In conclusion, our results do not suggest a generalized aberrant role for 
the ADMA/DDAH system in the regulation of NO synthesis in early stages 
of AD.
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SUMMARY
Choline containing phospholipids are essential for the integrity of the 
cell membrane. Minor changes in the lysophosphatidylcholine (lyso-PC)/
phosphatidylcholine (PC) ratio may lead to neuronal damage and cell 
loss. Several studies have shown protein and lipid oxidation in Alzheimer’s 
disease (AD) affected brain regions. Amyloid-β peptides may induce free-
radical oxidative stress which normally is counteracted by anti-oxidant 
defense mechanisms. We hypothesize that oxidation may lead to changed 
concentrations of choline containing phospholipids in cerebrospinal fl uid 
(CSF) of AD patients, because of the susceptibility of the unsaturated 
acyl-chains of PC for oxidation. PC and lyso-PC were determined in CSF 
of AD patients (n =19) and subjects with subjective memory complaints 
without dementia (n =19) by tandem mass spectrometry. No differences 
in total PC concentrations were observed between both study groups. 
Furthermore, we could not demonstrate different concentrations of PC 
species containing linoleic acid and PC species containing arachidonic 
acid. Interestingly, lyso-PC concentrations tended to be lower while the 
lyso-PC/PC ratio was signifi cantly decreased in CSF of AD patients 
compared to controls (0.36% versus 0.54%; P =0.017). A comparable 
decrease was found for the lyso-PC/PC ratio for PC containing linoleic 
acid (P =0.022) or arachidonic acid (P =0.010), respectively The lower 
lyso-PC/PC ratio in CSF of patients with AD may refl ect alterations in the 
metabolism of choline-containing phospholipids in the brain in AD, and 
suggests that PC species containing linoleic acid or arachidonic acid are 
equally involved.
Key-words: Phospholipids, phosphatidylcholine, lyso-phosphatidylcho-
line, linoleic acid, arachidonic acid, subjective memory complaints, 
Alzheimer’s disease 
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder 
of unknown etiology, characterized by irreversible cognitive and physical 
deterioration. It is the major dementing disorder of the elderly, with senile 
plaques and neurofi brillary tangles as neuropathological hallmarks. The 
fi nding that amyloid-β peptides (Aβ), the major constituent of senile 
plaques, are toxic to neurons, led to the concept that mismetabolism of 
amyloid precursor protein is central to the pathogenesis of AD. Free-
radical induced oxidative damage, particularly of neuronal lipids, is 
extensive in those AD brain areas in which Aβ is abundant (Markesbery, 
1997). Recent studies suggest that Aβ-induced oxidative stress may lead 
to neurodegeneration in AD brain (Butterfi eld et al., 2001; Kontush et al., 
2001; Butterfi eld and Lauderback, 2002). 
Levels of glycerophospholipids are decreased in brain autopsy 
samples from AD patients compared to age matched controls (Stokes and 
Hawthorne, 1987; Söderberg et al., 1990; Nitsch et al., 1991; Nitsch et al., 
1992). The decrease in glycerophospholipids in AD is accompanied by 
increased activities of lipolytic enzymes (Farooqui et al., 1990) and elevated 
concentrations of phospholipid degradation metabolites (Pettegrew et al., 
1988; Pettegrew, 1989; Pettegrew et al., 2001).
Changes in phospholipid content in neuronal cell membranes may result 
from excess release of arachidonic acid and subsequent generation and 
accumulation of prostaglandins and lipid peroxides, which may contribute 
to the neurodegenerative changes in AD (Farooqui and Horrocks, 1994).
The principal function of phospholipids is maintaining the normal integrity 
of cell membranes. Changes in membrane phospholipids occur very early 
in the molecular pathophysiology of AD and may provide the molecular 
basis for synaptic loss in AD (Pettegrew et al., 1995). Phosphatidylcholine 
(PC) is the major phospholipid of eukaryotic membranes representing 
approximately 40% of phospholipids in most cellular membranes 
(Klein, 2000). Pathological breakdown of phospholipids by oxidation 
is inevitably refl ected in changes of PC breakdown products like lyso-
phosphatidylcholine (lyso-PC). We determined PC, lyso-PC, and the 
lyso-PC/PC ratio in cerebrospinal fl uid (CSF) of AD patients and subjects 
with subjective memory complaints, in order to gain more insight into the 
phospholipid metabolism of AD patients. 
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MATERIALS AND METHODS
Subjects
The 38 subjects participating in the study were referred to the 
Memory clinic at Huddinge University Hospital (Huddinge, Sweden). 
They underwent an extensive dementia investigation including physical 
and psychiatric examinations, MRI, SPECT and neuropsychological and 
laboratory tests. The defi nite clinical diagnosis was made after a 6-12 
months follow-up and yielded two groups: 19 patients (M/F =11/8) fulfi lling 
criteria for “probable” AD according to the NINCDS-ADRDA working group 
and 19 subjects (M/F =8/11) with subjective memory complaints but no 
dementia or mild cognitive impairment according to established criteria 
(APA 1997; Petersen et al., 2001). Given the long follow-up this group 
may be considered as a non-demented reference (control) group. The 
MMSE and CDR scores of the two groups were used as measures of 
global cognitive decline.
CSF analysis
CSF was obtained by lumbar puncture in the L3/L4 or L4/L5 interspace. 
The samples were collected in the forenoon with the patient sitting in an 
upright position. The samples were centrifuged at 1000 rev./min for 10 min, 
aliquoted in 1 mL fractions, frozen immediately at -70oC and stored until 
assayed. Concentrations of Aβ1-42 and tau were determined by sandwich 
ELISAs (Innogenetics, Ghent, Belgium).
PC and lyso-PC in CSF were measured with electrospray ionization 
tandem mass spectrometry (Scheffer et al., 2001) using an API 3000 mass 
spectrometer (PE Sciex, Toronto, Canada). After lipid extraction (Bligh and 
Dyer, 1959) of 0.4 mL CSF, the extracts were taken to dryness under a 
stream of nitrogen and redissolved in 0.4 mL eluent (methanol/chloroform 
2:1, containing 1% ammonium acetate). Diarachidoyl PC (Sigma, St. Louis, 
MO, USA) was used as internal standard at a concentration of 1 nmol/
mL and was added before lipid extraction. Mass spectrometric analysis 
using fl ow injection analysis was performed in the positive ion mode. 
Precursors of the ion m/z 184.0 which corresponds to the phosphocholine 
Decreased CSF lysoPC/PC ratio in AD
111
ion, characteristic for all choline containing phospholipids, were detected 
as [M+H]+ ion. In total four major molecular species of PC were detected, 
esterifi ed at sn-1 with palmitic (C16:0) or stearic acid (C18:0), and with 
linoleic (C18:2) or arachidonic acid (C20:4) at sn-2 with m/z 758.6, 782.6, 
786.6 and 810.6, respectively. Lyso-PC with m/z 496.4 and 524.4 were 
detected, representing C16:0 lyso-PC and C18:0 lyso-PC, respectively. For 
each ion transition a dwell time of 20 ms was used. The spray voltage 
was set at 5000 V, the declustering potential was set at 96 V, and a spray 
temperature of 350°C was used. The intra-assay coeffi cients of variation 
for measuring PC and lyso-PC were 5.5% and 5.1%, respectively. It 
should be noted that using mass spectrometric analysis differences in 
ionization and fragmentation effi ciency between (lyso)phospholipids with 
different fatty acyl chains results in differences in signal intensity (Brügger 
et al., 1997). Absolute quantifi cation therefore requires the use of multiple 
internal standards to correct for this phenomenon. As we used a single 
internal standard (di-arachidoyl PC) for all assayed (lyso)phospholipids 
we expressed our results in arbitrary units (A.U.).
Statistics
Comparison of patients and subjects with subjective memory complaints 
was performed by Student’s t-test for parameters with a parametric 
distribution or the Mann-Whitney test for nonparametric distributions. For 
calculation of correlations, the nonparametric method of Spearman was 
applied. The level of statistical signifi cance was set at 0.05. All analyses 
were performed using SPSS v9.0 (SPSS Inc, Chicago, USA).
RESULTS
PC and lyso-PC were determined with electrospray ionization tandem 
mass spectrometry in CSF samples of 19 cases that meet the criteria for 
AD and of 19 control cases. The CSF levels of Aβ1-42 of AD patients were 
found to be decreased, compared to subjects with subjective memory 
complaints (281 ± 101 versus 415 ± 161 ng/L; P= 0.004). On the other 
hand, CSF levels of tau in the AD patients tended to be increased (425 ± 
236 versus 281 ± 246 ng/L; P= 0.072). 
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Between AD patients and controls no difference in total PC in CSF 
was observed. Although no statistical difference was reached (P= 0.10), 
the lyso-PC levels in CSF of AD cases tended to be lower than those in 
controls. Furthermore, we could not demonstrate different concentrations 
of PC species, esterifi ed at sn-2 containing linoleic acid or PC species 
containing arachidonic acid (Table 1). Since the absolute content varies to 
a relatively large extent between cases, we determined the ratio of lyso-PC 
over total PC in the CSF samples. The lyso-PC/PC ratio was signifi cantly 
decreased in the AD group as compared to the controls (Figure 1). When 
the lyso-PC/PC ratios of linoleic acid and arachidonic containing PC were 
separately determined, these showed a similar decrease as the ratio of 
lyso-PC/total PC (Table 1).
Table 1. Phosphatidylcholine (PC), lyso-phosphatidylcholine (lyso-PC), and lyso-
PC/PC ratio in CSF. PC species containing only linoleic acid (PCL.A.) and the 
PC species containing only arachidonic acid (PCA.A.) are given as well as the 
corresponding lyso-PC/PC ratios.
AD Cases (n= 19)
Median (P25-P75)
Controls (n= 19)
Median (P25-P75)
P
PC (A.U.)
 PCL.A. (A.U.)
 PCA.A. (A.U.)
943 (881-1031)
510 (419-570)
433 (372-480)
971 (683-1204)
534 (372-677)
377 (324-526)
0.91
0.67
0.82
Lyso-PC (A.U.) 3.4 (2.7-4.0) 5.4 (2.6-9.2) 0.10
Lyso-PC/PC ratio (%)
 Lyso-PC/PCL.A. ratio (%)
 Lyso-PC/PCA.A. ratio (%)
0.36 (0.29-0.45)
0.65 (0.52-0.81)
0.79 (0.66-0.99)
0.54 (0.37-0.79)
0.95 (0.64-1.39)
1.26 (0.80-1.81)
0.017
0.022
0.010
A.U.: arbitrary units
No signifi cant correlations between the age of controls and AD patients 
and the determined parameters were found (data not shown).
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DISCUSSION
Changes in membrane phospholipids occur very early in AD 
pathogenesis and may provide the molecular basis for synaptic loss in AD 
(Pettegrew et al., 2001).
In the present study we focused on choline containing phospholipids 
because these are important constituents of eukaryotic membranes of 
which the major component, PC, contributes about 40% of the total (Klein, 
2000). Pathological breakdown of PC by oxidation is accompanied by 
increased production of lyso-PC. 
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Figure 1. The lyso-phosphatidylcholine/phosphatidylcholine ratio (%) in CSF of 
19 subjects with subjective memory complaints (controls) and 19 AD patients. 
Lines indicate the interquartile ranges: P25-median-P75
For measurement of PC and lyso-PC we used electrospray ionization 
tandem mass spectrometry, a sensitive and specifi c technique to analyze 
phospholipids at the level of individual molecular species. It should be 
noted that with this technique not the total PC and lyso-PC concentrations 
were measured, but rather the quantitatively most important molecular 
species of these phospholipid classes.
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Although no differences in CSF total PC, PC species containing only 
linoleic acid and PC species containing only arachidonic acid, and lyso-PC 
concentrations between AD patients and control subjects were observed, 
the lyso-PC/total PC ratio was lower in CSF of AD patients than in the 
control group. (Table1 and Figure 1). A comparable decrease was found 
for the lyso-PC/PC ratio for PC containing linoleic acid or arachidonic acid 
(Table 1).
Our total PC results, measured in CSF, are according to those 
of Prasad et al. (1998), who showed that there is no difference in PC 
content between AD and control brain. In contrast to total PC, a decrease 
of phosphatidylethanolamine and phosphatidylinositol, that are rich in 
oxidizable arachidonic acid and docosahexaenoic acid, was observed. In 
AD brains arachidonic acid may be converted into isoprostanes (Praticò, 
1999; Greco et al., 2000; Praticò et al., 2002), however, the contribution of 
arachidonic acid derived from PC seems to be limited.
Results of PC studies in brain are confl icting: an unchanged PC 
content, as well as increased or decreased PC values have been reported 
(Klein, 2000). The metabolite lyso-PC, normally present in relatively 
low concentrations, may be a more sensitive parameter for changes in 
PC turnover and breakdown. The lyso-PC concentrations in CSF of AD 
patients tended to be lower, and the lyso-PC/PC ratio was signifi cantly 
decreased in AD. This decreased ratio was unexpected as we anticipated 
an increased lyso-PC level due to oxidation. However, the lyso-PC/PC 
ratio is also regulated by the catabolic enzyme phospholipase A2 and 
lysophospholipid acyltransferase, which recycles lysophospholipids into 
intact phospholipids. The activity of phospholipase A2 has been reported 
to be signifi cantly decreased in parietal and temporal cortices of patients 
with AD (Gattaz et al., 1995; Ross et al., 1998). Furthermore, a correlation 
between the reduction of phospholipase A2 activity and the severity of 
the pathological process, as monitored by counting senile plaques was 
demonstrated (Gattaz et al., 1995). In contrast to the decreased activity 
of phospholipase A2, the activity of lysophospholipid acyltransferase, 
was found to be increased by 50-70% in the same brain areas (Ross et 
al., 1998). Alterations of both enzyme activities in AD may represent a 
compensatory mechanism that serves to reduce the rate of PC loss.
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It should be noted here that the way the groups were defi ned and 
recruited, represents normal clinical routine, since both groups underwent 
the same investigations as part of a screening procedure. In the patients 
diagnosed as having ‘probable’ AD, decreased concentrations of CSF 
Aβ1-42 compared to the subjects with subjective memory complaints were 
found (P=0.004). These data corroborate earlier studies and may confi rm 
the correct classifi cation of the AD patients (Galasko et al., 1998; Hulstaert 
et al., 1999).
In conclusion, our results suggest that in patients with AD the metabolism 
of PC is altered, resulting in lower lyso-PC/PC ratios, and that PC species 
containing linoleic acid or arachidonic acid are equally involved
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ABSTRACT
Homocysteine accumulation, frequently observed in plasma of AD 
patients, may be a sign of a reduced activity of the brain methionine-
homocysteine transmethylation cycle. S-adenosylmethionine (SAM) is the 
main methyl donor in several transmethylation reactions. The demethylated 
product of SAM, S-adenosylhomocysteine (SAH), is hydrolyzed to yield 
homocysteine, which can be remethylated to methionine by transfer of a 
methyl group of 5-methyltetrahydrofolate (5-MTHF). A reduced activity of 
the transmethylation cycle in the brain may result in hypomethylation of the 
promoter of the presenilin 1 (PS1) gene, which will lead to overexpression 
of presenilin 1 and, consequently, to increased Aβ1-42 (Aβ42) formation. 
Brain transmethylation was studied in 30 patients with ‘probable’ AD and 
28 age-matched non-demented controls by measuring the cerebrospinal 
fl uid (CSF) levels of SAM, SAH and 5-MTHF. 5-MTHF was determined by 
HPLC with electrochemical detection, while SAM and SAH were assayed 
by stable isotope dilution tandem mass spectrometry.
We found no statistical differences between AD patients and controls 
for 5-MTHF, SAM and SAH levels, and the SAM/SAH-ratio in CSF. These 
fi ndings argue against a possible change in methylation of the promoter 
and expression of PS1.
One of the neuropathological hallmarks of Alzheimer’s disease (AD) 
is the presence of senile plaques, which contain extracellular deposits 
of amyloid-β1-40 (Aβ40) and amyloid-β1-42 (Aβ42). According to the 
amyloid theory these plaques are important in the pathogenesis of AD. 
The enzyme presenilin 1 that hydrolyzes amyloid precursor protein into 
Aβ peptides is a key player in Aβ40 and Aβ42 formation. Overexpression 
of the presenilin 1 (PS1) gene will increase presenilin 1 levels, which will 
lead to increased production of Aβ peptides. One factor that may affect 
PS1 expression is the methylation status of its promotor: methylation of 
cytosine bases in CpG dinucleotides in the promotor will silence the gene 
while hypomethylation will lead to overexpression.1,9 
Methylation of cytosine bases occurs by DNA methyltransferases that 
require S-adenosylmethionine (SAM) as donor of the methyl groups. In 
this transmethylation reaction SAM is demethylated into 
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S-adenosylhomocysteine (SAH), which can be hydrolyzed to yield 
homocysteine.12 Homocysteine can be methylated to methionine by 
transfer of a methyl group from 5-methyltetrahydrofolate (5-MTHF) in a 
process requiring vitamin B12 and folic acid. The transmethylation cycle is 
completed by the conversion of methionine and ATP into SAM (Figure 1).
Serum homocysteine levels are an early and sensitive marker for 
cognitive impairment. In patients with dysmentia no less than 39% 
had a pathologically increased serum homocysteine.4 An increased 
plasma homocysteine level is a strong, independent risk factor for the 
development of AD.6 A plasma homocysteine level greater than 14 μmol/L 
nearly doubles the risk of AD11 compared to plasma homocysteine levels 
of less than 14 μmol/L. 
tetrahydrofolate methionine
S-adenosyl-methionine
S-adenosyl-homocysteine
homocysteine
Me
5-methyl-tetrahydrofolate
Phosphatidylcholine
myelin, melatonin
catecholamines, DNA
RNA
MeVitamin B12
Figure 1. Transmethylation cycle. Methionine is converted to S-adenosyl-
methionine. From S-adenosylmethionine a methylgroup is transferred to various 
biochemical components.
Since homocysteine formation from SAH is a reversible process, increased 
homocysteine levels may be associated with accumulation of SAH.7 
SAH has been shown to be a strong inhibitor of DNA methyltransferases 
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and increased SAH levels will induce DNA hypomethylation.3 Since 
the expression of many genes is regulated by the methylation status of 
cytosine bases in CpG moieties in their promotor, the SAM/SAH ratio could 
affect the level of gene expression. Methylation of the promotor of the PS1 
gene will silence the gene and will decrease presenilin 1 expression, thus 
reducing Aβ40 and Aβ42 formation. This is illustrated by the fi nding that 
administration of SAM to neuroblastoma cell cultures downregulates both 
PS1 gene expression and Aβ40 production.10
We hypothesized that the transmethylation cycle in the brain of AD 
patients may be altered and that this alteration leads to hypomethylation of 
the promotor of the PS1 gene, to overexpression of PS1 and to increased 
levels of Aβ peptides. To study this hypothesis we measured the levels of 
several metabolites involved in transmethylation in CSF from AD patients 
and from age-matched controls.
Thirty patients who fulfi lled the NINCDS-ADRDA criteria for ‘probable’ 
AD and twenty-eight non-demented controls were recruited. The mean 
age of the AD patients was 67 years (range 53-77 years), while the mean 
age of the controls was 62 years (range 49-79 years; P =0.16). Patients 
and most controls went through an extensive dementia investigation 
including physical examination, MRI, neuropsychological tests and 
laboratory tests. The medical records of the patients showed no history of 
anemia, gastrectomy or supplementation with vitamin B12 and folate. The 
control group consisted of 20 persons with subjective memory complaints, 
who had undergone the same battery of examinations as the patients. 
Four were spouses of patients and two subjects were screened because 
of a positive family history for AD, but had had no memory complaints. 
One subject had been diagnosed with fi bromyalgia and one subject 
underwent a lumbar puncture for a suspected neuritis vestibularis. None 
of the controls had developed dementia within 1 year of follow up. CSF 
samples, obtained by lumbar puncture, were centrifuged at 3000 rpm for 
10 min, and were stored at -80°C until assayed. 
SAM and SAH were determined simultaneously using tandem mass 
spectrometry with stable isotope labeled internal standards.12 5-MTHF 
was assayed by HPLC separation followed by coulometric electrochemical 
detection.5 Methylmalonic acid (MMA), a marker of B12 defi ciency, 
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was determined by stable isotope dilution tandem MS (manuscript in 
preparation). 
Comparison of patients and controls was performed by the non-
parametric Mann-Whitney test. The level of statistical signifi cance was 
set at 0.05. All analyses were performed using SPSS v9.0 (SPSS Inc., 
Chicago, USA). The results of the study are summarized in Table I. 
There were no statistical differences in SAM, SAH, 5-MTHF and MMA 
levels and in SAM/SAH ratio in CSF between the AD patients and the age-
matched controls.
These results suggest that there are no signifi cant alterations 
in transmethylation reactions in the brain. Thus, it is unlikely that 
overexpression of the PS1 gene caused by undermethylation of its 
promotor is a contributing factor in the pathogenesis of AD. 
Table 1. The median (range) and statistical signifi cance of parameters, involved 
in the transmethylation cycle, of AD patients and age-matched controls.
AD cases (N =30) Controls (N =28) P-value
5-MTHF (nmol/L) 49 (17-62) 52 (24-72) 0.53
MMA (μmol/L) 0.27 (0.16-0.92) 0.27 (0.14-0.46) 0.81
SAM (nmol/L) 184 (113-245) 156 (104-227) 0.06
SAH (nmol/L) 18 (13-59) 18 (12-44) 0.46
SAM/SAH-ratio 9.2 (3.4-16.6) 9.0 (3.3-16.1) 0.70
As far as we know SAM levels in CSF of AD patients have only been 
studied by the group of Bottiglieri et al.2 These authors found that in 
AD patients SAM values were below the normal range, the mean value 
being 41% lower than that of the neurological control group (P =0.0001). 
However, the mean age of the AD patients was signifi cantly higher than 
that of the controls (60.3 ± 5.5 years versus 49.7 ± 16.4 years). Thus, the 
observed increase in CSF SAM in the AD patients might be explained by 
the well-known increase of homocysteine levels with increasing age. 
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Another group studied SAM levels in post-mortem brain samples of 
AD patients and age-matched controls with the same post-mortem time 
interval (10±1 hours for AD patients and 11 ± 1 for controls). In all brain 
areas of AD patients (cerebral cortex subdivisions, hippocampus, and 
putamen) decreased levels of SAM (-67% to -85%) and SAH (-56% to 
-79%) were observed.8 However, other experiments with biopsied and 
autopsied control human brain indicated that SAM levels decrease by 60% 
and SAH levels increase by 80% over a 15-hour post-mortem interval, 
indicating that post-mortem analyses of SAM and SAH in brain are diffi cult 
to interpret. 
In conclusion, the results of our study suggest that there are no 
changes in the level of metabolites of the transmethylation cycle in CSF 
of AD patients. Deposits of Aβ in plaques in AD brain may result from 
posttranscriptional or posttranslational changes in PS1 activity rather than 
from overexpression of the PS1 gene by undermethylation of its promotor. 
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To the Editor: Vitamin B6 is important in the reduction of a potentially 
toxic excess of homocysteine.1 Low levels of vitamin B6 are related to 
cognitive decline, but the underlying mechanism is not known. We 
hypothesized that vascular lesions in the brain may mediate this and 
studied the relation between vitamin B6 levels and the presence of white 
matter lesions (WMLs) on magnetic resonance imaging (MRI) in patients 
with Alzheimer’s disease (AD).
METHODS
One hundred twenty-three patients with AD who visited the outpatient 
memory clinic of the Alzheimer Center VU University Medical Center 
between 1997 and 2002 were included. All patients underwent a 
standardized examination that included blood tests, neuropsychological 
examination, and MRI. The standard MRI protocol included a coronal 
3-mm T1-weighted and transverse 5-mm proton density or FLuid 
Attenuated Inversion Recovery (FLAIR) images on a 1.0T scanner 
(Impact, Siemens AG, Erlangen, Germany) with an in-plane resolution of 
1 x 1 mm2. Cortical atrophy was assessed as the mean of the maximum 
width of the left and right Sylvian fi ssure divided by the maximum brain 
width measured transpineally. Medial temporal lobe atrophy (MTA) was 
rated using a visual assessment of atrophy of the left and right medial 
temporal lobe separately. WMLs were rated semi quantitatively and 
were distinguished in the subcortical (number) and periventricular region 
(degree) separately.2 The Mini-Mental State Examination (MMSE) score 
was used as a measure of dementia severity. Plasma vitamin B6 levels 
were determined using measurement of the active cofactor plasma 
pyridoxal-5-phosphate applying high-performance liquid chromatography 
using precolumn derivatization with semicarbazide and fl uorescence 
detection. The overdispersed Poisson regression model was applied to 
investigate the relationship between the reciprocally transformed vitamin 
B6 concentration and WMLs, adjusted for potential confounders.
Low vitamin B6 levels are associated with white matter lesions in Alzheimer’s disease
129
RESULTS
The plasma vitamin B6 levels ranged from 9 nmol/L to 401 nmol/L. 
Sixty-three patients demonstrated any periventricular WMLs, and 88 
patients any subcortical WMLs (Table 1). 
Table 1. Characteristics of the Study Population (N =l23)
Characteristic  Value
Age, mean ± SD 69.3 ± 8.2
Male/female 59/64
Mini-Mental State Examination score, mean ± SD 20.5 ± 5.5
Plasma vitamin B6, nmol/L, median (range) 33 (9-401)
Medial temporal lobe atrophy, mean ± SD 1.6 ± 0.1
Cortical atrophy, mean ± SD 0.1 ± 0.03
Periventricular WMLs, degree, median (range) 1 (0-9)
Subcortical WMLs, number, median (range) 8 (0-758)
SD = standard deviation; WMLs = white matter lesions.
Poisson regression analysis showed that periventricular WMLs were 
dependent on the reciprocal of plasma vitamin B6 [regression coeffi cient B 
=9.22 ± 4.75, P <.05] as well as subcortical WMLs [B =17.71 ± 6.69, P <.01], 
after adjusting for MMSE, MTA, cortical atrophy, and overdispersion, 
indicating that low B6 levels were associated with higher WML load (Figure 
1).
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Figure 1. Scatter diagram depicting the association between periventricular 
white matter lesions (WMLs) (degree) and plasma vitamin B6 concentrations 
(upper panel) and between subcortical WMLs (number) and plasma vitamin B6 
concentrations (lower panel).
COMMENTS
We have demonstrated, for the fi rst time, that there is a strong 
relationship between periventricular and subcortical WMLs and low 
vitamin B6 levels in patients with AD. Low levels of B6 could be the result 
of malnutrition as part of the already ongoing dementia process. We do not 
think that this infl uenced our fi ndings because the patients were relatively 
mildly affected. Homocysteine, which is partially metabolized through the 
transsulfuration pathway, where homocysteine condenses with serine to 
cystathionine, a vitamin B6-dependent reaction, may mediate the observed 
effect of B6 on WMLs. Consequently, low vitamin B6 levels may cause high 
homocysteine levels, thus promoting the proliferation of smooth muscle 
cells and initiating or accelerating the progression of atherosclerosis,3 
which is related to WMLs. There is confl icting evidence on the relationship 
between vitamin B6 and vascular disease in dementia. A previous study4 
showed that low vitamin B6 levels in patients with AD were not related to 
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cardiovascular disease, whereas another study5 showed that patients with 
subcortical vascular dementia had lower vitamin B6 values. Both studies 
demonstrated a signifi cant relationship between high homocysteine levels 
and vascular disease in their patients. The implication of the current 
fi ndings is that low vitamin B6 levels may increase the vascular burden 
in the brain of patients with AD. These results may provide a rationale for 
intervention studies examining the effect of vitamin B6 supplementation 
on vascular changes in the brain in relation to the incidence and course 
of AD.
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To the editor: In an earlier study,1 we described in patients with 
Alzheimer’s disease (AD) an inverse relationship between plasma vitamin 
B6 levels and the number of white matter hyperintensities (WMH), as seen 
using magnetic resonance imaging (MRI). We suggested the involvement 
of homocysteine (Hcy) metabolism, because high levels of Hcy are 
considered to be a risk factor for WMH.2 Hcy is partially metabolized 
through the transsulfuration pathway, in which Hcy condenses with serine 
to cystathionine, in a vitamin B6-dependent reaction. Thus, Hcy could form 
the link between B6 levels and the degree of WMH. Hcy is also converted 
into methionine by the transmethylation pathway, which requires folate 
and vitamin B12. 
In the present study, plasma samples of patients with AD visiting the 
memory clinic during 2003-2006 were collected to investigate whether 
Hcy metabolism (Hcy, vitamin B12, folate, and vitamin B6) is associated 
with the occurrence of WMH in AD. 
Seventy-six patients with probable AD from the VU University Medical 
Center memory clinic with complete data records were included. The 
median age was 71 years (range 51-86) and the mean Mini Mental State 
Examination (MMSE) score3 19.7 (SD =5.7). 
All patients underwent standardized examinations including medical 
history, physical and neurological examinations, laboratory tests, and 
MRI. Clinical diagnosis was made in a multidisciplinary meeting.
The local ethical committee approved the study. All patients gave 
informed consent to use their data for research purposes. 
The patients were scanned on a 1.0 T MRI (Impact, Siemens AG, 
Erlangen, Germany) according to the standard protocol, including a 
transverse fl uid attenuated inversion recovery sequence. WMH was 
visually assessed using the 4 point Fazekas scale (0-3).4
Vitamin B6 determinations, pyridoxal and pyridoxal-phosphate to-
gether, were performed according to a method previously published.5 
Hcy levels were measured using fl uorescence polarization immunoassay 
(IMx, Abbott Diagnostics, Abbott Park, IL). Vitamin B12 and folate 
were assayed using competitive immunoassays with luminescence 
(Architect, Abbott Diagnostics). All determinations were performed in 
ethylenediaminetetraacetic acid plasma.
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WMH grade was dichotomized (0 or 1 =absence vs 2 or 3 =presence). 
Logistic regression analysis was performed with WMH as the dependent 
variable and Hcy, B6, B12 and folate as predictors. Age and MMSE were 
entered as covariates. The level of statistical signifi cance was set at 0.05.
Plasma levels of Hcy, vitamin B12, folate, and vitamin B6 are shown 
in Table 1. Compared with the reference values, fi ve subjects had slightly 
increased Hcy levels, seven had vitamin B12 values below the reference 
levels, four had low folate levels, and 16 patients had vitamin B6 values 
above the reference range. 
Table 1. Plasma levels of biochemical parameters involved in the homocysteine 
metabolism of 76 patiens with Alzheimer’s disease, compared with the applied 
reference values.
Parameter Median Range Normal range
Homocysteine, μmol/L 11.2 5-28  6-19
Vitamin B12, pmol/L 248 91-660 150-700
Folate, nmol/L 10.3 3-76  ≥ 6
Vitamin B6, nmol/L  41 12-385 13-80 
The WMH of subjects with AD, classifi ed according to the Fazekas 
scale, demonstrated the following distribution: n =20 (26%) no WMH 
(score =0), n =30 (39%) mild WMH (score =1), n =18 (24%) moderate 
WMH (score =2), and n =8 (11%) severe WMH (score =3). 
The previously demonstrated inverse relationship between plasma 
vitamin B6 concentrations and grade of WMH in the brain of AD patients 
was confi rmed (Spearman correlation coeffi cient r= -0.28, p <0.05). There 
was also correlation between Hcy and WMH (Spearman r =0.29, p <0.05). 
There were no associations between WMH and vitamin B12 or folate.
Logistic regression demonstrated that, after correction for age and 
MMSE score, only B6 was a predictor of WMH (odds ratio =0.985; 95% 
confi dence interval =0.972-0.998; p =0.03), whereas Hcy, B12, and folate 
were not.
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These fi ndings are in accordance with previous observations on the 
association between white matter lesions and vitamin B6,1 although 
a relationship could not been demonstrated between WMH and Hcy 
metabolism, in contrast to the Rotterdam Scan Study2 This composition of 
the investigated population may explain this discrepancy. The Rotterdam 
Scan study primarily included an aging population, whereas the current 
study included patients with AD, who had Hcy, vitamin B12, vitamin B6, 
and folate levels mainly in the normal range. 
In a case-control study,6 the transmethylation cycle in the brain of 
patients with AD was studied in patients with probable AD and age-
matched controls by analyzing cerebrospinal fl uid. No changes in the Hcy 
metabolism in brain were found. The results from the current study on 
plasma are in agreement with these earlier fi ndings in cerebrospinal fl uid.
Antioxidant properties, especially the strong quenching effect of the 
pyridoxine moiety within vitamin B6 on singlet molecular oxygen, may 
explain the inverse relationship between plasma vitamin B6 and WMH.7-
9 Metabolic generation of singlet molecular oxygen occurs in stimulated 
neutrophils during the process of phagocytosis.10
Normal vitamin B6 levels may increase vascular burden in the brain of 
patients with AD, although the data from the current study do not support 
the hypothesis that plasma levels Hcy and the Hcy metabolism, adjusted 
for age and MMSE, determine the occurrence of WMH. 
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ABSTRACT 
Background: To improve ante-mortem diagnostic accuracy of 
Alzheimer’s disease (AD) the use of biomarkers amyloid-beta(1-42) (Aβ42), 
total tau (Tau) and hyperphosphorylated tau181 (pTau) in cerebrospinal fl uid 
(CSF) has been proposed. We have used these markers and evaluated 
their performance.
Methods: From January 2001 till January 2007 Aβ42, Tau and pTau 
were assessed by commercial ELISAs in CSF from 248 consecutive AD 
patients and 131 patients with subjective memory complaints attending 
our outpatient memory clinic. Diagnoses were made blind to the results 
of the biomarker assays. Sensitivity and specifi city were assessed and 
trends over time were analyzed. 
Results: Inter-assay CV’s (mean±SD) as judged from results of pools 
of surplus CSF specimens were 11.3 ± 4.9% for Aβ42; 9.3 ± 1.5% for Tau 
and 9.4 ± 2.5% for pTau respectively (n =7-18). To achieve 85% sensitivity, 
cut-off values were 550 ng/L for Aβ42 (95%CI: 531-570); 375 ng/L for Tau 
(95%CI: 325-405) and 52 ng/L for pTau (95%CI: 48-56). Corresponding 
specifi cities were 83% (95%CI:76-89) for Aβ42, 78% (95%CI:70-85) for 
Tau and 68% (95%CI: 60-77) for pTtau. Logistic regression to investigate 
the simultaneous impact of the three CSF biomarkers on the diagnosis 
yielded a sensitivity of 93.5% and specifi city of 82.7%, at a discrimination 
line: Aβ42=373+0.82*Tau. Over time only the area under the ROC curve 
of pTau showed signifi cant fl uctuation.
Conclusions: CSF biomarkers Aβ42 and Tau can be used as a 
diagnostic aid in AD. pTau did not have additional value over these two 
markers. Cut-off values, sensitivities, specifi cities, and discrimination lines 
depend on the patient groups studied and laboratory experience.
CSF biomarkers Aβ (1-42), total Tau and pTau for the AD diagnosis
141
INTRODUCTION
An ante-mortem diagnosis of “probable Alzheimer’s disease” (AD) 
is achieved by application of the National Institute of Neurological and 
Communicative Disorders and Stroke and Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA) criteria1 using a 
standardized protocol including medical history, physical and neurological 
examination, screening laboratory tests, psychometric evaluation, electro 
encephalography (EEG), and brain magnetic resonance imaging (MRI) or 
computed tomography (CT). Although the NINCDS-ADRDA criteria have 
been reported to have a high accuracy rate of 80%-90%,2,3 studies of the 
diagnostic accuracy came from specialized centers, and most data are 
from patients in later stages of the disease who were studied for several 
years before death and autopsy.
To improve the clinical diagnostic accuracy, assessment of biomarkers 
in cerebrospinal fl uid (CSF) has been proposed.4 Candidate biomarkers 
obviously are proteins that occur in senile plaques (SP) and neurofi brillary 
tangles (NFT). The principal component of the SP is the hydrophobic 
amyloid-beta (1-42) (Aβ42), whereas hyperphosphorylated tau (pTau), 
a fraction of the concentration of total tau (Tau), is a characteristic 
component of NFT.5-7 Previous studies showed that these biomarkers can 
discriminate AD patients from healthy controls with a good sensitivity and 
specifi city but cut-off levels differ between laboratories.8,11-13,15-18
The aim of the study was to establish the sensitivity and specifi city 
of assays or determination of Aβ42, Tau, and pTau in CSF to distinguish 
patients with probable AD from patients with subjective complaints (SMC) 
in a memory clinic setting. This paper describes our experience with the 
use of CSF biomarkers during a six year period.
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MATERIALS AND METHODS
Patients
From January 2001 till January 2007, 379 patients, referred to the 
Alzheimer Center of the VU University Medical Center, were included. 
All patients underwent a standard clinical assessment, including medical 
history, physical and neurological examination, screening laboratory 
tests, psychometric evaluation, EEG, MRI. Diagnosis of “probable AD” 
was made according to the NINCDS-ADRDA criteria1 by consensus in 
a multidisciplinary team, which was blinded to the results of the CSF 
analyses. When all investigations yielded normal results, subjects were 
considered to have subjective complaints and were designated as controls. 
After evaluation, 131 subjects aged 61.4 ± 10.1 years, 52% female, with 
mini mental state examination (MMSE) score 28.5 ± 1.8 were classifi ed 
as having subjective memory complaints and were designated as controls 
while 248 patients aged 66.7 ± 9.2 years, 48.4% female, with MMSE score 
20.8 ± 5.1 were diagnosed as ”probable AD”. Seventy three percent of the 
AD patients carried ApoEe4, as compared to 30% of the controls.
CSF was obtained by lumbar puncture between the L3/L4 or L4/L5 
intervertebral space, and collected in 12 mL polypropylene tubes. The 
protocol has been approved by the ethical review board of our institution 
and all subjects have given written consent to undergo the lumbar punction. 
CSF analysis
Within two hours CSF samples were centrifuged at 2100g for 10 minutes 
at 4°C. A small amount of CSF was used for routine analysis, including 
total cells, total protein, and erythrocytes. The remaining CSF was mixed 
and aliquoted into 0.5- or 1-mL polypropylene tubes, and stored at -80°C 
until further analysis of the biomarkers which occurred within a month.
Aβ42, Tau, and pTau concentrations were determined with sandwich 
ELISAs [INNOTEST™ β-Amyloid(1-42), INNOTEST™ hTAU-Ag, and 
Innotest Phosphotau(181P); Innogenetics, Ghent, Belgium]. As the manu-
facturer does not supply control specimens, the performance of the assays 
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was monitored with pools of surplus CSF specimens. In the study period 
multiple specimens with various concentrations which were included in 7 
– 18 runs have been used for this purpose. The inter-assay CV’s obtained 
(mean ± SD) were 11.3 ±4.9% for  Aβ42; 9.3 ± 1.5% for Tau and 9.4 ± 
2.5% for pTau respectively.
Data analysis
Cut-off values to achieve the 85% sensitivity as advocated in the Reagan 
Consensus Report,9 were determined and corresponding specifi cities were 
calculated. Receiver Operating Characteristic (ROC) curves were drawn 
by plotting the true-positive rate (sensitivity) against the false-positive rate 
(100-specifi city). In addition, the areas under the ROC curve (AUC) and its 
standard error were calculated. The ROC curves were compared with the 
Hanley and McNeil method10 using Medcalc V 4.30 Software (Mariakerke, 
Belgium). Logistic regression analysis with backward stepwise selection 
was used to estimate the simultaneous impact of the continuous variables 
Aβ42, Tau, and pTau in CSF on the diagnosis “probable AD”. Correlations 
were calculated with the Spearman method.
RESULTS 
Cut-off values to distinguish AD patients from controls with a sensitivity 
of 85% and the associated specifi cities are shown in Table 1. Clearly, Aβ42 
at a cut-off value of 550 ng/L demonstrates the highest discriminatory 
power. 
To investigate whether the performance of the biomarker tests was 
reproducible over time, the study period was divided in four quarters of 18 
months each and cut-off levels and specifi cities were calculated for each 
period (Figure 1). 
Over time, the cut-off value for Aβ42 turned out to be the most stable 
(532 ± 31 ng/L) showing a coeffi cient of variation of only 5.7% over the four 
study periods. Cut-off values for Tau and pTau showed modest fl uctuation 
(9.1% resp. 9.6%). Also with respect to the specifi city at 85% sensitivity 
Aβ42 showed less fl uctuation than the other two markers (9.1% vs. 13.8% 
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and 28.9%). It appears from Figure 1 that the highest fl uctuation was 
observed in periods 1 and 2, whereas in periods 3 and 4 a more stable 
performance was observed. We therefore considered the fi rst two periods 
as learning or profi ciency time and restricted further analysis to periods 
3 and 4, covering the last three year period of our study in which 155 AD 
patients and 84 SMC patients were included.
Table 1. Discrimination between 248 patients with probable Alzheimer’s Disease 
and 131 controls by CSF biomarkers during 2001-2007
CSF Marker Cut-off for 85% sensitivity
[ng/L; (95%CI)] 
Specifi city
[%; (95%CI)]
Amyloid β42 550 (531-570) 83 (76-89)
Tau 375 (325-405) 78 (70-85)
pTau  52 (48-56) 68 (60-77)
Both in AD and SMC patients concentrations of Tau and pTau were highly correlated (both 
groups rs =0.89).
ROC curves for the three CSF biomarkers are shown in Figure 2. Pair 
wise comparison of the ROC curves for Aβ42, Tau and pTau in CSF showed 
no signifi cant difference for Aβ42 (AUC 0.928; 95%CI: 0.888-0952) vs. 
Tau (AUC 0.911; 95%CI: 0.868-0.944; p =0.51) or Aβ42 vs. pTau (AUC 
0.880; 95%CI: 0.832-0.918; p =0.082). By contrast, the AUC’s of Tau and 
pTau were found to be statistically different (p =0.017).
Logistic regression analysis with diagnosis (probable AD and controls) 
as dependent variable and Aβ42, Tau, and pTau in CSF as independent 
continuous variables resulted in correct classifi cation of 145/155 (93.5%) 
probable AD patients and 76/84(90.5%) controls, with an overall correct 
percentage of 92.5%, at a cut-off line Aβ42=373+0.82*Tau (Figure 3). In 
this model pTau did not contribute to distinguish patients with “probable” AD 
from controls. We also investigated whether pTau would have additional 
diagnostic value in the non ApoE-e4 carriers. In a logistic regression 
model, no such value was observed.
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Figure 1. Performance of CSF biomarkers in AD over time (from 2001 to 2007). 
Cut-off values for Aβ42, Tau and pTau yielding 85% sensitivity and specifi city at 
85% sensitivity.
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Figure 2. ROC curves of Aβ42, Tau and pTau in CSF. Sensitivity vs. specifi city 
was calculated for all subjects in period 3 plus 4. The graph was drawn with 84 
controls and 155 probable AD patients studied in 2004-2007.
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Figure 3. Scatterplot of CSF Aβ42 vs. Tau in 155 patients with “probable” AD 
and 84 controls. The equation of the line for optimal separation is: [Aβ42] = 
373+0.82*[Tau]. 
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DISCUSSION
This paper describes our experience with assays for CSF biomarkers 
during six years of clinical research. An important lesson to be learnt is 
that a certain degree of experience appears to be required in order to 
have confi dence in the results obtained. This conclusion is based on the 
fact that results appear to reach stability only in the second half of our 
study period. Reasons for the lack of stability in the fi rst half may include 
lack of experience with the assays, also as a result of the relatively low 
number of assays in the fi rst years; and differences in the patient groups 
referred for analysis, such as age, severity of symptoms etc. Also the 
mere fact that more patients are referred in the second half of the study 
may be of infl uence. Despite efforts to prevent pre-analytical variation 
such as time between lumbar puncture and storage, this may also have 
contributed. Finally, analytical variation is a source of variation. This may 
have had several reasons, ranging from lot-to-lot variations in reagents 
and variation in technical skills. Although we have carefully reviewed all 
possibilities, we have not been able to identify the reason(s) for the higher 
fl uctuation in the fi rst half of our study. In order to overcome the issue 
of lot-to-lot variation, we nowadays purchase large numbers of kits from 
the same lot. Obviously, this is only possible since our request load has 
signifi cantly increased recently. We anticipate to see a decrease in the 
inter-assay variation in the near future.
The second fi nding of our study is that despite variation in time, the 
assays for CSF biomarkers Aβ42 and Tau appear to be suffi ciently stable 
to be used to distinguish AD from controls. CSF pTau was ruled out in 
the logistic regression model and hence had no additional value in the 
separation of patients with AD from controls.
Optimal sensitivity and specifi city are obtained when the contrast 
between the AD patients and controls is optimal, i.e. the AD patients are 
correctly classifi ed as AD patients and the controls as healthy subjects. 
The accuracy of the clinical diagnosis for ‘probable’ AD has been reported 
to be relatively low, with a sensitivity of 81% and a specifi city of 70%.11 
The power of biomarkers for separating AD patients from healthy controls 
has been demonstrated by Riemenschneider et al.12 who investigated 74 
patients with AD and 40 cognitively healthy control subjects. These authors 
Chapter 11
148
reported higher cut-off levels than we found. It is unclear whether this has 
to be attributed to differences in the patient groups or to experimental 
differences. It does illustrate the necessity for laboratories to establish 
their own reference values. The importance of the composition of the 
patient groups and co-morbidity has been shown in a multicenter study13 
as well as in a meta-analysis.8 Although patient groups differed in the 
various studies, for Aβ42 the sensitivity was always >75%, whereas the 
lowest value for Tau a broader range was reported, the lowest value being 
30%.
After completion of our study it became clear that in non-demented 
individual subjects Aβ42 levels may show signifi cant diurnal variation, 
the lowest values being observed in the morning.14 It is presently unclear 
whether this also applies to patients with AD. We could not evaluate this 
phenomenon in our material due to a lack of serial samples over the day, 
but it highlights the fact that diurnal variation of CSF biomarkers requires 
further investigation. Until the issue is settled, time of collection of CSF 
should be taken into account and lumbar punctures should preferably be 
performed at the same time of the day per center.
Many studies have demonstrated an association of low Aβ42 and high 
Tau levels with AD.15-18 Calculation of a separation line, e.g. by logistic 
regression, may be helpful in the classifi cation of the subjects with low 
Tau/low Aβ42 and high Tau/high Aβ42, which otherwise would be diffi cult 
to classify. We found that the best discrimination between 84 patients 
with mild cognitive impairment and 155 patients with probable AD was 
achieved by the line Aβ42 =373 + 0.82*Tau, leading to an overall correct 
classifi cation of 92.5%. Other discrimination lines have been published, 
e.g. by Hulstaert et al.13 who reported that the line Aβ42 =240 + 1.18*Tau 
discriminated AD patients from a group of healthy volunteers and patients 
with other neurological disorders with 85% sensitivity and 86% specifi city. 
As this was a multicenter study and the control group differed from ours, 
a direct comparison is not possible. Using the same discrimination line, 
Andreasen et al.19 reported a sensitivity of 94% for probable AD, 88% for 
possible AD, and 75% for mild cognitive impairment, whereas specifi city 
was 100% for discrimination from psychiatric disorders and 89% for non 
demented individuals. Riemenschneider et al.12 found a 92% sensitivity 
and a 95% specifi city for separation of AD vs. controls with the line Aβ42 
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=644 + 0.25*Tau. The differences in the equations of the discrimination 
lines, illustrate considerable variation between institutions with respect 
to experimental procedures, composition of patient group and urgently 
calls for standardization. One approach to this is the establishment of 
international quality control schemes for the assessment of the biomarkers. 
Our group20 has recently reported on such an initiative.
One other result of the logistic regression was the elimination of pTau 
as a valuable marker to distinguish patients with AD from controls both in 
the entire group and in the ApoE-e4 carriers. CSF pTau is claimed to refl ect 
the pathology of microtubules and was, therefore, expected to contribute 
signifi cantly. Nevertheless, this parameter was removed as a variable in 
the equation of the logistic model (p =0.64). The high correlation coeffi cient 
between pTau and Tau (rs =0.93; p <0.001) is probably the reason for this. 
Despite this, pTau is considered to be of importance in the differential 
diagnosis of AD.
There are two important diagnostic issues, e.g.: the dicscrimination 
between AD and non AD on one hand and the conversion of MCI to AD on 
the other.21,22 Our study deals with the performance of CSF biomarkers 
to distinguish AD from Non AD. In the daily practice of a memory clinic, 
all patients have memory complaints and the number one issue is 
to distinguish between AD and Non AD. Conversion of MCI to AD is a 
separate issue. Previous work of our group has shown that for the three 
CSF biomarkers used serial measurement is of limited value.23,24 
When the concentration of one analyte is increased and that of the 
other is decreased, a ratio might be more informative.15,25,26 When results 
of biomarker measurements are clearly method dependent, as is the 
case with CSF biomarkers, calculation of a ratio has only local value and 
is not useful for comparison with other studies. We have calculated the 
sensitivity and specifi city of the Tau/Amyloid beta ratio. We found a ratio 
of 0.59 to yield a 91.2 sensitivity (95% CI: 87-96) and a 91.7% specifi city 
(95% CI: 84-97). 
The high Tau level observed in some patients (Figure 3) might raise the 
question whether these patients may be suffering from Creutzfeldt-Jakob 
disease.27 As implied in the methods section, such a diagnosis was not 
made in any of our patients. We have re-evaluated the records of patients 
in whom a CSF Tau level higher than 1300 ng/L was reported. No reason 
for the high Tau concentration became apparent.
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In conclusion, CSF Aβ42 and Tau are useful as biomarkers to identify 
patients with probable AD from controls in a memory clinic setting. Cut-off 
values, sensitivities, specifi cities, and discrimination lines are dependent 
of the subjects referred and laboratory experience.
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1 SUMMARY
In this thesis the diagnosis of AD in a memory clinic setting is described, 
focusing on the use of biochemical markers (Chapter 1 and 2). The most 
important biomarkers for the diagnosis are Aβ42, Tau, and Ptau in CSF. 
These biomarkers are derived from the characteristic hallmarks of AD, 
the senile plaques and the neurofi brillary tangles in brain. However, other 
pathological processes, associated with AD, are also studied to obtain 
more insight in the etiology of the disease.
The most important fi nding was that the post-mortem hallmarks of AD 
provide ante-mortem biomarkers for the diagnosis. The use of biomarkers 
Aβ42, Tau and Ptau was studied using commercial ELISAs in CSF from 
AD patients and patients with subjective memory complaints. Inter-assay 
CV’s were about 10% for the three parameters. The cut-off values were 
550 ng/L for Aβ42 , 375 ng/L for Tau, and 52 ng/L for Ptau at a chosen 
sensitivity of 85%. Corresponding specifi cities were, respectively 83%, 
78%, and 68%. Logistic regression to investigate the simultaneous impact 
of the three CSF biomarkers on the diagnosis yielded a sensitivity of 94% 
and specifi city of 83%, however, in this setting Ptau did not have additional 
value. (Chapter 11).
At the start of these investigations, preanalytical infl ucences on the 
levels of the CSF biomarkers to be studied were largely unknown. We, 
therefore, investigated the stability of the biomarker levels, also from 
the perspective that in the beginning accrual of samples was low and 
specimens had to be stored prior to analysis. Stored for a long period at 
-80°C the concentrations of Aβ42 and Tau in CSF are remarkably stable. 
CSF Aβ42 decreased by 20% during the fi rst 2 days at 4, 18 and 37°C 
compared with -80°C. CSF Tau decreased after storage for 12 days at 
37°C. After three freeze/thaw cycles, CSF Aβ42 decreased 20%, and 
CSF Tau was stable during six freeze/thaw cycles. However, freezing/
thawing of fresh CSF samples did not have any infl uence. In addition, 
centrifugation did not infl uence the biomarker concentrations (Chapter 3).
The Aβ42 concentrations were measured by two different assays in the 
same CSF samples (‘split samples’) on two locations. The fi rst assay is 
widely used in Europe while the second assay is used mainly in the United 
States of America. The concentrations, measured by both methods did not 
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differ statistically signifi cant from each other. In AD patients vs controls, the 
sensitivity and specifi city were 90%, for both assays. Comparing the AD 
and FTLD patient groups, we obtained specifi city of 71% at a sensitivity of 
85%, with a trend of better discrimination for the USA method (p =0.045) 
(Chapter 4). 
In chapter 5 we studied two new potential markers SAP and C1q, which 
showed comparable CSF levels in AD patients and controls. For CSF-SAP 
and CSF-C1q confl icting results have been reported, perhaps due to the 
use of different control groups. More likely, however, there are differences 
in sensitivity and specifi city of the antibodies used in the assay methods. In 
our study, well defi ned and documented AD patients and healthy controls 
were compared, yielding a large ‘black and white’ contrast, probably more 
adequate to investigate the potential value of a new biological marker. Our 
results render these new markers probably useless for AD diagnosis.
In chapter 6, CSF concentrations of the NOS inhibitor ADMA and its 
hydrolysis product dimethylamine in AD patients were studies and showed 
no difference when compared to age-matched control subjects. In addition, 
concentrations of arginine, the substrate of NOS, and SDMA also did not 
differ between AD patients and controls. These results suggest that in 
AD there are no alterations of NOS activity on the concentration of either 
substrate or the endogenous inhibitor ADMA.
In chapter 7, no difference in total PC concentrations was found 
between AD patients and controls. The lyso-PC/PC ratio was signifi cantly 
decreased in CSF of AD patients, suggesting alterations in the metabolism 
of choline-containing phospholipids in the brain in AD, but the difference 
between both groups was small and considerable overlap was present, 
also rendering it less useful as biomarker for AD.
The level of the metabolites of the transmethylation cycle in CSF of 
AD patients was similar to that of controls (Chapter 8). These fi ndings 
argue against a possible change in methylating of the promoter and 
expression of PS1. Deposits of Aβ in plaques in AD brain may result from 
posttranscriptional or posttranslational changes in PS1 activity rather than 
from over expression of the PS1 gene by undermethylating of its promoter. 
In chapter 9, a strong relationship between white matter changes on 
MRI (WMH) and low plasma vitamin B6 levels in patients with AD was 
identifi ed. Homocysteine, which is partially metabolized through the 
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transsulfuration pathway, where homocysteine condenses with serine 
to cystathionine in a vitamin B6-dependent reaction, may mediate the 
observed effect of B6 on WMH. Consequently, low vitamin B6 levels 
may cause high homocysteine levels, thus promoting the proliferation 
of smooth muscle cells and initiating or accelerating the progression of 
atherosclerosis, which is related to WMH. 
The previously demonstrated inverse relationship between plasma 
vitamin B6 concentrations and grade of WMH in the brain of AD patients 
was confi rmed in chapter 10. Only vitamin B6 level was linked to WMH, 
whereas homocysteine, vitamin B12, and folate were not. Antioxidant 
properties, especially the strong quenching effect of the pyridoxine moiety 
within vitamin B6 on singlet molecular oxygen, may explain the inverse 
relationship between plasma vitamin B6 and WMH. 
2 FUTURE PERSPECTIVES
The neuropathological hallmarks of AD are refl ected in the 
aforementioned specifi c tests. A disadvantage of these markers is the 
lack of sensitivity in early disease stages of AD. The search for new 
biomarkers, supplementary to the known triplet, should follow the following 
four directions.
2.1 CSF Oligomers
Hardy and Higgins1 postulated the amyloid cascade hypothesis in 
1992. Aβ-derived fi brils and neuritic plaque formation play a primary role in 
the AD pathogenesis. Currently, the hypothesis is under scrutiny because 
plaque formation may also occur in healthy people2 and plaque burden 
correlates poorly with dementia.3,4 Furthermore most transgenic mouse 
models of AD manifest little or no death of neurons.
It was discovered that Aβ self-assembly does not inexorably lead to 
protofi brils or larger fi bril aggregates. A powerful tool for accessing the 
spectrum of structures, earlier shown to be valuable for characterizing 
fi bril structure, is atomic force microscopy.5 It was demonstrated that the 
same monomers can generate not only fi brils but also fi bril-free solutions of 
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oligomers, comparable to soluble globular proteins smaller than 100 kDa.
The crucial and earliest symptoms of AD are memory loss and executive 
dysfunction. These have been in many studies to loss of synaptic function. 
Assaying long-term potentiation and long-term depression, the classical 
electrophysiologic models for learning and memory, Aβ oligomers are 
neurologically potent CNS toxins that rapidly disrupt synaptic information 
storage. Evidence suggest that oligomers disrupt glutamate receptor 
traffi cking.6,7 Thus, identifi cation of oligomers may be useful in detecting 
the earliest stage of AD. The determination of oligomers is a challenge to 
neurological laboratories worldwide. It should become feasible soon with 
two novel ultra-sensitive methods which both use the PCR reaction to 
reach the desired sensitivity.
 — The fi rst of these potentially useful methods is based on the so-
called Imperacer™ technology (Chimera Biotec GmbH, Dortmund, 
Germany) and its development is integrated in the EDAR project, an 
European collaborative study which aims to develop and validate 
new biomarkers for AD. Oligomers are captured with an antibody 
and determined with an immuno-PCR, combining the advantage of 
conventional ELISA with the exponential signal amplifi cation of PCR 
resulting in a typically 100-10,000-fold increase in sensitivity as 
compared to standard immunoassays.8 The project started in 2007 
and will be fi nished in 2010 Preliminary results are not yet available.
 — The second of these promising new techniques to determine 
oligomers in CSF is the ultrasensitive nanoparticle-based “Bio-
Barcode” assay.9 In this assay pAbs and mAbs against oligomers are 
respectively coupled to magnetic microparticles and complementary 
Barcode-DNA-nanoparticles. After incubation of CSF with the 
particles a sandwich of oligomers is magnetically separated from 
CSF and the Bio-Barcode DNA is fi nally dehybridized from the 
nanoparticles and isolated for quantifi cation. 
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2.2 Proteomics (MALDI-TOF-MS)
Several proteomic methodologies have been developed that now make 
it possible to identify, characterize, and quantify the level of expression 
of hundreds of proteins that are co-expressed in a given cell type or 
tissue, or that are found in biological fl uids such as CSF or serum. Today, 
no single method exists that by itself can quantify and identify all the 
components of a protein sample. The range of molecular weights and types 
of proteins that are optimally detected vary between different proteomic 
methods. Therefore, different methods for pre-fractionation, separation, 
identifi cation and quantifi cation of proteins are often used either alone or 
in combination.10 Immunoprecipitation (IP) can be used to enrich proteins, 
present in low concentrations of interest in CSF. IP of various Aβ splice 
variants followed by MALDI-TOF-MS may be used to analyse those Aβ 
peptides. With this technique it is possible to identify and quantify the 
series of Aβ peptides truncated at the N-sites and at the C-site.
The most important separation technique in proteomics is two-
dimensional gel electrophoresis (2-DGE) a method in which proteins are 
separated according to their charge and molecular weight. 
Matrix assisted laser desorption/ionization time-of-fl ight mass 
spectrometry (MALDI-TOF-MS) is a technique in proteomics of transferring 
molecules into the gas phase, thereby adding predominantly only one 
charge to these molecules. Essential for the method is the embedding of 
such molecules into a crystal-like structure of weak organic acids referred 
to as “matrix”, responsible for ionization, facilitating desorption and 
preventing the analytes from decomposition. MS can be used to determine 
the primary structure, i.e. the amino acid sequence of the peptide. This is 
often accomplished through the so-called tandem MS or MS/MS (mass 
selection/mass separation) experiments. 
In conjunction with multidimensional chromatography, followed by MS/
MS, a multiplex quantitative proteomics method was employed to measure 
simultaneously relative changes in the proteome of CSF obtained from 
patients with AD, Parkinson’s disease, and Lewy body disease compared 
to healthy controls.11 In this study, the proteomic fi ndings showed 
quantitative changes as compared to controls in the level of 136 proteins, 
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among more than 1,500 identifi ed CSF proteins. Further case-control 
studies are warranted to validate these results for the individual proteins. 
The identities of all possible CSF biomarkers for AD, assayed in two 
ore more independent studies that presented a reasonable amount of 
quantitative data (mean, standard deviation and p-values) are recently 
summarized by Zetterberg, et al.12 In a large number of studies, a number 
of factors that are either up- or down-regulated of which certain isoforms 
are detectable, have been reported. These include different Aβ forms, as 
well as the different isoforms of apoE and apoA and complement factors. 
The different isoforms, which can be detected in CSF and plasma, probably 
result from post-translational modifi cations.
The isoforms of the complement proteins C3b, C4b, factor B and factor 
H can be detected in CSF on 2D gels and confi rmed with MS.13,14 Despite 
the relatively small groups tested, patients with AD, multiple sclerosis 
and Parkinson’s disease all showed more than one complement isoform 
with a signifi cant change (p <0.05) compared to controls. However, the 
patterns in expression levels differed. In Parkinson disease CSF samples 
a large number of changed isoforms are present at low expression levels, 
whereas in AD only two isoforms of C4b were changed compared to 
controls. Therefore, when searching for disease biomarkers, measuring 
the expression level of individual protein isoforms in addition to the total 
protein expression level may improve the diagnostic utility of the protein. 
2.3 Arrayed sandwich ELISAs 
It is clear from the above that single molecular markers are insuffi cient 
and that combinations of markers may perform better. In this context and 
in the assumption that neurodegenerative changes somehow should be 
refl ected in the peripheral circulation 120 known signalling proteins were 
measured in 259 plasma samples from individuals with presymptomatic to 
late-stage AD and from various controls in arrayed sandwich ELISAs.15,16 
The data set obtained was analyzed with predictive analysis of microarrays, 
and 18 predictors out of the 120 proteins classifi ed Alzheimer’s and non 
demented controls with 95% positive agreement and 83% negative 
agreement with the clinical diagnosis, respectively. 
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The 18 signalling proteins identifi ed included cytokines, chemokines, 
an adhesion factor, growth factors, as well apoptosis related factors. 
Investigation of the biological relevance of the 18 predictors for AD 
pointed to an overall reduction in the abundance of factors associated 
with haematopoiesis and infl ammation during AD, as well as to defi cits 
in neuroprotection, neurotrophic activity, phagocytosis and energy 
homeostasis. The performance of the 18 predictors in the prediction of 
unknown samples resulted in 90% positive agreement for AD and 88% 
negative agreement for non demented controls plus individuals with other 
dementias. It is reassuring for the laboratories working with CSF that the 
sensitivity and specifi city as reported from this study is comparable to what 
is achieved with three CSF markers. Nevertheless, since future biomarker 
tests preferably would be performed with easily accessible body fl uids, 
these results obtained in plasma may pave the way for multi-marker tests 
to be used in future.
2.4 MicroRNAs
MicroRNAs (miRNA) are single-stranded RNA molecules of about 21-
23 nucleotides in length, which regulate gene expression. The miRNA 
are encoded by genes that are transcribed from DNA but not translated 
into protein (non-coding RNA; instead they are processed from primary 
transcripts to short stem-loop structures and fi nally to functional miRNA. 
Mature miRNA molecules are partially complementary to one or more 
messenger RNA (mRNA) molecules, and their main function is to regulate 
gene expression. They were fi rst described in 1993 by Lee and colleagues 
in the Victor Ambros lab,17 yet the term microRNA was introduced 8 year 
later in Science.18
Just as miRNA is involved in the normal functioning of eukaryotic cells, 
so has dysregulation of miRNA been associated with disease. The initial 
research focus based on products and services requested was on cancer 
and heart disease research, broadened to include neurosciences as well.
Using a sensitive qRT-PCR platform Cogswell et al.19 identifi ed 
regional and stage-specifi c deregulation of miRNA expression in brains of 
AD patients. Investigated were age matched hippocampus, medial frontal 
gyrus, and cerebellum samples from different Braak stages. Many miRNA 
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were identifi ed whose expression was altered both early in disease as well 
as in the regions of the brain most affected by AD pathology. Obviously, 
investigation of brain tissue is only possible post-mortem.
The sample of a biomarker test should be easily obtainable. For the 
diagnosis of AD the composition of CSF may refl ect the processes in the 
brain. To detect miRNAs in CSF a sensitive pre-amplifi cation was employed 
that permitted the detection of 201 out of 242 miRNAs tested.19 Observed 
was an even distribution of under- and overexpressed miRNAs and a low 
standard error overall except for the low abundances. Sixty miRNAs were 
detected as signifi cantly different (p <0.05) between Braak stage 1 and 
Braak stage 5 samples. Notably all of the members of the miR-30 family 
were induced although relevant targets have not been described. Applying 
the pathway enrichment algorithm to this dataset suggested up-regulation 
of genes in T cell signalling and infl ammation. These results show that 
the miRNAs can be recovered from frozen CSF and their expression can 
distinguish Braak 5 AD from Braak 1 patients.
It is required to characterise those miRNAs that are associated with the 
hyperphosphorylated tau and Aβ1-42, corresponding with the hallmarks of 
AD. Hebert et al.20 assessed in a pilot study the expression profi les of 328 
human miRNA from sporadic AD patients. MiRNA of fi ve AD cases and fi ve 
age-matched controls were compared and miRNA that were signifi cantly 
altered were identifi ed. The miR-29a/b-1 cluster was signifi cantly (and AD 
specifi cally) decreased in AD patients displaying abnormally high BACE1 
protein. Similar correlation between the expression of this cluster and 
BACE1 was found in neuronal cultures. Another miRNA, miRNA-107,21 
may also be involved in the disease progression of AD through regulation 
of BACE1. 
Further research is needed to couple miRNA to the metabolic aberrations 
in order to get more insights into AD pathogenesis and to investigate if 
miRNA could be reliable and early biomarkers for the diagnosis of AD.
All in all, it appears that the identifi cation of new (combinations of) 
biomarkers for Alzheimer’s Disease is a matter of time and effort. Markers 
will likely be identifi ed on the protein as well as on the (micro-)RNA level.
Chapter 12
162
REFERENCES
1. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 
1992;256:184-5.
2. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P et al. Clinical, pathological, and 
neurochemical changes in dementia: a subgroup with preserved mental status and numerous 
neocortical plaques. Ann Neurol 1988;23:138-44.
3. Glabe CG. Amyloid accumulation and pathogensis of Alzheimer’s disease: signifi cance of 
monomeric, oligomeric and fi brillar Abeta. Subcell Biochem 2005;38:167-77.
4. Neve RL, Robakis NK. Alzheimer’s disease: a re-examination of the amyloid hypothesis. 
Trends Neurosci 1998;21:15-9.
5. Stine WB, Jr., Snyder SW, Ladror US, Wade WS, Miller MF, Perun TJ et al. The nanometer-
scale structure of amyloid-beta visualized by atomic force microscopy. J Protein Chem 
1996;15:193-203.
6. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M et al. Abeta oligomer-
induced aberrations in synapse composition, shape, and density provide a molecular basis for 
loss of connectivity in Alzheimer’s disease. J Neurosci 2007;27:796-807.
7. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY et al. Regulation of NMDA receptor 
traffi cking by amyloid-beta. Nat Neurosci 2005;8:1051-8.
8. Adler M, Wacker R, Niemeyer CM. Sensitivity by combination: immuno-PCR and related 
technologies. Analyst 2008;133:702-18.
9. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA. 
Nanoparticle-based detection in cerebral spinal fl uid of a soluble pathogenic biomarker for 
Alzheimer‘s disease. Proc Natl Acad Sci U S A 2005;102:2273-6.
10. Nakazawa T, Yamaguchi M, Okamura TA, Ando E, Nishimura O, Tsunasawa S. Terminal 
proteomics: N- and C-terminal analyses for high-fi delity identifi cation of proteins using MS. 
Proteomics 2008;8:673-85.
11. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E et al. Detection of 
biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fl uid of patients 
with neurodegenerative disorders. J Alzheimers Dis 2006;9:293-348.
12. Zetterberg H, Ruetschi U, Portelius E, Brinkmalm G, Andreasson U, Blennow K, Brinkmalm A. 
Clinical proteomics in neurodegenerative disorders. Acta Neurol Scand 2008;118:1-11.
13. Finehout EJ, Franck Z, Lee KH. Complement protein isoforms in CSF as possible biomarkers 
for neurodegenerative disease. Dis Markers 2005;21:93-101.
14. Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H et al. Characterization 
of amyloid beta peptides in cerebrospinal fl uid by an automated immunoprecipitation procedure 
followed by mass spectrometry. J Proteome Res 2007;6:4433-9.
15. Huang RP. Cytokine protein arrays. Methods Mol Biol 2004;264:215-31.
16. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K et al. Classifi cation 
and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med 
2007;13:1359-62.
17. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small 
RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.
18. Ruvkun G. Molecular biology. Glimpses of a tiny RNA world. Science 2001;294:797-9.
19. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B et al. Identifi cation of miRNA 
changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into 
disease pathways. J Alzheimers Dis 2008;14:27-41.
20. Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN et al. Loss 
of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased 
BACE1/beta-secretase expression. Proc Natl Acad Sci U S A 2008;105:6415-20.
21. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q et al. The expression of 
microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease 
progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J 
Neurosci 2008;28:1213-23.
Nederlandse samenvatting
 
 164
ACHTERGROND
Dementie wordt gekenmerkt door een progressieve achteruitgang 
van de cognitieve functies, die groter is dan die welke bij het normale 
ouder worden optreedt. De mogelijkheid om onderscheid te kunnen 
maken tussen de meest voorkomende vormen van dementie – ziekte 
van Alzheimer (ZvA), vasculaire dementie, frontotemporale dementie, en 
dementie met Lewy bodies – is van belang voor een optimale zorg en 
behandeling.
Neuropathologische veranderingen in de hersenen van patiënten met 
dementie worden al ruim honderd jaar bestudeerd. In 1907 beschreef 
Alois Alzheimer een patiënte met geheugenverlies, desoriëntatie en 
hallucinaties. In de hersenen werden buiten de cellen amyloïd afzettingen 
gevonden en de neuronen bevatten inclusies van tau proteïne. De 
postmortem diagnose ZvA is in 2009 nog steeds gebaseerd op deze 
zelfde bevindingen.
Voor de dood kan de ZvA met toenemende zekerheid worden 
gediagnosticeerd. De ante-mortem criteria voor de “probable” ZvA, die 
tot de jaren 90 gebruikt zijn, waren primair gericht op de uitsluiting van 
andere types van dementie. Maar tegenwoordig kan men door aanvullend 
onderzoek het percentage patiënten dat juist geclassifi ceerd wordt 
verhogen.
Naast beeldvormende technieken, waardoor de structuur en werking 
van hersenen bij levende mensen bestudeerd kan worden, kunnen 
ook biochemische markers in hersenvocht (liquor) worden bepaald. De 
kenmerken van de ZvA, amyloïd afzettingen en tau inclusies in neuronen 
waren aangrijpingspunten om hieruit afgeleide potentiële biomarkers te 
onderzoeken.
Amyloïd-β(1-42), totaal Tau, gefosforyleerd Tau
Amyloïd neerslagen bij de ZvA kunnen veroorzaakt worden door 
abnormale degradatie van het membraangebonden eiwit “amyloïd 
precursor protein”. Een alternatieve splitsing van het eiwit door β- en 
γ-secretase geeft vorming van Aβ(1-40) en Aβ(1-42). Normaal bestaat 
90% uit oplosbaar Aβ(1-40) en slechts 10% uit onoplosbaar Aβ(1-42). 
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Overproductie van Aβ(1-42), of gebrek aan klaring van dit peptide, leidt 
tot de ZvA door de karakteristieke amyloïd neerslagen, die met celdood 
zijn geassocieerd.
Het Tau eiwit in de menselijke hersenen bindt aan microtubuli van het 
neuronale axon. Aangetoond is dat bij een vroeg stadium van de ZvA de 
totale Tau concentratie in liquor verhoogd is. Maar verhoogde concentraties 
van totaal Tau in liquor worden ook aangetoond bij andere vormen van 
dementie en andere acute of chronische neurologische ziektes.
Kenmerkend voor de inclusies in neuronen is de aanwezigheid van 
hypergefosforyleerd tau (Ptau). Bij de ZvA zijn in liquor verschillende 
Ptau epitopen aangetoond met verhoogde concentraties, zoals Ptau 
gefosforyleerd aan threonine 181, 231 en serine 199, 235, 396, 404. 
Hiervan zijn de meeste Ptau bepalingen met z.g. “in house” bepalingen 
gedaan. Voor Ptau-181, wereldwijd de meest onderzochte isovorm, is een 
commerciële ELISA beschikbaar (Innogenetics NV, Gent, België).
Dezelfde fi rma verkoopt daarnaast ook ELISAs voor Aβ(1-42) en totaal 
Tau, die veelvuldig gebruikt worden, waaronder ook in het VUmc. 
Omdat de stabiliteit van Aβ(1-42) en totaal Tau afhankelijk kan zijn 
van de opslagtijd en temperatuur, het aantal vries/dooi cycli, en de tijd tot 
centrifugeren is dit onderzocht. Ptau is hierbij niet meegenomen omdat de 
bepaling destijds nog niet operationeel was. 
Vervolgens is de Aβ(1-42) test vergeleken met een “in house” test, die 
veel in de VS gebruikt wordt. Deze detecteert zowel Aβ(1-42) als kortere 
fragmenten Aβ(N-42). Daarnaast is met beide methodes een groep AD 
patiënten vergeleken met controles zonder dementie en patiënten met 
frontotemporale kwab degeneratie. Tenslotte wordt zes jaar ervaring met 
de drie genoemde commerciële bepalingen geëvalueerd. De Ptau bepaling 
is later ingevoerd, maar de ontbrekende waarden zijn in monsters, die 
langdurig bij -80 ºC opgeslagen waren, bepaald.
Oxidatieve stress hypothese
Vetzuren en zuurstof spelen een belangrijke rol in het proces waarbij de 
cellen hun energie krijgen. Deze energie is vereist voor elke functie van het 
lichaam, van ademen en celdeling tot het functioneren van de hersenen en 
het hart. Bij het verbrandingsproces worden een molecuul rijk aan energie 
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(adenosine trifosfaat), water, kooldioxide en vrije radicalen, waaronder 
waterstofperoxide, geproduceerd. Wanneer deze vrije radicalen in grote 
aantallen vrijkomen of niet op een goede manier door het lichaam worden 
verwerkt, kan een verstoord evenwicht tussen de productie en afbraak 
optreden. Het negatieve verschil tussen de hoeveelheid anti-oxidanten 
capaciteit en de vrije radicalen in het lichaam wordt oxidatieve stress 
genoemd.
Peroxisomen zijn belangrijk voor de oxidatie van vetzuren. Hierbij 
ontstaat het reactieve waterstofperoxide dat door catalase, ook in de 
peroxisomen aanwezig, wordt afgebroken. Waarschijnlijk neemt tijdens het 
ouder worden de functie van de peroxisomen af, zodat de balans tussen 
pro- en anti-oxidanten verstoord wordt. Hierdoor treden veranderingen 
in de vetzuursamenstelling van de membranen op, zodat de stabiliteit 
vermindert en cellen, waaronder neuronen, kapot kunnen gaan. De functie 
van de peroxisomen zou dus de ZvA ten gevolge van het ouder worden 
kunnen veroorzaken.
Fosfatidylcholine (PC), een belangrijk molecuul van de cel-membranen, 
kan door oxidatie omgezet worden in lysofosfatidylcholine (lyso-PC) omdat 
de onverzadigde vetzuurketens gevoelig zijn voor oxidatie. Dit veroorzaakt 
instabiliteit en celverlies. In onze hypothese zou deze oxidatie kunnen 
leiden tot veranderde concentraties van PC en lyso-PC in liquor, wat 
weerspiegeld zou worden in een stijgende lyso-PC/PC-ratio bij patiënten 
met de ZvA. 
Ontstekingshypothese
Amyloïd neerslagen in de hersenen zijn het gevolg van een verstoord 
evenwicht van de productie en verwijdering. Omdat in de hersenen van 
patiënten met de ZvA geen toename van de productie is gevonden, 
wordt daarom verondersteld dat de stapeling van amyloïd in plaques 
veroorzaakt wordt door ineffi ciënte verwijdering. Normaal gebeurt dit door 
proteolytische enzymen, die amyloïd afbreken, gevolgd door opname 
en verdere intracellulaire degradatie door gliale cellen, astrocyten 
en microglia. Als de klaring van amyloïd verminderd is, worden gliale 
cellen geactiveerd en treedt er plaatselijk een ontstekingsreactie op. 
Deze reactie gebeurt relatief vroeg in het ziekteproces en amyloïd kan 
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door de geactiveerde gliale cellen verwijderd worden, maar er kan ook 
neurodegeneratie optreden.
Verder vinden we immunohistologisch in de amyloïd neerslagen bij 
de ZvA een groep zogenaamde amyloïd geassocieerde factoren. Deze 
bestaan uit een heterogene groep eiwitten, waaronder complement 
factoren, acute fase eiwitten en cytokines.
In liquor zijn de amyloïd geassocieerde eiwitten serum amyloïd P 
component (SAP) en de complement factor C1q onderzocht. SAP is een 
normaal plasma eiwit dat geproduceerd wordt in de lever en in alle types 
amyloïdose neerslaat. Recent is aangetoond dat SAP ook in de hersenen 
wordt gemaakt en dat de lokale productie is toegenomen, evenals de 
expressie van C1q, in aangedane hersengebieden van patiënten met de 
ZvA. We hebben onderzocht of SAP en C1q bruikbare biomarkers zijn om 
de diagnose ZvA te ondersteunen.
Gemethyleerd arginine
Dimethylarginine dimethylaminohydrolase (DDAH), een enzym dat 
asymmetrisch dimethyl arginine (ADMA) in citrulline en dimethylamine 
hydrolyseert, is specifi ek verhoogd in neuronen van patiënten met de 
ZvA, waarvan het cytoskelet abnormaal was en die oxidatieve stress 
vertoonden. Het enzym is echter niet aantoonbaar in neuronen van 
gezonde controles die even oud zijn. Door de toegenomen DDAH activiteit 
kan de ADMA concentratie verlaagd worden, zodat de productie van 
stikstof oxide toeneemt en door stikstof oxide geïnduceerde oxidatieve 
stress ontstaat. Onderzocht zijn de arginine, ADMA, symmetrisch dimethyl 
arginine (SDMA), en dimethylamine concentraties in liquor van patiënten 
met de ZvA vergeleken met controles van dezelfde leeftijd.
Homocysteïne en methylering van DNA
Het toevoegen van S-adenosylmethionine (SAM) aan celkweken van 
neuroblastoom cellen remt zowel de expressie van het preseniline 1 (PS1) 
gen als de Aβ(1-40) productie. Het is mogelijk dat veranderingen in de 
transmethyleringscyclus in de hersenen van patiënten met de ZvA leidt tot 
hypomethylering van de promotor van het PS1 gen, tot overproductie van 
PS1 en tot verhoogde concentraties van Aβ peptiden.
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Methylering van DNA gebeurt door DNA methyltransferases, die 
SAM als methyl donor nodig hebben. Bij deze transmethyleringsreactie 
wordt SAM gedemethyleerd tot S-adenosylhomocysteïne (SAH), dat 
gehydrolyseerd wordt tot homocysteïne. Homocysteïne kan gemethyleerd 
worden tot methionine door overdracht van een methyl groep van 
5-methyltetrahydrofolaat (5-MTHF), waarbij vitamine B12 en foliumzuur 
nodig zijn. De transmethyleringscyclus wordt voltooid doordat methionine 
met ATP in SAM wordt omgezet.
De transmethyleringscyclus in de hersenen is bestudeerd van patiënten 
met de ZvA en vergeleken met niet-demente controles. In liquor zijn de 
concentraties bepaald van SAM, SAH, 5-MTHF en methylmalonzuur 
(MMA), waarbij MMA als indicatie voor B12 defi ciëntie diende.
Homocysteïne en witte stof afwijkingen
Een moeilijkheid is dat veel ouderen ook andere hersenpathologie 
hebben, vooral degenen met dementie. In een retrospectieve studie zijn 
1050 oudere mensen met dementie nader bekeken. De klinische diagnose 
Alzheimer is gesteld bij 63%, en hiervan had bij autopsie 86% pathologie 
die overeenkwam met de ZvA. Van die 86% had de helft, 43%, zuiver 
Alzheimer, 23% Alzheimer en vasculaire laesies, en 11% Alzheimer en 
Lewy body pathologie. Soortgelijke bevindingen zijn gedaan in een groot 
longitudinaal onderzoek van ouderen in een grote stad in de USA. Bij 
autopsie zijn onafhankelijke verbanden aangetoond van microinfarcten in 
de hersenen (33%), ZvA (45%) en Lewy body’s in de neocortex (10%). 
Daarom kan verwacht worden dat de meeste oudere patiënten met de ZvA 
secondaire pathologie hebben. Omdat hoge concentraties homocysteïne 
een risicofactor is voor witte stof afwijkingen, wordt de betrokkenheid van 
het homocysteïne metabolisme bij het ontstaan van vasculaire laesies in 
de hersenen verondersteld.
Homocysteïne wordt gedeeltelijk gemetaboliseerd door transsulfurering, 
waarbij homocysteïne met serine condenseert tot cystathionine in een 
vitamine B6 afhankelijke reactie. Dus vitamine B6 is belangrijk om de 
te grote concentraties van homocysteïne te verminderen. Het is bekend 
dat lage concentraties vitamine B6 geassocieerd zijn met cognitieve 
achteruitgang. Hoewel het oorzakelijke verband onbekend is, zou 
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homocysteïne het verband kunnen zijn tussen vitamine B6 concentraties 
en de graad van witte stof afwijkingen.
Aangenomen wordt dat toegenomen homocysteïne concentraties de 
vasculaire laesies in de hersenen veroorzaken en daarom is de relatie 
tussen vitamine B6 concentraties in plasma en de aanwezigheid van witte 
stof afwijkingen bij patiënten met de ZvA bestudeerd. 
Onderzocht is of de homocysteïne concentratie en het homocysteïne 
metabolisme via de route van transmethylering (homocysteïne, vitamine 
B12 en folaat) geassocieerd is met de aanwezigheid van witte stof 
afwijkingen bij de ZvA. In dit kader werd weer de relatie tussen vitamine 
B6 en witte stof afwijkingen onderzocht. 
CONCLUSIES
In dit proefschrift wordt de diagnose van de ZvA in een geheugenkliniek 
beschreven, waarbij vooral het gebruik van biochemische markers in kaart 
is gebracht (Hoofdstuk 1 en 2). De voornaamste biomarkers zijn Aβ42, 
Tau en Ptau in CSF. Deze zijn afgeleid van de karakteristieke kenmerken, 
de amyloïd plaques en neurofi brillaire inclusies in neuronen, die post-
mortem in de hersenen van Alzheimer patiënten worden aangetroffen. 
Andere pathologische processen, die samenhangen met de ZvA, zijn ook 
bestudeerd om meer inzicht in de etiologie van de ziekte te krijgen.
De voornaamste conclusie is dat de neuropathologische kenmerken 
die post-mortem bij Alzheimer patiënten worden aangetroffen goede 
aanknopingspunten zijn voor biochemische markers voor de ante-
mortem diagnostiek (Hoofdstuk 11). Concentraties van amyloïd-β(1-42) 
in hersenvocht zijn verlaagd ten opzichte van patiënten met een andere 
neurologische aandoening en gezonden. In combinatie met Tau eiwit en 
Ptau worden goede resultaten verkregen.
Wanneer de hersenvocht monsters bij -80 ºC worden opgeslagen zijn 
Aβ(1-42) en totaal tau eiwit gedurende een lange periode stabiel. Vries/
dooi cycli hebben geen invloed op de tau concentratie, terwijl bij één vries/
dooi cyclus Aβ(1-42) niet verandert, in tegenstelling tot de volgende cycli 
(Hoofdstuk 3).
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De door ons gebruikte methode voor Aβ(1-42) is vergeleken met 
de amyloïd β bepaling, die vaak in de Verenigde Staten van Amerika 
wordt toegepast. Concentraties in “split” samples zijn op beide locaties 
gemeten. Over het algemeen komen de resultaten van beide methodes 
goed overeen. De Alzheimer patiënten vergeleken met controles zijn niet 
verschillend en de sensitiviteit en specifi citeit zijn 90%. Maar ten opzichte 
van een andere patiënten groep is het onderscheidend vermogen minder 
(Hoofdstuk 4).
Serum amyloïd P component en complement C1q kunnen afgevoerd 
worden van de lijst van mogelijk bruikbare biomarkers. Andere 
onderzoekers hebben in hersenvocht voor deze parameters wel een 
verschil aangetoond tussen Alzheimer patiënten en controles, maar wij 
konden dit niet reproduceren. Mogelijk komt dit door verschillen in de 
gebruikte controlegroepen, maar ook verschillen in sensitiviteit van de 
antilichamen kunnen een rol spelen (hoofdstuk 5).
Voor de concentratie van asymmetrisch dimethylarginine in hersenvocht 
van Alzheimer patiënten, vergeleken met controles, is geen verschil 
aantoonbaar. Een eerder onderzoek door een Japanse groep liet wel 
verschil zien bij Alzheimer patiënten, die cognitief aanzienlijk slechter 
waren, zodat secundaire pathologie ook een rol kan spelen (Hoofdstuk 6).
Er is geen verschil gevonden in de hersenvochtconcentraties van 
fosfatidylcholine en lyso-fosfatidylcholine tussen Alzheimer patiënten 
en controles. De ratio is echter verlaagd, zodat het metabolisme van 
choline-bevattende fosfolipiden in de hersenen mogelijk anders kan zijn 
(Hoofdstuk 7). Dit verschil is echter te klein, met een te grote overlap 
tussen beide groepen, om de ratio als biomarker te gebruiken.
In hersenvocht van Alzheimer patiënten kunnen geen veranderingen 
in de concentraties van metabolieten, die betrokken zijn bij de 
transmethyleringscyclus, worden aangetoond. Overexpressie van 
het preseniline 1 gen door hypomethylering van de promotor is dus 
onwaarschijnlijk (Hoofdstuk 8).
Er is een sterk verband gevonden tussen witte stof afwijkingen en 
lage plasma vitamine B6 concentraties bij patiënten met de ziekte van 
Alzheimer (Hoofdstuk 9 en 10). Er is bovendien een positieve correlatie 
tussen witte stof afwijkingen en plasma homocysteïne aangetoond, 
terwijl deze associatie met plasma vitamine B12 of plasma folaat 
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ontbrak (Hoofdstuk 10). Waarschijnlijk is het homocysteïnemetabolisme 
via de transmethyleringscyclus niet veranderd, in tegenstelling tot de 
transsulfureringsroute. Antioxidatieve eigenschappen van vitamine B6 
kunnen deze negatieve correlatie mogelijk verklaren.
Hoewel met de in dit proefschrift beschreven combinatie van biomarkers 
een goede specifi citeit aan een goede sensitiviteit wordt gekoppeld, 
is er toch ruimte voor verbetering, met name op het gebied van de 
differentiaaldiagnose. Technologische veranderingen en voortschrijdende 
kennis over de processen die leiden tot de vorming van de plaques en 
tangles zullen daarin leidinggevend zijn. Nieuwe markers kunnen op 
eiwit en micro-RNA niveau zijn. Omdat ook een verschuiving van het 
relatief moeilijk verkrijgbare hersenvocht naar makkelijker toegankelijke 
lichaamsvloeistoffen, zoals plasma of urine, zich zal aandienen, zullen 
nieuwe markers wellicht niet direct betrokken zijn bij de vorming van de 
neuropathologische verschijnselen, maar eerder een weerspiegeling van 
de perifere reactie van het lichaam op het neurodegeneratieve proces. 
Het biomarkeronderzoek gaat daarmee een fascinerende tijd tegemoet.
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